



Provided by the author(s) and University of Galway in accordance with publisher policies. Please cite the published version when available.

Title	Local pharmacological induction of angiogenesis: drugs for cells and cells as drugs
Author(s)	Gaspar, Diana; Peixoto, Rita; De Pieri, Andrea; Striegl, Britta; Zeugolis, Dimitrios I.; Raghunath, Michael
Publication Date	2019-06-19
Publication Information	Gaspar, Diana, Peixoto, Rita, De Pieri, Andrea, Striegl, Britta, Zeugolis, Dimitrios I., & Raghunath, Michael. (2019). Local pharmacological induction of angiogenesis: Drugs for cells and cells as drugs. <i>Advanced Drug Delivery Reviews</i> , 146, 126-154. doi: https://doi.org/10.1016/j.addr.2019.06.002
Publisher	Elsevier
Link to publisher's version	https://doi.org/10.1016/j.addr.2019.06.002
Item record	http://hdl.handle.net/10379/15896
DOI	http://dx.doi.org/10.1016/j.addr.2019.06.002

Downloaded 2024-05-15T20:39:45Z

Some rights reserved. For more information, please see the item record link above.



Manuscript Number:

Title: Local pharmacological induction of angiogenesis: drugs for cells and cells as drugs

Article Type: Wound healing & Scar War

Keywords: Angiogenesis; vascularisation; drug delivery; cell therapy; secretome; small compounds; cellular gases; progenitor cells; endothelial cells

Corresponding Author: Professor Michael Raghunath, M.D., Ph.D.

Corresponding Author's Institution: National University of Singapore

First Author: Diana Gaspar, PhD

Order of Authors: Diana Gaspar, PhD; Rita Peixoto, MSc; Andrea de Pieri, MSc; Britta Striegl, BSc; Dimitrios I Zeugolis, PhD; Michael Raghunath, M.D., Ph.D.

Abstract: The past decades have seen significant advances in pro-angiogenic strategies based on delivery of molecules and cells for conditions such as coronary artery disease, critical limb ischemia and stroke. Currently, three major strategies are evolving. Firstly, various pharmacological agents (growth factors, interleukins, small molecules, DNA/RNA) are locally applied at the ischemic region. Secondly, preparations of living cells with considerable bandwidth of tissue origin, differentiation state and preconditioning are locally, and occasionally, systemically delivered. Based on the notion, that cellular effects might mostly be attributed factors they secrete in situ, the cellular secretome (conditioned media, exosomes) has come into the spotlight. We review here these three strategies to achieve (neo)angiogenesis in ischemic tissue with a view towards angiogenic mechanisms they tackle such as transcription cascades, specific signalling steps and cellular gases. We also include cancer-therapy relevant lymphangiogenesis, and shall seek for an explanation why there are often conflicting data between in vitro and in vivo. The lion's share of data encompassing all three approaches has been generated with experimental animal work and we shall highlight common technical obstacles in the delivery of therapeutic molecules, cells, and secretome. We look into the reasons why not more clinical studies have been forthcoming and that completed trials have yet to reveal a successful and efficacious strategy. A lack of adequate delivery vehicles and standardised assessment of clinical outcomes might play a role here, as well as regulatory, IP, and manufacturing constraints of candidate compounds. As angiogenesis is well enough understood for clinical purposes, it will be a matter of time to achieve success for well-stratified patients and most probably with a combination of compounds, and most probably all of them small molecules.

**School of Life Sciences
and Facility Management**Institute for Chemistry & Biotechnology
Competence Centre Tissue Engineering
for Drug Development (TEDD)**P.P.** CH-8400 Winterthur

Post CH AG

Prof Katja Schenke-Layland
Executive Editor
Advanced Drug Delivery Reviews**Michael Raghunath, MD**
(Dr. med.habil.)Professor for Protein Technology,
Cell Biology and Tissue EngineeringHead, Center of Cell Biology and Tissue
Engineering

ragh@zhaw.ch

RT 410.1
Einsiedlerstrasse 31
Postfach
CH-8820 WädenswilPhone +41 58 934 5518
Mobile +41 (0)76 481 0146
Fax +41 58 935 71 71Phone Main office +41 58 934 71 71
Fax Main office +41 58 935 71 71
www.zhaw.ch/lsvm

Wädenswil 18 September 2018

Review Angiogenesis for Wound Healing & Scar Wars
“Local pharmacological induction of angiogenesis: drugs for cells and cells as drugs”

Dear Prof Schenke-Layland,

I am very pleased to submit on behalf of my co-authors a substantial review on angiogenetic strategies in wound healing and tissue regeneration by Gaspar et al. The review encompasses three current strategies – pharmacological, cell-based, and cell product-based. We review these strategies to achieve (neo)angiogenesis in ischemic tissue with a view towards angiogenic mechanisms they tackle such as transcription cascades, specific signaling steps and cellular gases. We also include cancer-therapy relevant lymphangiogenesis, and shall seek for an explanation why there are often conflicting data between in vitro and in vivo.







We have made sure to cover the current state of art as evidenced by clinical studies for a reality-check where we stand right now with angiogenic therapies at the bedside. With almost 500 references this review is very thorough.

I therefore hope that this manuscript meets the rigorous standards of ADDR and can be deemed acceptable.

With my very best regards

A handwritten signature in black ink that reads 'M. Raghunath'.

Michael Raghunath
Zürich University of Applied Sciences

Drugs for cells	Cells as drugs	Pre-conditioning tools for secretome modulation
 <p data-bbox="262 657 514 698">Growth factors</p>  <p data-bbox="252 1015 525 1055">Small molecules</p>  <p data-bbox="325 1412 441 1453">Genes</p>	 <p data-bbox="924 657 1113 698">Naïve cells</p>  <p data-bbox="808 1015 1239 1055">Genetically modified cells</p>  <p data-bbox="892 1412 1144 1453">Cell secretome</p>	 <p data-bbox="1617 657 1764 698">Hypoxia</p>  <p data-bbox="1449 1015 1921 1055">Electromagnetic stimulation</p>  <p data-bbox="1491 1412 1879 1453">Mechanical stimulation</p>

Title

Local pharmacological induction of angiogenesis: drugs for cells and cells as drugs

Authors

Diana Gaspar (1, 2), Rita Peixoto (1, 2), Andrea De Pieri (1, 2, 3), Britta Striegl (4),
Dimitrios I. Zeugolis (1, 2), Michael Raghunath (4)¹

Affiliations

1. Regenerative, Modular & Developmental Engineering Laboratory (REMODEL), Biomedical Sciences Building, National University of Ireland Galway (NUI Galway), Galway, Ireland.
2. Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM), Biomedical Sciences Building, National University of Ireland Galway (NUI Galway), Galway, Ireland.
3. Proxy Biomedical Ltd., Coilleach, Spiddal, Galway, Ireland
4. Competence Centre Tissue Engineering for Drug Development (TEDD), Centre for Cell Biology & Tissue Engineering, Institute for Chemistry and Biotechnology, Zurich University of Applied Sciences, Zurich, Switzerland.

¹Corresponding author: email: michael.raghunath@zhaw.ch; Tel: +41 (0) 58 934 55 18

Abstract

The past decades have seen significant advances in pro-angiogenic strategies based on delivery of molecules and cells for conditions such as coronary artery disease, critical limb ischemia and stroke. Currently, three major strategies are evolving. Firstly, various pharmacological agents (growth factors, interleukins, small molecules, DNA/RNA) are locally applied at the ischemic region. Secondly, preparations of living cells with considerable bandwidth of tissue origin, differentiation state and preconditioning are locally, and occasionally, systemically delivered. Based on the notion, that cellular effects might mostly be attributed factors they secrete *in situ*, the cellular secretome (conditioned media, exosomes) has come into the spotlight. We review here these three strategies to achieve (neo)angiogenesis in ischemic tissue with a view towards angiogenic mechanisms they tackle such as transcription cascades, specific signalling steps and cellular gases. We also include cancer-therapy relevant lymphangiogenesis, and shall seek for an explanation why there are often conflicting data between *in vitro* and *in vivo*. We find the lion's share of data encompassing all three approaches has been generated with experimental animal work and we shall highlight common technical obstacles in the delivery of therapeutic molecules, cells, and secretome. We look into the reasons why not more clinical studies have been forthcoming and that completed trials have yet to reveal a successful and efficacious strategy. A lack of adequate delivery vehicles and standardised assessment of clinical outcomes might play a role here, as well as regulatory, IP, and manufacturing constraints of candidate compounds. As angiogenesis is well enough understood for clinical purposes, it will be a matter of time to achieve success for well-stratified patients and most probably with a combination of compounds, and most probably all of them small molecules.

Keywords

Angiogenesis; vascularisation; drug delivery; cell therapy; secretome; small compounds;
cellular gases; progenitor cells; endothelial cells

List of abbreviations

α -SMA: alpha smooth muscle actin

aFGF: acidic fibroblastic growth factor

ADSCs: adipose derived stem cells

Akt: serine /threonine specific protein kinase

Ang1: angiopoietin 1

FGF2: basic fibroblastic growth factor

BMSCs: bone marrow mesenchymal stem cells

BM-MNCs: bone marrow mononuclear cells

CABG: coronary artery bypass grafting

CAD: coronary artery disease

CAM: chorioallantoic membrane

CD: cluster of differentiation

CLI: critical limb ischemia

COX-1: cytochrome c oxidase subunit 1

CST: compressive sleeve therapy

EC: endothelial cells

ECM: extracellular matrix

ELF: extremely low frequency

EMF: electromagnetic field stimulation

eNOS: endothelial nitric oxide synthase 3

EPCs: endothelial progenitor cells

ePTFE: polytetrafluoroethylene

ERK: extracellular signal regulated kinases

GAG: glycosaminoglycan

G-CSF: granulocyte -colony stimulating factor

GF: growth factor

hB-EGF: heparin binding endothelial growth factor

HGF: hepatocyte growth factor

HIF: hypoxia inducible factor

HUVEC: human umbilical vein endothelial cells

ICAM: intercellular adhesion molecule

Id1: DNA-binding protein inhibitor

IGF-1: insulin-like growth factor 1

IL: interleukin

ISL1: insulin gene enhancer protein

iNOS: inducible nitric oxide synthase

JNK: c-Jun N-terminal kinases

LIPUS: low-intensity pulsed ultrasounds

LLLT: low-level laser therapy

miRNA: micro ribonucleic acid

MMPs: metalloproteinases

MVEs: multi-vesicular endosomes

NGF: nerve growth factor

NO: nitric oxide

NOS: nitric oxide synthase

PAD: peripheral artery disease

PDGF: platelet derived growth factor

PEG: polyethylene glycol

PEMF: pulsed electromagnetic field stimulation

PH: prolyl hydroxylase

PI3K: phosphatidylinositol-3-kinases

PLGA: poly(lactic-co-glycolic acid)

PlGF: placental growth factor

PMA: phorbol 12-myristate 13-acetate

PRF: platelet rich fibrin

Prox-1: prospero homeobox protein 1

PRP: platelet rich plasma

Rac1: ras-related C3 botulinum toxin substrate 1

SDF-1 α : stromal cell-derived factor 1 alpha

SMCs: smooth muscle cells

Src: proto-oncogene tyrosine-protein kinase Src

Tie2: angiopoietin 1 receptor

TIMP: tissue inhibitor of metalloproteinase

TGF- β : transforming growth factor beta

uPa: urokinase-type plasminogen activator

VCAM-1: vascular cell adhesion protein

VE-cadherin: vascular endothelial cadherin

VEGF: vascular endothelial growth factor

VEGFR: vascular endothelial growth factor receptor

UC-MSCs: umbilical cord mesenchymal stem cells

Table of contents

1	Introduction.....	10
2	Drugs for cells.....	16
2.1	Delivery of growth factors and cytokines	16
2.2	Delivery of interleukins, ions, gases, and small molecules.....	22
2.3	Delivery of genes	27
2.4	Delivery of growth factors and genes for therapeutic lymphangiogenesis	32
2.5	Physical stimuli for secretion of angiogenic factors	33
3	Cells as drugs	36
3.1	Delivery of naïve cells.....	37
3.1.1	Endothelial progenitor cells (EPCs).....	37
3.1.2	Mononuclear cells (MNCs).....	39
3.1.3	Bone marrow (BMSCs) and adipose derived stem cells (ADSCs)	40
3.1.4	Pericytes and blood-derived angiogenic cells.....	43
3.2	Delivery of pre-conditioned cells	44
3.2.1	Biochemical pre-conditioning.....	44
3.2.2	Physical pre-conditioning	46
3.3	Delivery of genetically modified cells	50
3.4	Delivery of cell secretome and cell-derived vesicles	53
3.5	Delivery of cells for therapeutic lymphangiogenesis	56
3.6	General approaches for cell retention and survival after implantation	58
4	Conclusions and future perspectives.....	60

5	Acknowledgments.....	62
6	References.....	63

1 Introduction

For almost all human tissues, a direct vascular perfusion at the micro level (4 - 7 μm capillaries, lymphatics), derived from a network of blood vessels at the macro level (1 mm to 2 cm, arterioles, arteries, venules, veins, lymph vessels and ducts), is mandatory to sustain metabolic function for tissue maintenance, growth and repair [1, 2]. The continuous flow of blood and its corpuscular elements ensures constant exchange of nutrients, metabolic waste and gases via diffusion through capillary walls [3]. Lymphatic vessels serve as a transport system for fluid and large proteins collected from the interstitial space, immune cells and also lipid droplets after resorption in the intestine [4, 5]. Tissues that are not vascularised, such as cartilage and cornea, are dependent on the exchange of nutrients, waste and gases via diffusion from adjacent vascularised tissues [6, 7]. Microangiogenesis is a prerequisite for tissue growth. First, in the embryo, angioblasts, progenitor cells for both endothelial cells (EC) and hematopoietic cells, form clusters that are sustained via diffusion of oxygen and nutrients through the uterine wall. In these aggregates, the inner cells will become the hematopoietic precursors while the outer cells will give rise to EC [8]. The endothelial cells start forming a primitive capillary network along which tissue grows and more complex structures form. When tissue size reaches the limit of oxygen diffusion, further vessel growth is prompted through hypoxia and increased expression of hypoxia inducible transcription factors (HIF) [9]. The vascular network increasingly expands through sprouting mediated by EC, which later are covered by pericytes and vascular smooth muscle cells (SMCs) to provide strength and stability to the new vessel [8]. In adulthood, EC also proliferate in response to stimuli, (e.g. hypoxia) to initiate angiogenesis [10]. Once EC are activated, vasodilation of the parental vessel occurs, creating space between the EC, which allows them to migrate to the interstitial space and proliferate to form the elongating tip of a new capillary [11]. This process also involves activation of metalloproteinases (MMPs) to degrade the basement membrane also

releasing / activating growth factors trapped within the ECM. Furthermore, this is also mediated by RhoA/Rho kinase signalling as it involves significant cytoskeletal remodelling [12]. To stabilise the blood vessel, similarly to vasculogenesis, pericytes and SMCs are recruited and ECM is secreted. The increasing shear stress from the blood flow will contribute to vessel stability derived from further ECM remodelling and EC – pericytes / smooth muscle cell interactions [13].

As for the formation of lymphatic vessels, lymphangiogenesis, in the embryo, is only initiated after the vascular system is already established. A distinct subpopulation of EC commits to the lymphatic lineage and sprouts to form primitive structures that constitute the lymph sacs, from which peripheral lymphatic vessels are derived through centrifugal sprouting. Different lymphatic capillary networks eventually connect and undergo further remodelling and maturation [14]. In adulthood, lymphangiogenesis occurs primarily through sprouting from pre-existing vessels during wound healing and development of corpus luteum. However, growth of lymphatic vessels is also associated with various pathophysiologies including tumour metastasis and inflammation [15, 16]. Disorders in the lymphatic system can occur due to malformations, as a consequence of localised trauma and after surgery or radiation therapies for malignancies, particularly of the breast or pelvic organs [17, 18]. The impaired lymphatic fluid flow leads to lymphoedema, for which there are currently very limited treatments mostly dependent on physiotherapy [19].

Restriction of blood flow on the macrolevel leads to reduced perfusion of the capillary bed downstream of the feeder vessel. Thus, the affected area becomes underperfused, or ischemic, there is a shortage of oxygen, leading to hypoxia in the tissue, and metabolic waste accumulates [20]. This is characteristic of pathological conditions such as coronary artery disease (CAD), critical limb ischemia (CLI), myocardial infarction or ischemic stroke. Ischemia onset is usually gradual, caused by changes in the vessel walls leading to stenosis,

but can progress to dangerous levels (CLI, crescendo angina pectoris) and be suddenly aggravated by a blood clot that either rapidly forms at a wall lesion (thrombosis) and occludes the lumen or has formed there but is transported to another location in the vasculature where it finally occludes a vessel (embolus) [21, 22].

On the microlevel, a diffuse obliteration process of small vessels and capillaries can lead to ischemia as well, triggered by metabolic aberrances such as hyperglycaemia in diabetes, but also homocystinuria and inflammatory conditions such as lupus erythematosus [23-25]. Damage of retinal capillaries, nerves and loss of filtration function of renal glomeruli are all manifestations of capillary injury [26-28]. Furthermore, diabetes also causes a macroangiopathy which can be explained by direct damage of vessel wall constituents, but also the obliteration of capillaries nourishing the vessel wall (vasa vasorum) [29, 30].

Depending on anatomical locations vascularisation strategies tackling the macro level have to be different from those on the micro level, though in many cases pathologies on both levels occur simultaneously.

Current clinical treatments to restore blood flow are mainly focussing on the macro level with the expectation that the micro level is then served as well. In essence these strategies either seek to bypass or substitute the occlusion or directly address the stenotic lesion directly by mechanical and pharmacological means [20]. These strategies can be categorised as reperfusion therapies and encompass long term revascularisation, however, their application depends on the blood vessels to be treated or replaced, respectively. Synthetic vascular grafts, such as polytetrafluoroethylene (ePTFE), polyethylene terephthalate (Dacron[®]) or polyurethane are extensively utilised clinically but are more successful for applications with a vessel diameter larger than 6 mm , with neointimal hyperplasia being the major cause of failure when these are used in smaller calibre applications [31, 32]. For coronary bypasses, a homograft is used. The saphenous vein, internal mammary artery, or radial artery are suitable

options for small diameter grafts (< 6 mm) [31]. Alternatively to homografts, balloon dilation with subsequent stenting is also utilised. Complications of stenting are restenosis due to hyperplasia of smooth muscle cells leading to a neointima formation and restenosis [33]. To mitigate this, drug eluting stents and balloons are in clinical use [34, 35]. With regards to long term patency, coronary artery bypass grafting (CABG) and stenting are comparable in clinical outcomes. Functionalisation of synthetic grafts with various molecules (e.g. proteins, glycosaminoglycans, growth factors, peptides) has also been attempted [36-38], however, clinical studies to date have focussed on larger calibre vessels (e.g. femoropopliteal bypass or aortic reconstruction procedures) [39-43].

An acute perfusion problem on the micro level occurs also when *in vitro* cultured tissue is implanted into living tissue and immediately requires vascularisation to survive. The issue in tissue engineering for regenerative procedures is the fact that standard culture runs at atmospheric oxygen, meaning 21% oxygen saturation in culture media (depending on diffusion conditions in the culture vessel) which constitutes hyperoxia. Physiological oxygen levels range from 0.5% to 9% (~1% in the intervertebral disc and certain areas of the brain [44, 45], ~6% in bone marrow [46], ~5% in cartilage [47]) and implanting a typically non vascularised hyperoxic tissue piece into a living tissue will lead to a race between central necrosis of the implant and capillaries sprouting into the implant from outside from a pre-existing capillary network. In summary, strategies on the macro level are primarily to establish reperfusion by surgical means, and to prevent restenosis by mechanical and pharmacological means [48, 49]. The obvious, yet challenging, solution lies on promoting vascular perfusion of the implanted constructs or ischemic tissue through angiogenesis, the formation of new capillaries from pre-existing blood vessels. Increasing efforts are being directed towards developing pro-angiogenic therapies that locally stimulate native or implanted cells to revascularise ischemic areas. This can involve the delivery of drugs (e.g.

growth factors, cytokines, small molecules) or cells (untreated, pre-conditioned, genetically modified, secretome). Growth factors are the most frequently used category of pro-angiogenic molecules. These can include vascular endothelial growth factor (VEGF), fibroblastic growth factor 2 (FGF2) and hepatocyte growth factor (HGF), which are all powerful mitogens, platelet derived growth factor (PDGF), transforming growth factor beta (TGF- β), angiopoietins (Ang) and placental growth factor 1 (PIGF-1). Nonetheless, other molecules have shown angiogenic potential, such as interleukins (IL), nitric oxide (NO), copper and calcium ions and phorbol 12-myristate 13-acetate (PMA) [50-53]. Regarding cell delivery, although EC are favoured for *in vitro* testing, progenitor (e.g. bone marrow mononuclear cells [BM-MNCs], EPCs) and stem cells (bone marrow mesenchymal stem cells [BMSCs], adipose derived stem cells [ADSCs]) have been preferentially used *in vivo* and clinically [54, 55]. BM-MNCs present a significant advantage as they do not require expansion in culture, however, similarly to the EPCs, they are a heterogeneous, poorly defined population. BMSCs and ADSCs are also appealing sources due to their multipotency and ease of extraction and expansion, however, their implantation has been associated with restenosis and atherogenicity [56]. Therefore, conditioning of cells prior to implantation with hypoxia, mechanical stimulation, or genetic manipulation can be used to better control the behaviour of the cells and their secretion profile to overcome such issues [57, 58]. As an alternative to whole cell implantation, cell-derived vesicles, such as exosomes can be utilised to make use of the cell secretome, since they have been shown to contain both proteins and nucleic acids and to play a crucial role in cell-cell communication [59, 60].

Several of these approaches have been extensively assessed *in vitro*, *in vivo*, and clinically. There are well-established two- and three- dimensional *in vitro* models that allow for the assessment of the suitability of a therapeutic agent or a cell source. Two-dimensional models comprise seeding cells on tissue culture plastic coated with adhesive proteins, while three-

dimensional models typically use hydrogels (e.g. collagen, fibrin, plasma clot, Matrigel, or mixtures) and are based on the ability of EC to invade the substrate in response to a drug / treatment. Cells can be directly seeded on top of gels, sandwiched between two gel layers, seeded dispersedly, clustered as spheroids or attached to microcarrier beads and scattered throughout the gel [61, 62]. The three-dimensional models present the advantage of allowing for representation of the different stages of angiogenesis: sprouting, branching and network formation. *Ex vivo* models based on culture of rat aortic rings and assessment of outgrowths or rat mesentery for study of lymphangiogenesis alongside angiogenesis have also been described [63, 64]. More recent *in vitro* models use microfluidic channels fabricated by soft lithography [65]. Other models attempt to imitate the complexity of cell-cell interactions and their paracrine effect by resorting to co-culture methods or conditioned media [66, 67]. Nonetheless, preclinical assessment remains the most accurate way of assessing the angiogenic potential of cells or drugs. Most commonly used preclinical animal models include the chick embryo chorioallantoic membrane (CAM) assay, dorsal skinfold chamber, cornea micro-pocket assay, subcutaneous implantation, hindlimb ischemia and myocardial infarction models [68, 69].

Current advancements in pro-angiogenic therapies can be grouped as delivery of drugs and delivery of cells. Herein, we critically assess the *in vitro*, *in vivo* and clinical progress that has been made in the field of drug delivery and cell delivery for promotion of angiogenesis for micro-vascularisation.

2 Drugs for cells

The most common pro-angiogenic therapeutic approach is based on the delivery of therapeutic molecules that can include inorganic compounds, cytokines or growth factors; from the group of the latter VEGF, FGF2, PDGF and HGF, being the most frequently used [70]. *In vitro* testing of these molecules involves culture media supplementation, while *in vivo* and clinically, these molecules are typically injected directly into the tissue location of interest. Defined mixtures of different therapeutic factors have also been used or, alternatively, platelet rich plasma (PRP) or similar mixtures including various proteins, cytokines and growth factors [71].

However, injections present challenges regarding half-life and, as discussed above with cell delivery, the local retention of the active molecules [72]. To overcome these issues, sustained delivery using scaffolds (e.g. hydrogels, sponges, fibres, particles, liposomes) has been extensively tested along with binding to other molecules (e.g. peptides, glycosaminoglycans, sulphated molecules) [72, 73]. Another widely tested approach, is the delivery of DNA/RNA using vehicles for gene transfer of the cells *in situ*, thereby ensuring a more prolonged and sustained delivery of the molecule of interest. The most commonly delivered genes encode the most frequently used growth factors in peptide form, such as VEGF and FGF2, though other genes targeting relevant pathways have also been assessed [74-76]. In this section, we will focus on *in vitro*, preclinical and clinical studies that report the use of therapeutic factors to modulate cell behaviour for promotion of angiogenesis as well as their mode of delivery (e.g. injection, use of vehicle, gene transfer).

2.1 Delivery of growth factors and cytokines

The terms “growth factor” and “cytokine” often interchangeably used. Cytokines are a broad and loose category of small proteins ranging from 5–25 kDa), whereas growth factors can

generally be seen as a subset that can reach up to 100 kDa. Cytokines and growth factors are produced by a broad range of cells, and it is often/primarily non-endothelial cells that drive influence endothelial cell behaviour to promote angiogenesis by secreting growth factors or cytokines. The most frequently used growth factor to modulate angiogenesis *in vitro* and *in vivo* is VEGF due to its pivotal role in initiating angiogenesis, and as a survival factor for cultured endothelial cells [77]. *In vitro* supplementation with VEGF promotes EC proliferation, survival and capillary formation in Matrigel, collagen gels and poly(lactic-co-glycolic acid) (PLGA) / polyethylene glycol (PEG) microspheres [78, 79]. In high doses (50 ng/ml), VEGF appears to initiate endothelial differentiation of BMSCs, as evidenced by typical markers such as von Willebrand factor, and formation of capillary-like structures in a gel matrix [80]. VEGF-mimicking peptides promote endothelial sprouting and tube formation from aortic rings, promote EC proliferation, migration and survival through activation of VEGF receptor 2 (VEGFR2) [81]. To extend the half-life of VEGF in culture, sulphated molecules have been employed to emulate the physiological electrostatic interactions between growth factors and heparin and heparan sulphate proteoglycan, respectively [82, 83]. Sulphated chitosan coated PLGA scaffolds have also been employed successfully for this purpose [84]. Although the key role of VEGF in angiogenesis is beyond doubt, it also has become clear that VEGF alone is not enough to ensure cell proliferation, viability and creation of stable vascular networks *in vitro* [85-87] and *in vivo*. Animal experiments have repeatedly shown that the introduction of high VEGF concentrations locally in tissue leads to tortuous capillaries that appear to be leaky in addition [88, 89].

This has led to considering additional angiogenic factors. FGF2 is another potent inducer of angiogenesis. FGF2 stimulates proliferation, migration and VEGF expression in EC [90, 91]. BMSCs and fibroblasts are strong producers of VEGF and FGF2, particularly after hypoxic of growth factor stimulation, thus targeting EC and inducing capillary sprouting and network

formation [92-94]. When stimulated by FGF2 on the surface of collagen gels, EC produce more urokinase-type plasminogen activator (uPa), a protease involved in vascular permeability and ECM degradation [85, 95].

Furthermore, it has also been shown to promote proliferation of BMSCs [96] and increased capillary tube length in HUVEC/dermal fibroblast co-culture [97].

As with VEGF, sulphated molecules binding by electrostatic interaction with FGF2 can prolong its half-life. Suitable molecules are the glycosaminoglycans heparin and, heparin sulphate, but also sulphated polysaccharides like fucoidan that potentiate FGF2 action as evidenced *in vitro* by increased human umbilical vein endothelial cells (HUVEC) proliferation, migration and metalloproteinase 2 (MMP-2) activation in a p38 and JNK dependent-manner, pathways that are strongly associated with tubulogenic events [98]. Sustained delivery of FGF2 has also been attempted with enzymatic degradation of various carriers, such as chitosan nanoparticles [99], gelatine microspheres [96] and gelatine microspheres within collagen /nanocellulose porous scaffolds [100].

Several other growth factors contribute significantly to angiogenesis, yet do not act directly on EC. These factor recruit auxiliary cells for vessel stabilisation and maturation - fibroblasts smooth muscle cells (SMCs) and pericytes [101]. This is the case for TGF- β which inhibits EC proliferation *in vitro* while promoting angiogenesis *in vivo*. However, *in vitro*, when combined with FGF2 or VEGF, it can have a pro- or anti-angiogenic effect, depending on its concentration [102]. While this highlights the complexity of growth factor interactions during angiogenesis, it also sheds light on the influence of experimental conditions that vary widely across research groups.

Several of the above-mentioned factors have been assessed preclinically for their angiogenic potential. VEGF injection or sustained delivery using scaffolds have shown improved capillary density, maturation and neovascularisation in ischemic and subcutaneous models

[83, 103-108]. Similar results were obtained with FGF2 in subcutaneous and ischemic models using delivery systems for implantation [96, 100, 109-114]. Furthermore, HGF, although not extensively studied *in vitro*, has also shown increased capillary outgrowth in a rabbit cornea pocket model [115] and improved collateral vessel formation in a rat hindlimb ischemic model, when delivered in repeated doses [116]. PlGF1 has also shown promising results *in vivo*. Implantation in a subcutaneous rat model of a multidomain peptide hydrogel with PlGF1 loaded liposomes led to improved cell infiltration, vessel density and maturation over unloaded hydrogels [117].

Despite the extensive *in vitro* and preclinical efforts dedicated to delivery of angiogenic proteins, as monosubstances or in combination, their efficacy has been tested only in a few clinical trials (**Table 1**) mainly featuring VEGF [118]. Patients with CAD received intracoronary and intravenous injections of different VEGF doses. Significant improvements were observed with regards to exercise time and angina symptoms only with higher doses [119]. A few studies have assessed safety of FGF2 injection in humans [120]. The first studies investigated the efficacy of FGF2 for treatment of peripheral arterial disease [121, 122], showing encouraging results in terms of improved walking time. However, in patients with CAD, reduction of angina symptoms were observed, although improvements were not statistically significant at clinical end point due to continued recovery in the placebo group, even though no other treatment had been applied simultaneously [123, 124]. Heparin / alginate microcapsules have been used to deliver FGF2 in patients receiving surgery for coronary bypass, where a dose dependent effect was observed with only higher concentrations increasing blood perfusion in the target area [125, 126]. The sustained delivery appears to promote long-lasting effects [127]. Likewise, FGF1 has also been shown to promote sprouting of a new capillary network at injection site in patients with coronary heart disease [128]. There are two clinical trials currently registered on

www.clinicaltrials.gov that are assessing intracoronary delivery of growth factors for coronary artery disease, one where VEGF is injected alongside oral supplementation of L-arginine (phase 1) and the other is based on FGF1 injection (phase 2). Of note, human recombinant PDGF-BB has been FDA/EMEA approved for clinical since 1997 use in the form of a topical gel (becaplermin) for chronic wound repair due to its chemotactic and mitogenic effects within angiogenesis and consequent role during wound healing [129]. However, an increased neoplasm rate at the site of application has been reported in patients that have been exposed locally to more than three tubes of the gel over the treatment period. [130-132]. The amount of Becaplermin gel per application is calculated by the ulcer size, as (length in cm \times width in cm). Becaplermin gel 0.01% is distributed in a 15 g tube, and it is recommended that the amount per application be recalculated weekly by the health care provider. The Becaplermin gel product insert recommends that if there is not a 30% decrease in size after 10 weeks or complete healing in 20 weeks, the health care provider should consider the risks of continuing Becaplermin gel [133].

To better mimic spatiotemporal interaction of the various growth factors during angiogenesis and to overcome limitations using only single factors, combinations of different molecules have been tested *in vitro*. In some instances, growth factors act synergistically, as is the case with VEGF and FGF2. On their own, they promote EC invasion of gel matrices and tube formation *in vitro*, but their combination gives a larger than additive effect with a faster angiogenic response and use of lower concentrations, of both growth factors, in EC and ADSCs [134-138]. Co-delivery of VEGF and HGF in a heparin coacervate increased HUVEC proliferation as well as tube formation in a fibrin gel, presenting improved results over the individual growth factors [139]. Combined delivery of VEGF and heparin stabilised PDGF-BB in a fibrin gel, increased EC proliferation and promoted vessel outgrowth in an aortic ring assay [140]. Systems of increasing complexity can be found in the literature as

well, including cocktails composed of more than two molecules or controlled temporal delivery of multiple molecules [141]. An alternative to well-defined combinations of growth factors is the use of platelet rich plasma (PRP), as it contains important angiogenic factors such as VEGF, PDGF-BB, FGF2, angiopoietins and TGF- β [142, 143]. *In vitro*, both PRP and platelet rich fibrin (PRF), which also releases platelet derived factors, can promote EC proliferation and migration [144], likely derived from activation of ERK and serine/threonine specific protein kinase (Akt) pathway [71] and angiopoietin 1 (Ang1) – angiopoietin 1 receptor (Tie2) signalling [142].

Mixtures of bioactive molecules have also been tested in various animal models. For instance, VEGF, HGF and FGF2 have been implanted subcutaneously in rats and induced neo-capillary formation and granulation tissue formation [145]. Simultaneous delivery of VEGF and PDGF showed improved recovery of tissue in a rat myocardial infarction model over delivery of VEGF alone [146]. PDG-BB has been used in combination with both VEGF and FGF2 in a murine Matrigel plug angiogenesis assay and a myocardial infarction models and evidenced improved vessel maturation through alpha-smooth muscle actin (α -SMA) staining, highlighting the synergistic effect of these two growth factors during later stages of angiogenesis [140, 147]. Due to the intricate spatiotemporal action of growth factors during angiogenesis some studies focus on systems allowing delivery of more than two molecules. VEGF, PDGF-BB and TGF- β 1 have been delivered in a sequential manner from alginate sulphate/alginate sponges based on different binding constants of the individual factors, and shown improved results over individual growth factor use [148]. PRP and PRF have also been assessed *in vivo* and shown increased vessel formation, maturation and ECM deposition, observed by Masson's trichrome staining, in a CAM assay [144]

Considering the breadth of preclinical data on local delivery of angiogenic proteins, the amount of clinical data is quite limited. The reasons for that might be that growth factors are

more expensive to manufacture and to store, and have a short half-life after tissue delivery [149, 150]. It should not be underestimated, however, that these factors are all used in supraphysiological doses, because of the rapid decay of the protein factors once applied to a wound area or injected deeper into tissue. In the case of PDGF, safety concerns have emerged postmarketing. From the physiological point of view, it makes substantial sense to use different GF in combination to achieve angiogenic synergy and to be able to lower the concentration of each single GF locally required. The half-life issue of the GF in the host tissue can certainly be addressed by sulphated sugar moieties or manipulating amino acid sequences in the recombinant proteins. For example, dextran sulphate has been demonstrated to protect FGF2 from heat and acid inactivation and from proteolytic degradation [151]. Similarly, heparan sulphate has been shown to the selectivity and bioavailability of growth factors [152, 153]. However, they currently have to be purified from biological material (usually porcine gut) and therefore afford costly purification and manufacturing steps. Be it these stabilising factors, or sustained delivery materials, they add enormously to costs in terms of regulatory hurdles (multiple substances necessary and safety studies), and navigating of intellectual property issues.

2.2 Delivery of interleukins, ions, gases, and small molecules

Several IL appear to possess pro-angiogenic potential. While IL-17 appears to promote migration, cytoskeletal reorganisation and capillary formation through upregulation of Rac1 and RhoA, via the phosphatidylinositol 3-kinase (PI3K) signalling pathway [154], IL-18 does so by proto-oncogene tyrosine protein kinase (Src) and JNK signalling [155]. On Matrigel, both IL-2 and IL-6 increase tube formation by HUVEC (increase of VEGF and PDGF) and circulating EPCs, respectively [50, 156].

Other factors supporting angiogenesis are metals, earth alkaline metals [157-159] and gases. Indeed, copper is necessary for activation of EC and angiogenic growth factors, including VEGF and FGF2 [160]. It promotes EC proliferation, even in the absence of serum [52] and increases VEGF secretion in keratinocyte culture [161]. In an aortic ring culture, copper promoted angiogenesis in a concentration dependent manner, with high concentrations suppressing angiogenesis but showing increased VEGF production [162]. The proangiogenic effect of copper has been reported *in vivo* using copper nanoparticles which promoted development of a dense vascular network [163] and also in a subcutaneously implant in mice particularly when used alongside FGF2 [164]. Nonetheless, the mechanism by which copper influences angiogenesis is still controversial. Of note, copper is an essential co-factor for the copper-dependent amino oxidases. Lysyl oxidase (LOX) stabilises collagen and elastin by paving the path for covalent crosslinks, pyridinolines and desmosines, respectively [165-167]. Interestingly, of the three currently known lysyl oxidase homologs (LOX-like enzymes, LOXL), LOXL2 can also crosslink collagen type IV and hence influence the sprouting of new blood vessels [168]. Interestingly, copper has also been implicated in stabilisation of HIF-1 α through prolyl hydroxylase inhibition, which could also explain its role in the early phases of angiogenesis [169]. Despite the interesting results and the use of copper chelators for inhibition of angiogenic response in tumours, further work is required to fully elucidate the pro-angiogenic role of copper [170].

Although not widely assessed *in vitro*, earth alkali metals appear to play a role in angiogenesis. Calcium ions, released by degradation of from a bioglass scaffold, have also shown angiogenic potential when implanted subcutaneously on rats [171]. Additionally, several publications have recognised the potential of calcium, magnesium and silicate in vascularisation for regeneration of osteogenic tissue [171-173].

Two other unlikely choices for promotion of angiogenesis are nicotine and sodium arsenite, however, both, in well-defined low concentration ranges, have been shown to accelerate capillary tube formation in EC culture, with nicotine acting through nicotinic cholinergic receptors and sodium arsenite through VEGF and NO activity [174-177]. Interestingly, nicotine has been evaluated *in vivo* alongside FGF2 in a wound healing model where it appeared to reduce wound area and improve capillary formation [178].

PMA, although also reported as a tumour promoter, can induce formation of capillaries in EC culture and increase expression of angiogenic markers, such as CD31 and VE-cadherin [53, 86, 95]. Its angiogenic activity is likely derived from triggering cell invasiveness through increased production of collagenase and uPa [179].

Although the use of alternative molecules to growth factors presents an interesting approach, there is no solid evidence to conclude regarding their pro-angiogenic behaviour, be that due to contradictory results available in the literature, the lack of in-depth *in vitro* and preclinical analysis or absence of clinical data. Furthermore, analogous issues can arise in terms of half-life and activity of these agents considering that sustained delivery systems have not been thoroughly investigated with these molecules.

Cell signalling by gases is another route that has gained wide-spread attention also with regards to angiogenesis. Nitric oxide (NO) is produced by nitric oxide synthases from L-arginine and plays a key role in angiogenesis. When NO synthase (NOS) activity is reduced, VEGF-induced angiogenesis is hindered [180, 181]. NO - stimulating substances indirectly promote EC migration, proliferation and vascular permeability [51, 182, 183]. Upregulation of eNOS and consequent release of NO in EC is heavily dependent on different growth factors such as VEGF, heparin binding EGF (HB-EGF) and TGF- β 1, and on PI3K signalling and integrin α 5 β 3 activity [184-188]. However, there is controversy regarding the role of NO in angiogenesis, as exogenous supplementation of HUVEC cultures with organic NO donors,

presented decreased cell migration [189]. Furthermore, there is *in vivo* data available that appears to substantiate the anti-angiogenic effect of NO, since it has been demonstrated that the use of NO donors in a CAM model led to decreased collagen synthesis and vascular density [181, 190]. In addition, increasing the NO metabolite concentration inhibits EC proliferation [191], indicating the concentration of NO present on the intracellular compartment may dictate the effect it has on angiogenesis.

Hydrogen sulphide (H₂S) has also been known to stimulate angiogenesis. The administration of H₂S to EC culture simulates cell proliferation, migration and tube formation [192]. Exogenous H₂S has been shown increased collateral vessel growth, capillary density, and regional tissue blood flow in a hindlimb ischaemia model [193]. Additionally, in an *in vivo* model of mice Matrigel plug, exogenously administered H₂S significantly promoted neovascularization [194]. However, H₂S does not exhibit a pro-angiogenic effect at a high concentration and it might evoke mechanisms that counteract the pro-angiogenic pathways.

2.2.1 Hypoxia mimicking strategies

Finally, a group of small molecules modulating angiogenesis deserves particular attention due to their well characterised mechanism and their potential clinical value. These are the group of prolyl hydroxylase inhibitors which offer a pharmacological approach to stimulate angiogenesis is through oxygen-independent activation of hypoxia inducible factor (HIF). Under normoxia, HIF-prolyl-4-hydroxylase (PH), which is Fe(II) and 2-oxoglutarate dependent, catalyses the hydroxylation of prolines which target HIF subunits for degradation. PH inhibitors can be used to allow for HIF activation in the absence of hypoxic conditions. Various molecules including pyridine-2, 4-dicarboxylate, 5-oxaproline, alpha alpha-dipyridyl, hydralazine have been utilised, but others broadly grouped as 2-oxoglutarate analogues or iron chelators have also been assessed [195-199].

As a transcription factor modulating a number of hypoxia response genes, HIF-1 α stabilisation will generate not only one, but a variety of angiogenic gene products. These range from VEGF, Ang-1 to erythropoietin, while preparing cells to deal with hypoxia inducing glycolysis [200]. Thus, activating this angiogenic master switch is akin to the external delivery of several angiogenic factors, as discussed earlier.

In vitro, PH inhibitors on BMSCs have been shown to increase VEGF expression and promote capillary sprouting [201] *In vivo*, promising results have also been observed in terms of increased vascularisation and bone formation, improved neovascularisation in oxygen-induced retinopathy in a mouse model, protection from ischemia cerebral lesions in a gerbil model, induction of ectopic angiogenesis in zebrafish and enhanced wound healing in diabetic mice [89, 201-204]. Furthermore, this approach has been evaluated clinically for oral treatment of anaemia, to increase haemoglobin, but was not able to significantly increase endogenous erythropoietin and VEGF [205, 206]. PHs are a isoenzyme family, of which some members are also essential for thermostability of intracellular collagen triple helices and thus control collagen secretion [207]. Concerns might arise that a general PH inhibitor impairs normal ECM deposition. Therefore, selectivity or preference of PH-inhibitors for HIF-PH or collagen PH in terms of dissociation constants for these iso-enzymes has to be considered, as well as the differential requirement of molecular oxygen of these enzymes [208, 209]. However, lack of collagen deposition and thus impaired wound healing has not been an issue so far in preclinical and clinical trials. On the contrary, an antifibrotic effect exerted by a PH inhibitor that is a so-called dirty tool might add additional benefit to the angiogenic feature [89, 195, 210]. Importantly, compounds such as hydralazine and ciclopirox were originally developed and approved for different clinical indications (arterial hypertension and skin mycosis, respectively) and have been on the market since 1953 and 1997, respectively. Interestingly, the antifungal drug ciclopirox was first shown to act as PH

inhibitor in 2002 [211] and to be antiangiogenic, and similar predictions were made towards other PH inhibitors suggesting them as anti-cancer drugs. Of note this work was done in HUVEC monocultures in Matrigel angiogenesis assays and chick aortic arch ring sprouting assay. However, in context with mesenchymal cells and unwounded or wounded tissue it became clear that angiogenic HIF1- α effects of PH inhibitors, even as so-called dirty tool, prevail. Shortly after the publication by Clement, and the mesenchymal endothelial crosstalk leading to angiogenesis was later demonstrated in greater detail in microfluidics systems [210, 212] and diabetic wounds in experimental animal models [213, 214]. The change viewpoints on PH inhibitors over time in the literature over time shows the importance of considering and implementing cellular cross-talk in angiogenic assays in vitro, as ECs are not the greatest producers of angiogenic factors, but rather the recipients of signals through them. This might explain some of the controversial findings on angiogenic factors within in vitro settings, but also in comparison of in vitro data with those obtained in animal models. From the pharmacological point of view, PH inhibitors are currently the group of small molecules that progressed farthest and that have been employed in clinical trials.

2.3 Delivery of genes

Issues associated with the localisation and half-life of growth factors and cost associated with production of human recombinant proteins have fuelled interest into delivering genes rather than proteins. Genetic transfer, similarly to sustained delivery through an engineered construct, can facilitate overexpression of a molecule of interest in a localised manner for a longer period. Gene delivery for pro-angiogenic purposes has been performed using viral (adenoviruses, retroviruses) and non-viral vectors (plasmids, liposomes, oligonucleotides, peptides) [215]. Furthermore, scaffolds have also been used as carriers to try and promote localisation of delivery vehicles and sustained transfer [216]. In most cases, the targeted

genes encode the therapeutic molecules that were used in peptide form. *In vitro*, VEGF overexpression has been promoted in EPCs, through adenoviral transfer, and has increased cell proliferation, adhesion and incorporation into tube-forming HUVEC monolayers [217]. Similarly, delivery of a VEGF gene to HUVEC has also been performed alongside Ang1, which is known to interact on EC and SMCs, and promoted cell migration [76]. Co-delivery of VEGF and eNOS to SMCs through plasmids also promoted capillary tube formation in a fibrin matrix [218]. Similar results have been observed through FGF2 overexpression in HUVEC [75]. Another recurrent target via genetic manipulation is the NO signalling pathway. Non-viral delivery of eNOS to BMSCs promoted endothelial differentiation through VEGF /PDGFR and FGF2 / FGF2R signalling pathways, resulting in upregulation of CD31, VEGF and FGF2 [219]. Transfer of iNOS into EC can also inhibit apoptosis [220]. Contradictorily, NOS delivered to SMCs and EC has shown reduced proliferation and tube formation *in vitro* [221] and eNOS transfected into EPCS from patients with CAD impaired tube formation in Matrigel but did promote migration and proliferation alongside VEGF stimulation [222]. As discussed above, these partially contradictory results might largely reflect the lack of a mesenchymal cellular element in the *in vitro* assays and therefore assays considering including such an element might lead to more consistent data across the board.

Although some *in vitro* studies have been performed to assess for safety of gene delivery, interestingly, the majority of the work has been performed preclinically and clinically.

Preclinical delivery has focussed on several of the same therapeutic targets in mice, rat, rabbit, porcine and canine models of wound healing, myocardial infarction and hindlimb ischemia. Intramuscular injections of VEGF gene in rodent and rabbit models have shown increased vessel density and blood perfusion [223]. Plasmids have also been used to deliver VEGF using scaffold carriers such as PLGA nanospheres [224], which successfully transferred the gene into the skeletal muscle of mice ischemic limbs, and porous collagen scaffolds, which

promoted neo-vessel formation in the surrounding area of the construct in a subcutaneous model [225]. Similarly, viral vectors have also been applied in combination with other materials such as macro-porous PEG hydrogels, which facilitated cell infiltration *in vivo* and consequently improved vascularisation in mice [226]. Additionally, injectable fibrin matrices have also been shown to facilitate intramuscular delivery of the VEGF gene to ischemic limbs, where a dose-dependent effect was observed, with lower doses leading to formation of aberrant structures [227]. Interestingly, in this study, sustained delivery was achieved by incorporating aprotinin into the scaffold to inhibit degradation. Similar issues have been reported in the literature regarding inducing overexpression of VEGF. Upregulated expression of VEGF in an unregulated manner has been associated with haemangioma formation and fatal vascular leakage and it has been proposed that these effects are dose-dependent [228-230]. Several studies have highlighted the potential for exogenous VEGF supplementation or overexpression for excessive cell proliferation, hyperplasia, vessel leakage and malformation [229, 231-234] as these approaches typically result in supraphysiological dosages of VEGF.

Another study investigating the transduction of mouse and human VEGF in myoblasts proposed that angioma formation is not only associated with dose but with species-dependent VEGF receptor activation, since high doses of mouse VEGF induced angiomas in mice while human VEGF led to normal capillary formation [235]. In addition to VEGF, the transfer of several other genes has shown promising results *in vivo*. In hindlimb ischemic models, SFD-1 α , for instance, carried by a plasmid through an intramuscular injection, has been able to induce significant blood flow recovery, expression of CD31 and mobilisation of EPCs; effects mediated by VEGF regulation, eNOS and Akt signalling pathways [236]. Using a similar model, intramuscular delivery of secretoneurin also contributed to reduced necrosis, upregulation of FGF2 and PDGF and vessel maturation, assessed by the presence of CD31

and α -SMA. It was observed that these results were highly dependent on NO signalling, since secretoneurin induces activation of eNOS [237]. Regarding myocardial infarction and heart ischemia, viral delivery of IGF-1 has shown improved remodelling mediated by activation of α 5 integrins [238]; transfection of HGF can also promote functional recovery after intramuscular delivery [239]; Ang1 viral delivery also facilitated regression of hypertrophic tissue, though it did not affect cardiac function [240]. Remarkably, both HGF and Ang1 genes have been delivered using ultrasound mediated microbubble disruption. With HGF, naked plasmids were applied to the left ventricle and reduced scar tissue and improved vessel density were observed after infarction [241]. Ang1 gene delivery was successfully performed using bubbles with ICAM-1 antibodies in the surface to target specifically for overexpressing ICAM-1 EC in ischemic regions [242]. Analogous ultrasound mediated delivery has also been utilised with the VEGF [243, 244] and Akt genes. Akt gene delivery was achieved resorting to cationic microbubbles with enhanced DNA binding capacity. This led to reduced infarct size and apoptosis while increasing vessel density and function, mediated by survivin and phospho-BAD which are targeted by phosphorylated Akt and suppress apoptosis and enhance angiogenesis [245]. Acidic FGF (aFGF), although less utilised in the protein form and not extensively tested *in vitro*, has also been used for therapeutic recovery of myocardial infarction through viral vectors [246]. However, unlike most preclinical studies, the delivery was performed two weeks before induction of myocardial infarction as a preventive treatment. Although the time lapse between disease induction and therapeutic delivery is highly variable in the investigation of pro-angiogenic molecules, this is an unlikely scenario that hardly mimics the clinical setting, making results from such studies difficult to translate.

Dual gene delivery has also been achieved. For instance, delivery of polyplexes encoding for VEGF and FGF2 in electro-spun mats improved cell infiltration and blood vessel formation in a subcutaneous model. However, there was no significant advantages *in vivo* in utilising

two genes over their individual use [247]. However, co-delivery of VEGF and HGF genes improved blood perfusion in a mouse hindlimb ischemic model, with dual delivery having presented improvement over individual delivery of either growth factor [74]. Furthermore, transduction with PDGF-BB and VEGF genes proved that the relative amount of each growth factor is key in inducing normal angiogenesis more than the absolute level of VEGF [248].

In contrast to previous sections where the clinical data are somehow limited, there are extensive studies on angiogenic gene delivery in humans (**Table 2**). Several phase 1 and 2 clinical studies have assessed mostly plasmid and viral delivery of genes including VEGF, HGF, FGF1, FGF-4, with the majority focussing on VEGF. There seems to be a consensus in the literature regarding the safety of gene delivery in humans, with no major complications or permanent side effects arising. In terms of treatments for CAD, different VEGF splice variants have been utilised. It has been proposed that VEGF gene transfer therapeutic effect derives from improved EPCs recruitment and increased expression of markers such as VEGFR2, CD34, $\alpha 5\beta 3$ integrin and E-selectin [249]. Intramyocardial injection of adenovirus containing VEGF₁₂₁ has been reported to improve angina symptoms and exercise time however, without benefiting blood perfusion to ischemic areas [250-252]. VEGF₁₆₅ has been the most used in plasmid-mediated delivery, through intramyocardial or percutaneous route and results have been mixed. While several trials report improvements in angina and / or blood perfusion and collateral vessel formation [253-255], others failed to report statistically significant improvements [252, 256]. Furthermore, adenoviral delivery of FGF-4 has also failed to lead to significant improvements in patients with CAD. As for CLI, most investigations have also focussed on VEGF₁₆₅ delivery through intramuscular injection into affected limb. Adenoviral transfer of VEGF₁₂₁ has failed to produce significant improvements [257] whilst the use of plasmids with VEGF₁₆₅ have shown mixed results with regards to ulcer healing, rest pain, walking time, collateral vessel formation and limb survival [258-260].

Other less studied genes include FGF1 and HGF. Intramuscular plasmid mediated delivery of the FGF1 gene has shown improvements in ulcer healing and limb survival in a phase 1 study [261], whilst a phase 3 trial has failed to improve limb survival [262]. Overexpression of HGF has also shown decreased rest pain and increased walking time [263-265]. Furthermore, adenoviral delivery of hypoxia inducible factor 1 alpha (HIF-1 α) has failed to show therapeutic effects in ischemic limbs, although it appeared to lead to a trend in improved ulcer healing, there was also a high amputation rate in the treatment group [266].

Delivery of genes presents advantages over growth factors as it allows for a continued therapeutic effect. However, despite extensively assessments in both preclinical and clinical settings, a clear benefit in delivering a particular gene has not evolved yet, and further investigations are required to ensure safety of the transferred genes and vehicles.

2.4 Delivery of growth factors and genes for therapeutic lymphangiogenesis

Although pharmacologic therapies for lymphangiogenesis are still very much in their infancy when compared with angiogenesis, several targets of interest have been identified [19]. VEGF-C and VEGF-D are known to act on lymphatic EC through VEGFR-3 activation. In fact, VEGFR-3 and transcription factor prospero homeobox protein 1 (Prox-1) are essential for embryonic lymphatic development [267, 268]. Irreversible lymphatic phenotype commitment is characterised by simultaneous expression of not only VEGFR-3 and Prox-1 but also lymphatic vessel endothelial hyaluronan receptor (LYVE-1) and secondary lymphoid organ chemokine (SLC) [19]. *In vitro*, it has been shown that VEGF-C and VEGF-D play an important role in lymphatic EC proliferation and organisation. Furthermore, IGF-1 and IGF-2 have been reported to stimulate proliferation of primary lymphatic EC *in vitro* [269]. Most efforts have been focussed on *in vivo* testing using various models with particular emphasis on growth factor and gene delivery. Injections of VEGF-C have been shown to improve

lymphatic vessel formation and function in a rabbit ear model [270]. Delivery of VEGF-C has also been performed using carriers, such as fibrin, which has led to improved lymphangiogenesis in skin wound healing in a diabetic model [271]. IGF-1, IGF-2 and HGF have also shown increased lymphatic vessel density in mouse cornea assay model [269, 272]. As for gene delivery, VEGF-C transduction improved lymphatic network repair in an epigastric mouse model [273], while VEGFR-3 transfer enhanced lymphatic drainage in a lymphoedema skin mice model without collateral effects on the vascular system [274]. Interestingly, VEGF-C localised transduction has also led to improved lymph drainage in an inflammatory arthritis mice model [275]. Transfection with VEGF-C was also shown to improve lymphatic function in rabbit ear and mouse tail lymphoedema models [276]. Additionally, HGF gene transfer decreased lymphoedema thickness in a rat tail model [277]. Although particular interest has developed around VEGF-C, clear advantages for its use are still unclear, given that it has also been associated with lymphatic hyperplasia and side effects with regards to blood vessel growth and leakiness [278, 279]. Considering the limited data available for *in vitro* and *in vivo* studies, it is no surprise that these approaches are yet to be translated to a clinical setting.

2.5 Physical stimuli for secretion of angiogenic factors

Among the strategies to promote angiogenesis, external physical stimulation gained interest due to its non-invasiveness, the ease of use and promising preclinical data. Various types of stimuli have been tested with the rationale that localised physical stimulation can influence the angiogenic secretome, therefore becoming an important alternative to delivery of therapeutic molecules.

Ultrasound is clinically used for therapeutic applications, including tumour ablation, thrombolysis, bone regeneration, and facilitated drug delivery [9]. Therapeutic angiogenic

effects of low-intensity ultrasound are hypothesised to stimulate secretion of angiogenic factors, such as VEGF and FGF2 [280]. Ultrasound irradiation significantly improved limb perfusion and increased blood vessels formation and cell proliferation in a rat model of hindlimb ischemia. Moreover VEGF mRNA was significantly higher in moderate ischemia [281]. It has also been demonstrated that exposure of EC to safe levels of ultrasound irradiation causes a down-regulation and redistribution of the VEGFR-2, increased proliferation and enhanced migration and sprouting in 3D culture [282].

The effects of low-intensity pulsed ultrasounds (LIPUS) were also investigated in a porcine model of chronic myocardial ischemia. LIPUS therapy normalized global and regional myocardial function *in vivo*, increased capillary density and regional myocardial blood flow of the chronically ischemic region without any adverse effects, and enhanced protein levels of VEGF, eNOS, and FGF2 in the ischemic myocardium without affecting those in the non-ischemic myocardium [283].

Among non-invasive techniques to promote angiogenesis, low-level laser therapy (LLLT) have shown promising results in skin wound healing and ischemic animal models.

Illumination with both blue and red light emitting diodes (LEDs) light can enhance the wound healing process in a skin flap model in rats by improving angiogenesis. Blue laser irradiation improves local tissue perfusion in a controlled manner by stimulating NO release from NO-haemoglobin complexes [284]. It has been shown that NO stimulates angiogenesis via stimulation of VEGF expression.

Another study showed that the LLLT enhanced the skin wound-healing effect of human ADSCs by enhancing survival of the ADSCs and stimulating secretion of growth factors in the wound bed in mice. The light-treated group was evaluated to exhibit rapid wound closure, a higher histological score and increased numbers of hair follicles and sebaceous glands in wound bed compared with the non-treated ADSCs [285]. Similarly LLLT treatment of

ADSCs spheroids enhanced the functional recovery of the ischemic hind limb area in mice with respect to the regeneration of muscle tissue [286].

Pulsed electromagnetic fields (PEMF) have shown to enhance acute hindlimb ischemia-related perfusion and angiogenesis, associated with up-regulating FGF-2 expression and activating the ERK1/2 pathway in diabetic rats [287]. PEMF therapy improved postnatal neovascularization using murine model of hindlimb ischemia. PEMF therapy enhanced ischemia-mediated angiogenesis, through up-regulating VEGF expression and activating the PI3K-Akt-eNOS pathway [288]. PEMF therapy was examined also in a rat myocardial infarction model. PEMF treatment prevented cardiomyocytes against hypoxia-induced apoptosis and preserves cardiac systolic function. Moreover PEMF induced angiogenesis and vasculogenesis through activating VEGF-eNOS system and promoting EPCs mobilized to the ischemic myocardium [289].

Currently, an ongoing clinical trial aims to induce cardiac functional regeneration in patients with ischemic CAD by combining the ability of extracorporeal shock waves to increase growth factor secretion and induce homing of progenitor cell to the target tissue for intracoronary cell therapy (source: www.clinicaltrialsregister.eu).

3 Cells as drugs

The use of single or combinations of therapeutic molecules has produced promising outcomes *in vitro*, preclinically, and clinically. However, in view of the various cell types involved in angiogenesis and their continuous molecular cross-talk, this appears as a quite limited approach in comparison to the plethora of molecules comprising the entire cellular secretomes involved, and potentially available. By adding a relevant cell source to an ischemic tissue site, a modulating secretome will be introduced, influencing cellular responses in the immediate vicinity [290-292]. This therapeutic mode can be investigated by delivering conditioned media, cells (preconditioned or not), cell-derived vesicles (e.g. exosomes) or cells overexpressing a molecule of interest to the site of interest [293-295]. Relevant cells for angiogenic strategies not only comprise EC and EPCs but also BMSCs, which have been hypothesised to function as pericytes, ADSCs and BM-MNCs [54, 55, 296, 297]. An important aspect in this regard is the presence of external microenvironmental factors that steer cell behaviour and, consequently, their secretome. Therefore, different modulators, such as hypoxia, mechanical stimulation and electromagnetic field stimulation can be used to pre-condition cells for subsequent *in vivo* and clinical use. As with pharmacological agents, the same challenges arise, namely that of generating locally efficacious levels of active substances. Therefore, local retention of cells and their secretome need to be tackled, either by preventing the emigration of cells from the site of action into surrounding tissue, or simply retrogradely leaking out of puncture canals. To overcome this, materials such as collagen and fibrin, have also been utilised to ensure not only confinement of cells but also to promote their survival by providing initial attachment support structures [298-300]. In this section, we will analyse *in vitro*, preclinical and clinical studies that have investigated the delivery of untreated and pre-conditioned cells, and cell secretome delivery.

3.1 Delivery of naïve cells

Cell delivery is an attractive approach for pro-angiogenic therapies, where a range of paracrine factors is secreted locally in response to host tissue signals. Similarly, locally administered pharmacological agents, cells have been delivered topically in animal models of hindlimb ischemia, myocardial infarction, stroke, and skin wound healing. The majority of cell based therapeutic approaches for angiogenesis tested clinically have been focused on peripheral arterial disease, though some studies have also investigated coronary artery disease (**Table 3**). The preferred cell types investigated in these models include progenitor cells, EPCs, BM-MNCs, MSCs or ADSCs [301].

3.1.1 Endothelial progenitor cells (EPCs)

Since EPCs directly contribute to revascularisation by differentiating into EC, they are a promising source, though their extraction procedure is more laborious than other stem cell sources. They can be harvested from human umbilical cord blood, adult bone marrow, peripheral blood and human foetal liver [302, 303]. The mechanism of action of EPCs in promoting angiogenesis occurs by homing and direct incorporation into the existing vasculature, facilitating the growth of new capillaries, and by paracrine effects, through the secretion of cytokines and other proangiogenic growth factors, thus stimulating resident EC to proliferate within the vascular wall [304, 305]. These cells express CD133, CD34 and VEGF receptor-2 (VEGFR-2), also called Flk-1 [306, 307]. They also produce survival factors for EC such as platelet endothelial cell adhesion molecule-1 (PECAM-1 or CD31), VE-cadherin, von Willebrand factor and eNOS and encourage endogenous EC to migrate and proliferate [308-310]. Upon entry into the circulation, EPCs transform into differentiated mature EC by expressing CD144 (VE-cadherin) and von Willebrand factor, while losing CD133 and subsequently CD34 [308, 311].

Cultured and expanded EPCs demonstrated positive results when transplanted into ischemia murine models. Blood flow recovery and capillary density were noticeably improved and the rate of limb loss was significantly reduced after transplantation of human peripheral blood-derived EPCs [312-314]. These cells have also been transplanted in a bioactive nanofibrous scaffold, composed of collagen, polycaprolactone and bioactive glass nanoparticles, to full-thickness wound model in rats and significantly enhanced the formation of blood vessels by upregulating expression of HIF-1 α , VEGF, and stromal cell-derived factor 1 alpha (SDF-1 α) [315].

Some studies have translated the therapeutic potential of EPCs seen in animal models into human clinical trials using population of EPCs CD34+ or CD133+ enriched. In a phase 1/2 clinical trial, autologous CD34+ cells were injected into the severely ischemic leg of patients with atherosclerotic peripheral artery disease. CD34+ cell treated patients demonstrated significant recovery in the primary endpoints, including the efficacy score, toe brachial pressure index, pain score and total walking distance 12 weeks after cell transplantation [316]. Another pilot study assessed the efficacy and safety of autologous CD34+ cells injected intramuscularly in patients with moderate- or high-risk critical limb ischemia, verified a reduction in amputation rates without adverse events associated with the treatment at 6 and 12 months. However, toe brachial index, ankle-brachial index, pain and walking distance did not show significant differences [317]. The effect of autologous CD133+ cell implantation was also evaluated in a phase 1 trial in patients with Buerger's disease (1 patient), atherosclerosis (7 patients) or thromboembolic disorder (1 patient) [318]. The cell injection prevented leg amputation in seven of the nine patients and improved pain-free treadmill walking time and exercise capacity at 12 months.

3.1.2 Mononuclear cells (MNCs)

Mononuclear cells constitute mixed populations that can be derived from bone marrow, peripheral blood or umbilical cord and can contain lymphocytes, monocytes, MSCs or EPCs, depending on their origin. They are particularly attractive for cell therapy because they can be extracted in large numbers and be used in autologous applications without further expansion [319]. These cells can give rise to functional EPCs as well as secrete a broad spectrum of angiogenic factors (VEGF, FGF2 and Ang-1) or angiogenic cytokines (interleukin 1β and tumour necrosis factor α) [320].

The use of autologous BM-MNCs containing EPCs augmented neovascularisation and collateral vessel formation in a rabbit ischemic limb [305]. It was also reported the enhancement of angiogenesis by direct transplantation of BM-MNCs in mini swine coronary artery ligation ischemic area [321]. A study revealed that nitric oxide synthase, which is induced by VEGF, contributes to the angiogenesis that follows BM-MNCs transplantation in a mouse model of cerebral hypoperfusion [322]. Furthermore, injection of autologous BM-MNCs to ungraftable areas of the myocardium (no graftable coronary arteries were available, although the target myocardium remained viable) led to increased coronary perfusion in 3 out of 5 patients [323]. During coronary artery bypass grafting (CABG), the mononuclear cell fraction was prepared with a COBE Spectra Apheresis System and injected (0.1 mL; 5×10^7 to 1×10^8 cells/point) into the area of ischemic myocardium where was no graft.

UC-MNCs have been evaluated in combination with a hyaluronic acid hydrogel in a porcine myocardial infarction model. They showed significantly decreased scar area and promoted vessel formation in the infarcted region [324].

MNCs have also been tested clinically. In a trial comparing BM-MNCs and PB-MNCs mobilized by granulocyte colony-stimulating factor (G-CSF) in patients with Buerger's disease, PB-MNC patients showed significantly higher ankle-brachial index and reduced rest

pain than BM-MNC after 12 weeks [325, 326]. However, no difference was found in TcPO₂, ulcer healing rate and amputation frequency. It has been suggested that the successful results obtained with PB-MNCs are related to the secretion of angiogenic cytokines VEGF and HGF [327, 328]. Further clinical studies have suggested that the therapeutic outcome of BM-MNCs closely correlates with the absolute number of cells injected, which can involve multiple injections [329, 330]. A phase 2 clinical trial showed that intra-arterial injections of BM-MNCs appear to improve limb perfusion as measured by ankle-brachial index, reduction of rest pain and improved ulcer healing in patients with critical limb ischemia [329]. The beneficial effects of BM-MNCs injections have also been observed in diabetic patients with limb ischemia [28, 331].

3.1.3 Bone marrow (BMSCs) and adipose derived stem cells (ADSCs)

BMSCs and ADSCs also constitute relevant sources for angiogenic cell therapies due to their ease of extraction, accessibility in large numbers and endothelial differentiation potential. The therapeutic effect of BMSCs in angiogenesis includes the paracrine effects associated with the secretion of various cytokines like VEGF, IL-6, platelet-derived growth factor, FGF, HGF and SDF-1, and the stimulation of EC to migrate, differentiate and proliferate [332-334]. Direct injections of BMSCs into infarcted myocardium and ischemic thigh muscle have shown improved blood vessel formation in rat myocardial infarction and hindlimb ischemia models [335, 336]. In the latter study, BMSCs, isolated utilising the adherence method and expanded until passages 4-5, were compared to BM-MNCs, extracted with a Ficoll density gradient centrifugation. Both BMSCs and BM-MNCs induced angiogenesis, but BMSCs induced higher capillary density and stronger perfusion than BM-MNCs. The transplanted BMSCs highly differentiated into EC compared with transplanted BM-MNCs (when looking into the number of PKH26 / von Willebrand factor -double-positive cells) and only BMSCs

differentiated into vascular muscle cells in ischemic tissue. Additionally, *in vitro* studies showed that BMSCs secreted larger amounts of angiogenic factors compared with the amounts secreted by BM-MNCs and, when incubated under serum-free and hypoxic conditions, the majority of cultured BM-MNCs revealed cytoplasmic shrinkage, disintegration into small vesicles, and membrane blebbing. In contrast, these morphological changes were rarely observed in BMSCs. Furthermore, BMSCs have also been shown to promote vascularisation when injected intradermally in a mouse splinted skin wound model [337]. BMSCs were not found in the vascular structures, but in close proximity. This led the researchers to evaluate the paracrine effect of these cells in angiogenesis and found that BMSCs-conditioned medium promoted endothelial tube formation and that BMSCs expressed high levels of VEGF and Ang-1 but not Ang-2, suggesting that BMSCs engrafted in the wound released pro-angiogenic factors, which were partially responsible for MSC-mediated enhanced angiogenesis.

Different biomaterials have been employed to ensure local retention of cells at the ischemic site. Specifically with BMSCs, a collagen scaffold and a temperature responsive hydrogel improved healing, neovascularisation and MMP-9 expression in a rat full thickness wound model and in a mouse diabetic ulcer model [338, 339]. The promising data seen with BMSCs *in vitro* and *in vivo* has prompted clinical studies.

BMSCs have been shown to reduce rest pain and improve ulcer healing after intramuscular injection in patients with critical limb ischemia [340]. Patients that have received BMSCs through intracoronary injections after myocardial infarction have shown reduced infarct size and improved left ventricular ejection fraction [341-343], however, such therapeutic outcome has not been achieved in other studies focussing on cardiac function [344-346]. BMSCs have also been assessed as therapeutic modality in ischemic stroke. In a study of BMSC transplantation for ischemic stroke [347], patients were randomly divided into experimental

(intravenous BMSC infusion) and control groups (no treatment). The study found that BMSCs markedly improved the modified Rankin score and Barthel index, a scale that measures the degree of independence of stroke victims when performing daily activities. No adverse effects, such as venous thromboembolism, abnormal cell proliferation, systemic cancer, systemic infection, or neurological decline, were identified after BMSC transplantation [348, 349]. These findings provide suggest safety and function improvement of and after BMSC transplantation in ischemic stroke.

Other studies examined the safety and effectiveness of autologous and allogeneic BMSC transplantation, explored methods to shorten BMSCs cultured times, sought to determine the best time window for the administration of cells stroke after the stroke, and assessed therapeutic effects of various doses, and protocols aimed at additional improvements [350-353].

ADSCs can also secrete multiple angiogenic growth factors or cytokines such as VEGF and HGF that activate migration and proliferation of EC for new vessel formation [354, 355]. Research shows that ADSCs use their paracrine potential for induction of angiogenesis and support collateral vessel remodelling [356]. ADSCs have been found to improve cardiac function, attenuate anterior wall thinning, reduce fibrosis and increase peri-infarct density of both arterioles and nerve sprouts in a rat myocardial infarction model [357]. In hindlimb ischemic mouse models, ADSCs injected intravenously restored blood flow to the affected limb [138, 358, 359]. The implantation of ADSCs induced angiogenesis not through endothelial differentiation of these cells, but by chemokines such as SDF-1. Additionally, ADSCs in a fibrin scaffold improved arteriole density and heart function in infarcted rat hearts [360].

In a clinical phase 1/2 study, intracoronary infusion of ADSCs was performed in patients with acute anterior wall myocardial infarction [361]. At 6 months follow up, cardiac

magnetic resonance imaging showed a trend towards an improved left ventricular ejection fraction as compared to the placebo group, accompanied by a significant reduction in the perfusion defect and infarct size. Another clinical trial regarding transendocardial injection of ADSCs in patients with refractory ischemic cardiomyopathy was also performed. Injection of ADSCs preserved left ventricular mass and the regional wall motion and improved myocardial perfusion [362]. Moreover, a phase 1 study used intramuscular injection of autologous ADSCs to treat patients with critical limb ischemia. The ADSC injection resulted in improvement of transcutaneous oxygen pressure (TcPO₂), pain free walking time and ulcer size [363].

3.1.4 Pericytes and blood-derived angiogenic cells

Pericytes are specialised cells that can be found wrapped around capillaries and are crucial for vessel maturation and proper function [364, 365]. Although there are no fully pericyte-specific markers, a PDGFR- β and/or α -SMA, desmin, PDGFR- β , aminopeptidase N and high molecular weight melanoma antigen (known as NG2 in mice) have been proposed as pericyte signature in combination with their perivascular location [366, 367].

The origin of pericytes is controversial [366]. Some research groups have proposed that pericytes are a differentiated subpopulation of MSCs [296, 368], others have found monocyte-derived cells to express pericyte-markers and to attain a typical location around blood vessels [297, 369].

The intramyocardial transplantation of mesenchymal pericytes, derived from skeletal muscle, into a myocardial infarct has shown reduced fibrosis and improved cardiac function in mice [370]. Simultaneously, pericytes, purified from the saphenous vein, supported cardiac function and modulated cardiac wall thinning, while also enhancing angiogenesis in the peri-infarct and infarct area by reducing endothelial cell apoptosis and supporting endothelial cell

proliferation [371]. Blood-derived pericyte like cells have been described and as such can be derived from MNCs derived from buffy coats [297]. With a specific culture protocol (exposure of buffy coats to fibronectin coating and application of pulsed macromolecular crowding) blood-derived angiogenic cells (BDACs) with pericyte characteristics have been produced that in Matrigel assays tend to cluster at branch points of HUVEC tubular networks and migrate along endothelial tubes in this system. Moreover, the injection of BDACs in the calf muscle of mice with hind limb ischemia reduced the inflammation, fibrosis and adipose replacement in the affected muscle tissue.

3.2 Delivery of pre-conditioned cells

Delivery of naïve cells (cells that have not been exposed to any form of pre-conditioning or external stimuli during *in vitro* culture and expansion) are an appealing approach due to simplicity and low regulatory thresholds, but they can present issues related with low cell survival, inadequate secretion profile and differentiation towards other lineages which are not relevant to pro-angiogenic applications, therefore compromising functional recovery [372, 373]. Microenvironmental pre-conditioning *in vitro* can help with overcoming some of these issues as means to modulate cell phenotype and secretion pre-implantation.

3.2.1 Biochemical pre-conditioning

One of the most common stimuli assessed is hypoxia, given its prominent role of in initiating angiogenesis. Adult tissues experience oxygen tensions that are considerably different from the inhaled ambient oxygen tensions of 21%. Oxygen concentrations between 2%–9% are considered to constitute physiologic normoxia [374]. However, conventional *in vitro* conditions expose the cells to a non-physiological hyperoxic environment. Indeed, low oxygen tensions maintain undifferentiated states of embryonic, hematopoietic, mesenchymal,

and neural stem cell phenotypes and also influence proliferation and cell-fate commitment [45]. Therefore the *in vitro* hypoxic preconditioning of stem cells can increase their motility and therapeutic potential prior to transplantation [375]. Hypoxia is known to stimulate VEGF expression in EC culture [376] but pro-angiogenic effects have also been reported on other cell sources. Hypoxic pre-conditioning (anoxia) of peripheral blood MNCs improved their differentiation towards EPCs, as shown by increased expression of CD31, VEGFR-2 and VEGF. Furthermore, supplementation with VEGF under hypoxia also promoted the migration of newly differentiated EPCs and improved blood flow in an ischemic hindlimb rat model [57]. Furthermore, 2% oxygen tension also contributed for improved resistance to oxidative stress and cell viability, when transplanted into a rabbit hindlimb ischemia model, and induced new vessel formation and improved limb blood flow [377]. Hypoxic pre-conditioning of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) increased levels of pro-angiogenic genes, such as COX-2, VEGF, Tie-2, and TGF- β 1, when compared to cells in normoxic conditions. Moreover the injection of hypoxic (1% oxygen tension) UC-MSCs in a mouse hindlimb ischemia models triggered the upregulation of gene such as Ang-1, COX-1, PIGF, and MCP-1 and reduced the expression of proinflammatory genes such as IL-1 and IL-20 [378].

Furthermore, hypoxic pre-conditioning (0.5% oxygen tension) of BMSCs upregulated pro-survival and pro-regenerative genes and it has also been associated with improved vascular endothelial differentiation, leading to a better functional recovery after ischemic stroke in rats [379]. Additionally, hypoxia (2% oxygen tension) can enhance release of growth factors which, through promotion of angiogenesis, provide an effective strategy for treatment of osteonecrosis [380]. It has also been seen that pre-conditioned UC-MSCs (1% oxygen tension) may promote angiogenesis better than untreated UC-MSCs, as they secrete higher amounts of VEGF and enhance the proliferation and migration capacity of EC [381]. Hypoxic pre-

conditioning of BMSCs (0.5% oxygen tension) increased expression of HIF-1 α , VEGF, VEGFR2 and Ang1 *in vitro* and increased cell survival after implantation in a rat myocardial infarction model. Furthermore, hypoxic pre-conditioning (2% oxygen tension) promoted endothelial differentiation *in vivo*, evidenced by the presence of CD31, and reduced infarct area [382]. New capillary vessel formation has also been observed in BMSCs grown under hypoxia implanted in a rat cornea pocket model [383].

Hypoxic pre-conditioning (1.5% oxygen tension) of a tissue-engineered oral mucosa improved its capacity to support EC migration and proliferation. Engineered mucosa constructs produced soluble mediators that are upregulated under hypoxia including VEGF, PlGF, tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1, TIMP-2), MMP-2, and MMP-9 [384].

Although hypoxia has shown promising results when used to pre-condition EC, EPCs UC-MSCs and BMSCs, the oxygen tensions used vary considerably, even when the same cell source is utilised, highlighting the need for optimisation studies and protocol standardisation.

3.2.2 Physical pre-conditioning

3.2.2.1 Mechanical stimulation

In blood vessels, EC are exposed to various mechanical stimuli internally and externally which regulate angiogenesis [385, 386]. Mechanical forces regulate capillary morphogenesis and modulate EC phenotype, cytoskeletal reorganisation and vascular remodelling through shear stress from blood flow cyclic strain and from circumferential vessel deformation [387, 388]. Cyclic strain also inhibits EC apoptosis, increases EC proliferation and enhances MMPs and membrane-type MMPs expression suggesting it modulates vessel formation, because survival, alignment, and proliferation of EC and degradation of basement membrane are essential for neo-vessel formation. The use of cyclic stretch in HUVEC seeded in a collagen

gel significantly increased formation of invasive structures *in vitro* [58]. Combining stretching with growth factor supplementation, demonstrated an additive effect when higher strains were combined with FGF2. Interestingly, VEGF was also tested at the same concentration and did not show an increase comparable to FGF2. However, when VEGF concentration was reduced alongside cyclic stretching, there was a significant increase of invasive sprouts in the gel over the static, VEGF supplemented group, demonstrating a synergistic effect between the mechanical forces and growth factor activity. Furthermore, mechanical stimulation of BMSCs enhanced tube formation in a three-dimensional matrix by upregulating the pro-angiogenic MMP-2, which is involved in early angiogenic events associated with ECM remodelling and EC migration, particularly through the exposure of a cryptic epitope of collagen IV or cleavage of growth factors, such as pro-TGF- β or VEGF. [389].

Transplantation of mechanically stimulated muscle-derived stem cells (MDSCs) into mice with acute myocardial infarction showed improved cardiac contractility, increased numbers of host CD31⁺ cells, and decreased fibrosis, in the peri-infarct region, compared to the hearts treated with non-stimulated MDSCs [390]. Mechanical strain prevented apoptosis and increased the adhesive ability of dermal fibroblasts *in vitro*, conferring a survival advantage *in vivo* after transplantation into full-thickness wounds of diabetic mice. Cyclic stretch stimulated cellular survival mediated by the activation of extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs) and the Akt. The stretched fibroblasts also showed increased expression of VEGF and stromal cell-derived factor-1 α (SDF-1 α) [391], which would support local angiogenesis.

3.2.2.2 Electromagnetic stimulation

Electromagnetic field stimulation (EMFs) and pulsed electromagnetic field (PEMFs) pre-conditioning promote angiogenesis. EMF facilitates EC proliferation and formation of sprout-like structures *in vitro* in a 2D scratch assay [392]. PEMF increases EC proliferation and tube formation *in vitro* in fibrin gels. Moreover, the addition of conditioned media from PEMF-treated HUVEC to both fibroblasts and HUVEC cultures increased proliferation and migration, even though when applied directly to fibroblasts, PEMF had not induced any changes. The authors proposed that the pro-angiogenic effects were related with increased FGF2 secretion [393]. Another study demonstrated that extremely low frequency (ELF) EMFs increased HUVEC proliferation and tube formation in Matrigel system by acting on VEGF transduction pathways. In particular after EMF exposure, there was an increase in phosphorylation alongside expression of VEGFR2 [394]. Similar reports have shown that PEMF inhibited the process of hypoxia-induced apoptosis and augmented tube formation, migration and proliferative capacities of HUVEC acting on the Akt-eNOS-VEGF pathway [67, 395].

PEMFs have also been tested preclinically, though not many studies are available. Wound closure was accelerated in normal and diabetic mice splinted wound models after PEMFs were applied [396]. The use of PEMFs alongside ultrasound treatment has also been shown to improve blood perfusion, capillary density and decreased apoptosis in rats with hindlimb ischemia [397].

Preclinically and clinically, EMF is typically applied directly to the site of interest to stimulate local cell populations, its use as a pre-conditioning tool is yet to be fully explored. It has been proposed that PEMF act by mediating activity of voltage gated calcium channels, through stimulation of NO synthesis, facilitated by Ca^{2+} and calmodulin or through transient receptor potential channels (TRPs), similarly to other forms of mechanical stimulation [398,

399]. This explains some of the working mechanisms of PEMF and provides a rationale for exploring this technology further.

3.3 Delivery of genetically modified cells

Certain factors such as donors age, comorbidities and effects of *ex vivo* culture can affect cell potency, phenotype and consequently the secretion profile [400]. However, the efficacy can be improved by manipulating cellular paracrine activity by genetic manipulation to increase the expression of a molecule of interest. Pre-implantation genetic transfer has been explored in both permanently differentiated cells and stem cells. The most common approaches are based on viral gene delivery (retroviral, adenoviral and lentiviral) and are currently under evaluation for several clinical indications. Given its key role in initiating angiogenesis, VEGF is still a preferred target. Myoblasts transduced with VEGF were injected in a porcine myocardial infarction and implanted in mice ischemic limb models where they were shown to promote increased vessel density and blood perfusion [401, 402]. Keratinocytes overexpressing VEGF in a collagen / GAG material have also been utilised to accelerate wound healing through enhanced blood vessel formation, expression of CD31 and improved blood flow recovery [403]. Viral transfection of Id1 has been performed in HUVEC which were subsequently injected intramuscularly in a mouse ischemic hindlimb model. Id1 is a helix-loop-helix transcription factor that plays a key role in embryonic vascular development and is highly expressed in tumour vasculature. Its overexpression in HUVEC has led to improved limb salvage over unmodified HUVEC, through Ang1 regulation [404].

Although differentiated cells have been utilised, most of the efforts have focussed on delivery of modified stem or progenitor cells with particular emphasis on BMSCs. In BMSCs, VEGF transfer using biodegradable polymeric nanoparticles, improved capillary density and limb salvage in the mouse ischemic hindlimb [405]. Furthermore, adenoviral delivery of VEGF to BMSCs has shown increased capillary density, reduction of infarct size and presence of cardiomyocytic phenotype with implanted cells integrated in the vasculature following intramyocardial injection in rat infarction models [406-408]. Additional studies focussing on

myocardial infarction models have utilised retroviral delivery of protein Akt1, plasmid delivery of sonic hedgehog (Shh) and lentiviral delivery of LIM-homeobox transcription factor islet 1 (ISL-1) BMSCs. Akt1 has been associated with promotion of cell survival by acting through the phosphatidylinositide 3' -OH kinase (PI3K)/c-Akt kinase cascade. Injected Akt1-modified BMSCs were shown to reduce inflammation, myocyte hypertrophy, reduction of infarct size and improved cardiac function, although neo-vessel formation and blood flow recovery were not assessed [409]. Shh transfection into BMSCs was also shown to improve myocardial infarction recovery through improved cell survival post-injection mediated by protein kinase C (PKC) signalling, since upregulation of netrin-1 and iNOS were also observed, but also through subsequent upregulation of VEGF and angiopoietins [410]. ISL-1 overexpression in BMSCs has also been shown to improve cardiac function, decrease apoptosis and inflammation after intramyocardial injection in a rat model [411]. ISL-1 has an important role during cardiac development, is a marker for cardiac progenitors and is believed to promote vascularisation.

To a lesser extent, ADSCs have also been utilised. Overexpression of VEGF in ADSCs, following intramuscular delivery led to increased Ang1 secretion, improved neovascularisation and reperfusion in a hind limb ischemic model [412]. Transfection of Ang1 showed improved capillary density, infarction size reduction and enhanced ventricle function after intramyocardial injection in a rat infarction model [413]. It was proposed that Ang 1 protected cardiomyocytes from oxidative stress induced apoptosis, since, *in vitro*, Ang-1 overexpressing ADSCs were shown to promote proliferation and survival of cardiomyocytes after exposure to hydrogen peroxide.

Similarly to BMSCs and ADSCs, EPCs have also been a target of interest. EPCs overexpressing IGF-1 have shown increased capillary formation and cardiomyocyte proliferation and survival contributing to improved cardiac functional recovery in a rat

myocardial infarction model, confirming previous reports of antiapoptotic and proliferative activity of IGF-1 [414]. In ischemic hindlimb models, overexpression of VEGF and kallikrein in EPCs has also led to increased capillary density and blood flow [217, 415]. Expression of kallikrein has been associated with promotion of angiogenesis in skeletal muscle [416].

While there is extensive preclinical analysis available for genetically modified cells and clinical data regarding gene delivery, very little has been translated to the clinical setting in terms of genetically modified cells. Nevertheless, autologous EC and SMCs modified by transfer of angiogenic genes (VEGF₁₆₅, Ang-1, eNOS) are being evaluated in patients with peripheral arterial disease. Preliminary results suggest the administration is feasible and safe and has no apparent drug-related adverse events (NCT00390767; www.clinicaltrials.gov). A phase 2 study currently being performed is assessing the safety and efficacy of EPCs transfected with human endothelial nitric oxide synthase (eNOS) to restore functional tissue in regions that otherwise would form only scar (NCT00936819; www.clinicaltrials.gov). Another phase 2 trial is also evaluating EPCs transfected with eNOS. This study aims to enhance lung microvascular repair and regeneration in patients with severe symptomatic pulmonary arterial hypertension (NCT03001414; www.clinicaltrials.gov).

Genetic engineering can increase the potential of therapeutic cell delivery by facilitating overexpression of angiogenic genes or anti-apoptotic factors. However safe and efficient gene delivery has been challenging since transduction raises safety concerns such as immunogenicity, toxicity or mutagenesis [417], whereas the transfer efficiency of non-viral methods is still low [418]. Although overexpression of pro-angiogenic factors is relevant, current efforts are directed towards single gene transfer, which is likely to present similar issues to single growth factor delivery, particularly if VEGF or PDGF are used, given their association with formation of aberrant vascular structures and tumours. There is also a need for improvement of delivery strategies that improve cell survival. Several approaches were

focussing of transfer of anti-apoptotic or mitogenic factors. However, the preferred method of delivery of genetically modified cells is still the injection, which is associated with poor cell localisation and survival and relies on cells attaching to site of injury for *in situ* action. The use of scaffolds, for instance, which facilitates cell localisation, is more widespread for the delivery of naïve cells, than with genetically modified cells.

3.4 Delivery of cell secretome and cell-derived vesicles

As opposed to the local transfer of whole living cells, the local delivery of their secretome – either from conditioned media or cell-derived extracellular vesicle – is currently explored as a scalable and standardisable alternative. Conditioned media allow to evaluate the effects of a whole range of secreted soluble molecules, while exosomes not only carry proteins, lipids and nucleic acids, but also, as membrane derivatives, channels and receptors. Their cargo is not extensively characterised [295], but their receptor pattern will depend on the cell type they are derived from. For instance, UC-MSCs conditioned media promotes HUVEC migration, network and branch point formation in Matrigel [67, 419]. Conditioned medium has also been used to improve proliferation of stem cell sources [420]. BMSCs pre-treated with medium from healthy cardiomyocytes exposed to oxidative stress and high glucose, showed enhanced survival, proliferation, angiogenic ability and improved function in diabetic hearts [421]. Furthermore, the angiogenic effects of ADSCs and their conditioned media has been evaluated in a rodent hindlimb ischemia model. Even though ADSCs conditioned media was not as effective as injected ADSCs on restoring blood flow, it still led to neo-vessel formation in the ischemic hindlimbs. Analysis of these conditioned media revealed presence of TGF- β , VEGF, granulocyte colony stimulating factor (G-CSF), FGF2 and HGF [354]. Nonetheless, most approaches utilised *in vivo* based on the cell secretome are focussed on cell-derived vesicles or genetically modified cells that overexpress a factor of interest. Cell

secretome can also be applied using injectable carriers to further prolong the half-life of its factors. ADSC secretome delivered together with an injectable nanocomposite hydrogel showed increased capillary density, reduced scar area and improved cardiac function after myocardial infarction in a rat model [422].

As with complete cells, microenvironmental pre-conditioning plays a pivotal role in modulating the cell secretome and is therefore a useful tool to manipulate it. For instance, media from BMSCs cultured under hypoxia has been shown to improve HUVEC adhesion *in vitro*, whilst conditioned media from EPCs supported HUVEC proliferation independently of the oxygen tension used, indicating that BMSCs and EPCs have different roles during angiogenesis [423]. Additionally, conditioned media derived from EPCs cultured under hypoxia (1.5% oxygen tension) has also improved blood flow and restored muscle function in a rat hindlimb ischemic model in a comparable manner to injection of EPCs [63]. Conditioned media from mechanically stimulated BMSCs enhanced tube formation of EC in Matrigel. The paracrine effect of BMSCs was mediated by an upregulation of VEGFR and FGFR signalling cascade [424].

Exosomes are endosomal membrane vesicles with diameters of ~40–150 nm. They originate in the late endosomal compartment from the inward budding of endosomal membranes, which generates intracellular multi-vesicular endosomes (MVEs). Pools of exosomes are packed in the MVEs and released into the extracellular space after the fusion of MVEs with the plasma membrane. Although exosomes are present in conditioned media, various methods have been developed to isolate and concentrate them for various subsequent applications. There is emerging evidence that exosomes play important roles in intercellular communication by serving as vehicles for transferring various cellular constituents between cells [425-428].

Exosomes have advantages over the use of naked growth factors or conditioned media as they possess a lipid bilayer that protects them from proteolytic degradation, which greatly prolongs the half-life of their cargo. Several studies demonstrated that exosomes derived from EPCs enhanced migration, proliferation and tube formation of EC *in vitro*. Furthermore exosomes treatment increased the expression of angiogenesis-related genes such as FGF1, VEGFA, VEGFR-2, eNOS, IL-8 by activating Erk1/2 signalling [429, 430]. It was demonstrated that miR-214, which controls endothelial cell function and angiogenesis, plays a dominant role in exosome-mediated signalling between EC. Similarly, exosomes secreted by human ADSCs carrying miR-125a have been taken up by EC and significantly promoted angiogenesis *in vitro* and *in vivo*. miR-125a can repress the expression of the angiogenic inhibitor delta-like 4 (DLL4) and modulate endothelial cell angiogenesis through promotion of formation of endothelial tips [431]. BMSC exosomes were shown to enhance tube formation in HUVEC *in vitro* and to activate Akt, ERK 1/2 and STAT3 pathways in dermal fibroblasts which led to increased expression of HGF, IL-6, IGF-1, NGF and SDF-1 [432]. Additionally, BMSCs-derived exosomes have been shown to increase capillary network formation, blood flow, improved limb salvage and reduced necrosis in mice and rat hindlimb ischemic models [433, 434]. Similarly to BMSCs, UC-MSCs - derived exosomes have also promoted the proliferation, migration, and tube formation of EC in a dose-dependent manner [435]. Moreover, BMSCs-derived exosomes restored bioenergetics, reduced oxidative stress and activated pro-survival signalling, thus enhancing cardiac function and geometry after myocardial ischemia model [436]. When injected into mouse ischemic hindlimb tissue, CD34⁺ mononuclear cells derived exosomes improved ischemic limb perfusion and capillary density. These exosomes increased miR-126-3p levels, which enhanced angiogenesis by modulating the expression of angiogenic genes such as VEGF, Ang1, Ang2, MMP-9 [437].

In terms of wound healing, UC-MSCs – derived exosomes have improved healing and new blood vessel formation in a rat skin burn model. The exosomes promoted β -catenin nuclear translocation and increased expression of proliferating cell nuclear antigen, cyclin D3, N-cadherin, β -catenin and the decreased expression of E-cadherin, all mediated by Wnt / β -catenin signalling pathway [435].

Although the potential of cell secretome and cell-derived vesicles has been established in preclinical studies, their clinical evaluation it is still scarce. An ongoing phase 1 clinical trial aims to evaluate the effect of exosomes derived from autologous plasma on intractable cutaneous ulcers (NCT02565264; www.clinicaltrials.gov). Another phase 1 study is underway to assess the administration of BMSCs-derived exosome enriched with miR-124 on improvement of disability of patients with acute ischemic stroke. It was hypothesised that intravenous administration of BMSC-generated exosomes post-stroke will improve functional recovery and enhance neurite remodelling, neurogenesis and angiogenesis (NCT03384433; www.clinicaltrials.gov).

The use of conditioned medium and exosomes still requires further characterisation, because their cargo and resultant therapeutic effect will vary depending on the cell source, culture method and use of pre-conditioning. However, they still present advantages over delivery of cells, considering the potential for upscaling if bioreactors are utilised for culturing the cells of interest. Furthermore, exosomes offer the possibility of targeted delivery, due to the presence of membrane receptors, and of additional encapsulation of other relevant molecules [438].

3.5 Delivery of cells for therapeutic lymphangiogenesis

The lymphatic system is a blood vessels system that is generally under-researched but its physiological function becomes dramatically evident when there is a local loss function as

evident in parasitosis, such as filariasis, in lymphatic obstruction after irradiation for cancer treatment and following localised trauma or surgery [17, 18, 439]. Impaired lymphatic flow leads to lymphoedema, for which there are currently only limited treatments available, typically focussed on physiotherapy [19].

Cell therapy for lymphangiogenesis has been gaining interest and, although there are results from *in vivo* and clinical studies, further investigations are still required in terms of optimal cell sources and lymphatic phenotype control [440]. Microvascular EC and lymphatics EC have shown to induce reduction of lymphoedema and increase in lymphatic vessel density in a rat tail model [441]. However, stem cells appear to be the favoured cell source for most studies. ADSCs have shown increased VEGF-C expression and enhanced recruitment of M2 macrophages in a rat tail model [442] and increase of vessel density and expression of LYVE-1, VEGF-C and VEGFR-3 in a mouse hind limb oedema model [443]. Pre-conditioning of ADSCs *in vitro* with VEGF-C prior to implantation increased expression of VEGF-A, VEGF-C and Prox-1 which led to improved lymphangiogenesis in mice. Further enhancement of lymphangiogenesis was observed after TGF- β 1 signalling inhibition, given its association with decreased proliferation and migration of lymphatic EC [444]. Culture of BMSCs with lymphatic EC supernatant led to enhanced expression of VEGFR-2, VEGFR-3 and podoplanin and decreased oedema in a rat model [445]. Cells have also been delivered together with growth factors. ADSCs and BMSCs have been combined with VEGF-C and showed improved lymphatic vessel density in mouse dermal oedema and rabbit hindlimb oedema, respectively [446].

Given the promising results seen in preclinical tests, clinical testing of delivered cells has also been performed in women with secondary lymphoedema derived from breast cancer surgery and radiotherapy. Intramuscular injection of ADSCs was conducive to a similar reduction of limb swelling when compared with compression sleeve therapy (CST). However, CST led to

reoccurring swelling, while ADSCs injection promoted a more stable outcome [447]. Conversely, delivery of BMSCs reduced pain and lymphoedema volume significantly when compared with decongestive physiotherapy [448].

3.6 General approaches for cell retention and survival after implantation

Delivery of cells to the site of interest presents therapeutic advantages, however, there are still drawbacks that need to be overcome. Currently the main issues include poor local cell retention, cell death due to the lack of attachment or presence of adequate survival factors. Nonetheless, several methods have been developed as potential solutions. There are basically two options, systemic intravenous or intraarterial administration, or direct tissue injection of cells suspension with or without a carrier material. In a porcine myocardial infarction model, intracoronary infusion and endocardial injection gave better local cell retention in the heart than intravenous administration up to 14 days post-delivery [449]. Nonetheless, around 20% of injected cells were still found in the lungs after intracoronary and intravenous infusions. This clearly shows the need for development of different approaches that do not rely on infusion of cell suspensions. For instance, BMSCs in agarose, collagen and fibrin microcapsules have been delivered to the rat infarcted myocardium to further promote their localisation and survival [300]. Although scaffolds present a relevant alternative, other methods have focussed on utilising cell secreted ECM as a support structure for the implanted cells. This has the advantage of maintaining intact cell-cell and cell-matrix interactions. Cardiac cells have been grown *in vitro* in temperature responsive dishes to fabricate cell sheets, which, when placed directly on the infarcted area in a rat myocardial infarction model, led to improved cell survival, localisation and higher number of mature capillaries than cell injections [450]. Temperature sensitive gels with RGD adhesive peptides have also been investigated for myoblast sheet culture and were shown to lead to improved cell retention and

survival and perfusion recovery after implantation in a hindlimb ischemic model [451]. Magnetic nanoparticles can also be used *in vitro* to force cells into an organised cell sheet that can be implanted. BMSC sheets fabricated as such, showed increased VEGF secretion and further increased capillary density and blood perfusion to ischemic muscle [452]. It was also observed that the BMSC sheets contributed to increase skeletal muscle cell survival in the vicinity and it was suggested that this derived from intrinsic anti-oxidative peroxidase-like activity of the magnetic nanoparticles.

In an attempt to create more complex assemblies than sheets, cells have also been organised into spheroids. HUVEC spheroids implanted in a mouse ischemic hindlimb model increased cell survival over monolayer-grown cells and expression of VEGFR1 and VEGFR2 [453]. In an analogous model, UC-MSC spheroids also improved limb survival, decreased necrosis and increased expression of von Willebrand factor and NG2, indicating vessel maturation [454]. The use of such methods also allows for implanting co-cultured cells and positive results in terms of limb survival and blood perfusion recovery were observed in limb ischemic models when HUVEC and UC-MSCs aggregates were applied [455]. It was suggested that the encouraging outcome derived from the UC-MSCs starting to differentiate into SMCs and stabilising the newly formed HUVEC tubular network, however, further work is needed to confirm these assumptions.

4 Conclusions and future perspectives

Therapeutic angiogenesis is based on an exciting body of literature furthering the understanding of relevant mechanisms. There have been discrepancies between *in vitro* angiogenesis assays and *in vivo* data which can be partially attributed to using endothelial cells solely *in vitro*, while they are in reality influenced by cross-talk with non-endothelial cells *in vivo*. Nevertheless, remarkable progress has been made in the last decades with drug and cell delivery. As a new option, the use of the cell secretome has been gaining increasing interest. Although growth factors are unquestionably the most researched option due demonstrated efficacy in preclinical setting, issues arise regarding their cost, activity and need of suitable carriers. Their instability necessitates supraphysiological local concentrations and that can lead to undesired side effects in clinical settings, as exemplified by the case of PDGF. The use of small molecules should overcome most of those issues. As a scientifically attractive approach gene delivery has attracted much attention due to the promise of *in situ* sustained delivery of a protein of interest. However, previous fatal outcomes with adenoviral transfer have led to a re-evaluation of clinical gene therapy approaches. While this has not prevented continued animal experimentation, clinical evidence for efficacious angiogenic gene delivery has to be gathered yet. Regarding cell delivery, different permanently differentiated, progenitor and stem cell sources, undifferentiated, pre-conditioned or genetically modified, have been assessed. Although clinical evidence appears promising, additional efforts are required to evaluate the advantages of cell manipulation prior to implantation in full. Similarly, for the use of exosomes, significantly more *in vitro*, preclinical and clinical work is required to justify the labour and cost intensive extraction process. Additionally, given the complexity of angiogenesis, it is likely that further advancements will only come about with multicomponent delivery. In this regard, the most promising drug calls still might be prolyl hydroxylase inhibitors. Besides being stable small

molecules, they tackle an angiogenic master switch (HIF-1 α) and thus bring a variety of angiogenic factors into play simultaneously. This is a situation akin to multidrug/multigene or secretome application. Of note, some members of this compound class are already approved for clinical use and can be re-purposed in an indication-discovery approach for angiogenesis. While some encouraging results support the use of drugs and cells, their wider application is currently constrained to use as last resort in otherwise intractable patients. This, and high variability of treatment conditions (e.g. experimental treatments delivered alongside surgical grafting procedures) severely compromise the proof of clinical efficacy and statistical significance of the studies. There does not appear to be a clear consensus on the efficacy of some therapeutic agents and there is controversy over the use of others. The overarching need we see arising is the development of appropriate delivery vehicles to ensure local retention and continued biologic activity at the site of interest of angiogenic compounds.

5 Acknowledgments

The authors would like to acknowledge the following for financial support: DG and DZ to Science Foundation Ireland (SFI) Career Development Award (15/CDA/3629), RP and DZ to Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM) Grant Number: 13/RC/2073, ADP and DZ to H2020, Marie Skłodowska-Curie Actions, Innovative Training Networks 2015 Tendon Therapy Train project (Grant No. 676338); and MR to Swiss Biotechnet.

6 References

1. Carmeliet, P., *Angiogenesis in life, disease and medicine*. Nature, 2005. **438**(7070): p. 932-936.
2. Potente, M., H. Gerhardt, and P. Carmeliet, *Basic and therapeutic aspects of angiogenesis*. Cell, 2011. **146**(6): p. 873-887.
3. Nagy, J.A., L. Benjamin, H. Zeng, A.M. Dvorak, and H.F. Dvorak, *Vascular permeability, vascular hyperpermeability and angiogenesis*. Angiogenesis, 2008. **11**(2): p. 109-119.
4. Swartz, M.A., *The physiology of the lymphatic system*. Advanced Drug Delivery Reviews, 2001. **50**(1-2): p. 3-20.
5. Dixon, J.B., *Lymphatic lipid transport: Sewer or subway?* Trends in Endocrinology & Metabolism, 2010. **21**(8): p. 480-487.
6. Jackson, A.R. and W.Y. Gu, *Transport properties of cartilaginous tissues*. Current Rheumatology Reviews, 2009. **5**(1): p. 40-50.
7. Takahashi, G.H. and I. Fatt, *The diffusion of oxygen in the cornea*. Experimental Eye Research, 1965. **4**(1): p. 4-12.
8. Carmeliet, P., *Mechanisms of angiogenesis and arteriogenesis*. Nature Medicine, 2000. **6**(4): p. 389-395.
9. Carmeliet, P., *Angiogenesis in health and disease*. Nature Medicine, 2003. **9**(6): p. 653.
10. Ferrara, N., H.-P. Gerber, and J. LeCouter, *The biology of vegf and its receptors*. Nature Medicine, 2003. **9**(6): p. 669-676.
11. Risau, W., *Mechanisms of angiogenesis*. nature, 1997. **386**(6626): p. 671-674.
12. van Nieuw Amerongen, G.P., P. Koolwijk, A. Versteilen, and V.W. van Hinsbergh, *Involvement of rhoa/rho kinase signaling in vegf-induced endothelial cell migration and angiogenesis in vitro*. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003. **23**(2): p. 211-217.
13. Said, S.S., J.G. Pickering, and K. Mequanint, *Advances in growth factor delivery for therapeutic angiogenesis*. Journal of Vascular Research, 2013. **50**(1): p. 35-51.
14. Alitalo, K., T. Tammela, and T.V. Petrova, *Lymphangiogenesis in development and human disease*. Nature, 2005. **438**(7070): p. 946-953.
15. Tammela, T. and K. Alitalo, *Lymphangiogenesis: Molecular mechanisms and future promise*. Cell, 2010. **140**(4): p. 460-476.
16. Oliver, G., *Lymphatic vasculature development*. Nature Reviews Immunology, 2004. **4**(1): p. 35-45.
17. Saito, Y., H. Nakagami, Y. Kaneda, and R. Morishita, *Lymphedema and therapeutic lymphangiogenesis*. BioMed Research International, 2013. **2013**.
18. Norrmén, C., T. Tammela, T.V. Petrova, and K. Alitalo, *Biological basis of therapeutic lymphangiogenesis*. Circulation, 2011. **123**(12): p. 1335-1351.
19. Lohela, M., A. Saaristo, T. Veikkola, and K. Alitalo, *Lymphangiogenic growth factors, receptors and therapies*. Thrombosis and Haemostasis, 2003. **90**(2): p. 167-184.
20. Eltzschig, H.K. and T. Eckle, *Ischemia and reperfusion - from mechanism to translation*. Nature Medicine, 2011. **17**(11): p. 1391-1401.
21. Di Nisio, M., N. van Es, and H.R. Büller, *Deep vein thrombosis and pulmonary embolism*. The Lancet, 2016. **388**(10063): p. 3060-3073.
22. Deitcher, S.R. and T.L. Carman, *Deep venous thrombosis and pulmonary embolism*. Current Treatment Options in Cardiovascular Medicine, 2002. **4**(3): p. 223-238.
23. Langer, A., M.R. Freeman, R.G. Josse, G. Steiner, and P.W. Armstrong, *Detection of silent myocardial ischemia in diabetes mellitus*. American Journal of Cardiology, 1991. **67**(13): p. 1073-1078.

24. Wilcken, D.E., S.G. Reddy, and V.J. Gupta, *Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria*. *Metabolism*, 1983. **32**(4): p. 363-370.
25. Ishimori, M.L., R. Martin, D.S. Berman, P. Goykhman, L.J. Shaw, C. Shufelt, P.J. Slomka, L.E. Thomson, J. Schapira, and Y. Yang, *Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus*. *JACC: Cardiovascular Imaging*, 2011. **4**(1): p. 27-33.
26. Perrin, R., O. Konopatskaya, Y. Qiu, S. Harper, D. Bates, and A. Churchill, *Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor*. *Diabetologia*, 2005. **48**(11): p. 2422-2427.
27. Bonventre, J.V. and L. Yang, *Cellular pathophysiology of ischemic acute kidney injury*. *The Journal of Clinical Investigation*, 2011. **121**(11): p. 4210-4221.
28. Ruiz-Salmeron, R., A. de la Cuesta-Diaz, M. Constantino-Bermejo, I. Perez-Camacho, F. Marcos-Sanchez, A. Hmadcha, and B. Soria, *Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia*. *Cell Transplantation*, 2011. **20**(10): p. 1629-1639.
29. Orasanu, G. and J. Plutzky, *The pathologic continuum of diabetic vascular disease*. *Journal of the American College of Cardiology*, 2009. **53**(5): p. S35-S42.
30. Orrico, C., G. Pasquinelli, L. Foroni, D. Muscara, P. Tazzari, F. Ricci, M. Buzzi, E. Baldi, N. Muccini, and M. Gargiulo, *Dysfunctional vasa vasorum in diabetic peripheral artery obstructive disease with critical lower limb ischaemia*. *European Journal of Vascular and Endovascular Surgery*, 2010. **40**(3): p. 365-374.
31. Ravi, S. and E.L. Chaikof, *Biomaterials for vascular tissue engineering*. *Regenerative Medicine*, 2010. **5**(1): p. 107-120.
32. Kannan, R.Y., H.J. Salacinski, P.E. Butler, G. Hamilton, and A.M. Seifalian, *Current status of prosthetic bypass grafts: A review*. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*, 2005. **74**(1): p. 570-581.
33. Shaknovich, A., *Complications of coronary stenting*. *Coronary Artery Disease*, 1994. **5**(7): p. 583-589.
34. Fischman, D.L., M.B. Leon, D.S. Baim, R.A. Schatz, M.P. Savage, I. Penn, K. Detre, L. Veltri, D. Ricci, and M. Nobuyoshi, *A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease*. *New England Journal of Medicine*, 1994. **331**(8): p. 496-501.
35. Iakovou, I., T. Schmidt, E. Bonizzoni, L. Ge, G.M. Sangiorgi, G. Stankovic, F. Airolidi, A. Chieffo, M. Montorfano, and M. Carlino, *Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents*. *Journal of the American Medical Association*, 2005. **293**(17): p. 2126-2130.
36. Nishibe, T., S. O'Donnel, E. Pikoulis, N. Rich, Y. Okuda, T. Kumada, F. Kudo, T. Tanabe, and K. Yasuda, *Effects of fibronectin bonding on healing of high porosity expanded polytetrafluoroethylene grafts in pigs*. *The Journal of Cardiovascular Surgery*, 2001. **42**(5): p. 667-73.
37. Li, C., A. Hill, and M. Imran, *In vitro and in vivo studies of eptfe vascular grafts treated with p15 peptide*. *Journal of Biomaterials Science, Polymer Edition*, 2005. **16**(7): p. 875-891.
38. Randone, B., G. Cavallaro, A. Polistena, A. Cucina, P. Coluccia, P. Graziano, and A. Cavallaro, *Dual role of vegf in pretreated experimental eptfe arterial grafts*. *Journal of Surgical Research*. **127**(2): p. 70-79.
39. Lumsden, A.B., N.J. Morrissey, R. Staffa, J. Lindner, L. Janousek, V. Treska, P. Stadler, M. Moursi, M. Storck, and K. Johansen, *Randomized controlled trial comparing the*

- safety and efficacy between the fusion bioline heparin-coated vascular graft and the standard expanded polytetrafluoroethylene graft for femoropopliteal bypass.* Journal of Vascular Surgery, 2015. **61**(3): p. 703-712.
40. Devine, C. and C. McCollum, *Heparin-bonded dacron or polytetrafluorethylene for femoropopliteal bypass: Five-year results of a prospective randomized multicenter clinical trial.* Journal of Vascular Surgery, 2004. **40**(5): p. 924-931.
 41. Piffaretti, G., W. Dorigo, P. Castelli, C. Pratesi, R. Pulli, A.A. Innocenti, E. Giacomelli, A. Fargion, G. De Blasis, and L. Scalisi, *Results from a multicenter registry of heparin-bonded expanded polytetrafluoroethylene graft for above-the-knee femoropopliteal bypass.* Journal of Vascular Surgery, 2018. **67**(5): p. 1463-1471.
 42. Barber, G., A. Bouchard, W. Cole, N. McPhail, W. Waddell, J. Wellington, F. Gervais, J. Shuster, P. Roy, G. LaRoche, J. Lassonde, and F. Laurendeau, *Immunologic response to collagen-impregnated vascular grafts: A randomized prospective study.* Journal of Vascular Surgery, 1990. **12**(6): p. 741-746.
 43. Tofigh, A.M., G.W. De Wailly, and B. Rhissassi, *Comparing vein with collagen impregnated woven polyester prosthesis in above-knee femoropopliteal bypass grafting.* International Journal of Surgery, 2007. **5**(2): p. 109-113.
 44. Feng, G., L. Li, H. Liu, Y. Song, F. Huang, C. Tu, B. Shen, Q. Gong, T. Li, and L. Liu, *Hypoxia differentially regulates human nucleus pulposus and annulus fibrosus cell extracellular matrix production in 3d scaffolds.* Osteoarthritis and Cartilage, 2013. **21**(4): p. 582-588.
 45. Mohyeldin, A., T. Garzón-Muvdi, and A. Quiñones-Hinojosa, *Oxygen in stem cell biology: A critical component of the stem cell niche.* Cell Stem Cell, 2010. **7**(2): p. 150-161.
 46. Harrison, J.S., P. Rameshwar, V. Chang, and P. Bandari, *Oxygen saturation in the bone marrow of healthy volunteers.* Blood, 2002. **99**(1): p. 394-394.
 47. Wang, D.W., B. Fermor, J.M. Gimble, H.A. Awad, and F. Guilak, *Influence of oxygen on the proliferation and metabolism of adipose derived adult stem cells.* Journal of Cellular Physiology, 2005. **204**(1): p. 184-191.
 48. Chlupáč, J., E. Filova, and L. Bačáková, *Blood vessel replacement: 50 years of development and tissue engineering paradigms in vascular surgery.* Physiological Research, 2009. **58**(2): p. S119-S139.
 49. Herrman, J.-P.R., W.R. Hermans, J. Vos, and P.W. Serruys, *Pharmacological approaches to the prevention of restenosis following angioplasty.* Drugs, 1993. **46**(1): p. 18-52.
 50. Fan, Y., J. Ye, F. Shen, Y. Zhu, Y. Yeghiazarians, W. Zhu, Y. Chen, M.T. Lawton, W.L. Young, and G.-Y. Yang, *Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro.* Journal of Cerebral Blood Flow & Metabolism, 2008. **28**(1): p. 90-98.
 51. Papapetropoulos, A., G. García-Cardena, J.A. Madri, and W.C. Sessa, *Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.* The Journal of Clinical Investigation, 1997. **100**(12): p. 3131-3139.
 52. Hu, G.F., *Copper stimulates proliferation of human endothelial cells under culture.* Journal of Cellular Biochemistry, 1998. **69**(3): p. 326-335.
 53. Montesano, R. and L. Orci, *Phorbol esters induce angiogenesis in vitro from large -vessel endothelial cells.* Journal of Cellular Physiology, 1987. **130**(2): p. 284-291.
 54. Silvestre, J.S., *Pro-angiogenic cell-based therapy for the treatment of ischemic cardiovascular diseases.* Thrombosis Research, 2012. **130** p. S90-S94.

55. Hou, L., J.J. Kim, Y.J. Woo, and N.F. Huang, *Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease*. American Journal of Physiology, 2016. **310**(4): p. H455-H465.
56. Wang, C.-H., W.-J. Cherng, and S. Verma, *Drawbacks to stem cell therapy in cardiovascular diseases*. Future Medicine, 2008. **4**(4): p. 399-408.
57. Akita, T., T. Murohara, H. Ikeda, K.-i. Sasaki, T. Shimada, K. Egami, and T. Imaizumi, *Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization*. Laboratory Investigation, 2003. **83**(1): p. 65-73.
58. Wilkins, J.R., D.B. Pike, C.C. Gibson, A. Kubota, and Y.T. Shiu, *Differential effects of cyclic stretch on bfgf -and vegf -induced sprouting angiogenesis*. Biotechnology Progress, 2014. **30**(4): p. 879-888.
59. Lai, R.C., T.S. Chen, and S.K. Lim, *Mesenchymal stem cell exosome: A novel stem cell-based therapy for cardiovascular disease*. Regenerative Medicine, 2011. **6**(4): p. 481-492.
60. Ailawadi, S., X. Wang, H. Gu, and G.-C. Fan, *Pathologic function and therapeutic potential of exosomes in cardiovascular disease*. Biochimica et Biophysica Acta, 2015. **1852**(1): p. 1-11.
61. Vailhé, B., D. Vittet, and J.-J. Feige, *In vitro models of vasculogenesis and angiogenesis*. Laboratory Investigation, 2001. **81**(4): p. 439.
62. Arnaoutova, I. and H.K. Kleinman, *In vitro angiogenesis: Endothelial cell tube formation on gelled basement membrane extract*. Nature Protocols, 2010. **5**(4): p. 628-635.
63. Di Santo, S., Z. Yang, M.W. von Ballmoos, J. Voelzmann, N. Diehm, I. Baumgartner, and C. Kalka, *Novel cell-free strategy for therapeutic angiogenesis: In vitro generated conditioned medium can replace progenitor cell transplantation*. PLoS ONE, 2009. **4**(5): p. e5643.
64. Sweat, R.S., D.C. Sloas, and W.L. Murfee, *Vegf -c induces lymphangiogenesis and angiogenesis in the rat mesentery culture model*. Microcirculation, 2014. **21**(6): p. 532-540.
65. Zheng, Y., J. Chen, M. Craven, N.W. Choi, S. Totorica, A. Diaz-Santana, P. Kermani, B. Hempstead, C. Fischbach-Teschl, and J.A. López, *In vitro microvessels for the study of angiogenesis and thrombosis*. Proceedings of the National Academy of Sciences, 2012. **109**(24): p. 9342-9347.
66. Rohringer, S., P. Hofbauer, K.H. Schneider, A.-M. Husa, G. Feichtinger, A. Peterbauer-Scherb, H. Redl, and W. Holnthoner, *Mechanisms of vasculogenesis in 3d fibrin matrices mediated by the interaction of adipose-derived stem cells and endothelial cells*. Angiogenesis, 2014. **17**(4): p. 921-933.
67. Shen, C., P. Lie, T. Miao, M. Yu, Q. Lu, T. Feng, J. Li, T. Zu, X. Liu, and H. Li, *Conditioned medium from umbilical cord mesenchymal stem cells induces migration and angiogenesis*. Molecular Medicine Reports, 2015. **12**(1): p. 20-30.
68. Norrby, K., *In vivo models of angiogenesis*. Journal of Cellular and Molecular Medicine, 2006. **10**(3): p. 588-612.
69. Zaragoza, C., C. Gomez-Guerrero, J.L. Martin-Ventura, L. Blanco-Colio, B. Lavin, B. Mallavia, C. Tarin, S. Mas, A. Ortiz, and J. Egido, *Animal models of cardiovascular diseases*. BioMed Research International, 2011. **2011**.
70. Bhise, N.S., R.B. Shmueli, J.C. Sunshine, S.Y. Tzeng, and J.J. Green, *Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis*. Expert Opinion on Drug Delivery, 2011. **8**(4): p. 485-504.
71. Kakudo, N., N. Morimoto, S. Kushida, T. Ogawa, and K. Kusumoto, *Platelet-rich plasma releasate promotes angiogenesis in vitro and in vivo*. Medical Molecular Morphology, 2014. **47**(2): p. 83-89.

72. Lee, K., E.A. Silva, and D.J. Mooney, *Growth factor delivery-based tissue engineering: General approaches and a review of recent developments*. Journal of the Royal Society Interface, 2011. **8**(55): p. 153-170.
73. Chen, R.R. and D.J. Mooney, *Polymeric growth factor delivery strategies for tissue engineering*. Pharmaceutical Research, 2003. **20**(8): p. 1103-1112.
74. Makarevich, P., Z. Tsokolaeva, A. Shevelev, I. Rybalkin, E. Shevchenko, I. Beloglazova, T. Vlasik, V. Tkachuk, and Y. Parfyonova, *Combined transfer of human vegf165 and hgf genes renders potent angiogenic effect in ischemic skeletal muscle*. PloS ONE, 2012. **7**(6): p. e38776.
75. Takahashi, J.C., M. Saiki, S.-I. Miyatake, S. Tani, H. Kubo, K. Goto, T. Aoki, J.A. Takahashi, I. Nagata, and H. Kikuchi, *Adenovirus-mediated gene transfer of basic fibroblast growth factor induces in vitro angiogenesis*. Atherosclerosis, 1997. **132**(2): p. 199-205.
76. Cho, Y.-H., H. Park, E.-S. Cho, W.-J. Kim, B.-S. Kang, B.Y. Park, Y.-J. Kim, Y.-I. Lee, S.-I. Chang, and K. Park, *A novel way of therapeutic angiogenesis using an adeno-associated virus-mediated angiogenin gene transfer*. Experimental & Molecular Medicine, 2007. **39**(3): p. 412-418.
77. Gerber, H.-P., A. McMurtrey, J. Kowalski, M. Yan, B.A. Keyt, V. Dixit, and N. Ferrara, *Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/akt signal transduction pathway requirement for flk-1/kdr activation*. Journal of Biological Chemistry, 1998. **273**(46): p. 30336-30343.
78. Nör, J.E., J. Christensen, D.J. Mooney, and P.J. Polverini, *Vascular endothelial growth factor (vegf)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of bcl-2 expression*. The American Journal of Pathology, 1999. **154**(2): p. 375-384.
79. King, T.W. and C.W. Patrick, *Development and in vitro characterization of vascular endothelial growth factor (vegf) -loaded poly (dl -lactic -co -glycolic acid)/poly (ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique*. Journal of Biomedical Materials Research Part A, 2000. **51**(3): p. 383-390.
80. Oswald, J., S. Boxberger, B. Jørgensen, S. Feldmann, G. Ehniger, M. Bornhäuser, and C. Werner, *Mesenchymal stem cells can be differentiated into endothelial cells in vitro*. Stem Cells, 2004. **22**(3): p. 377-384.
81. Finetti, F., A. Basile, D. Capasso, S. Di Gaetano, R. Di Stasi, M. Pascale, C.M. Turco, M. Ziche, L. Morbidelli, and L.D. D'Andrea, *Functional and pharmacological characterization of a vegf mimetic peptide on reparative angiogenesis*. Biochemical Pharmacology, 2012. **84**(3): p. 303-311.
82. Freudenberg, U., A. Zieris, K. Chwalek, M.V. Tsurkan, M.F. Maitz, P. Atallah, K.R. Levental, S.A. Eming, and C. Werner, *Heparin desulfation modulates vegf release and angiogenesis in diabetic wounds*. Journal of Controlled Release, 2015. **220**: p. 79-88.
83. Tae, G., M. Scatena, P.S. Stayton, and A.S. Hoffman, *Peg-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor*. Journal of Biomaterials Science, 2006. **17**(1-2): p. 187-197.
84. Yu, Y., J. Chen, R. Chen, L. Cao, W. Tang, D. Lin, J. Wang, and C. Liu, *Enhancement of vegf-mediated angiogenesis by 2-n, 6-o-sulfated chitosan-coated hierarchical plga scaffolds*. ACS Applied Materials & Interfaces, 2015. **7**(18): p. 9982-9990.
85. Cartland, S.P., S.W. Genner, A. Zahoor, and M.M. Kavurma, *Comparative evaluation of trail, fgf-2 and vegf-a-induced angiogenesis in vitro and in vivo*. International Journal of Molecular Sciences, 2016. **17**(12): p. 2025-2036.

86. Ilan, N., S. Mahooti, and J.A. Madri, *Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis*. Journal of Cell Science, 1998. **111**(24): p. 3621-3631.
87. Jain, R.K., P. Au, J. Tam, D.G. Duda, and D. Fukumura, *Engineering vascularized tissue*. Nature Biotechnology, 2005. **23**(7): p. 821-823.
88. Ozawa, C.R., A. Banfi, N.L. Glazer, G. Thurston, M.L. Springer, P.E. Kraft, D.M. McDonald, and H.M. Blau, *Microenvironmental vegf concentration, not total dose, determines a threshold between normal and aberrant angiogenesis*. Journal of Clinical Investigation, 2004. **113**(4): p. 516-527.
89. Raghunath, M., Y. Sy Wong, M. Farooq, and R. Ge, *Pharmacologically induced angiogenesis in transgenic zebrafish*. Biochemical and Biophysical Research Communications, 2009. **378**(4): p. 766-771.
90. Seghezzi, G., S. Patel, C.J. Ren, A. Gualandris, G. Pintucci, E.S. Robbins, R.L. Shapiro, A.C. Galloway, D.B. Rifkin, and P. Mignatti, *Fibroblast growth factor-2 (fgf-2) induces vascular endothelial growth factor (vegf) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis*. The Journal of Cell Biology, 1998. **141**(7): p. 1659-1673.
91. Litwin, M., A. Radwanska, M. Paprocka, C. Kieda, T. Dobosz, W. Witkiewicz, and D. Baczynska, *The role of fgf2 in migration and tubulogenesis of endothelial progenitor cells in relation to pro-angiogenic growth factor production*. Mol Cell Biochem, 2015. **410**(1-2): p. 131-42.
92. Boomsma, R.A. and D.L. Geenen, *Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis*. PloS ONE, 2012. **7**(4): p. e35685.
93. Pankajakshan, D. and D.K. Agrawal, *Mesenchymal stem cell paracrine factors in vascular repair and regeneration*. Journal of Biomedical Technology and Research, 2014. **1**(1): p. 1-21.
94. Berse, B., J. Hunt, R. Diegel, P. Morganelli, K. Yeo, F. Brown, and R. Fava, *Hypoxia augments cytokine (transforming growth factor-beta (tgf- β) and il-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts*. Clinical and Experimental Immunology, 1999. **115**(1): p. 176-182.
95. Montesano, R., J.-D. Vassalli, A. Baird, R. Guillemin, and L. Orci, *Basic fibroblast growth factor induces angiogenesis in vitro*. Proceedings of the National Academy of Sciences, 1986. **83**(19): p. 7297-7301.
96. Zhao, Y., Z. Liu, C. Pan, Z. Li, J. Zhou, J. Wang, Z. Yin, and X. Wang, *Preparation of gelatin microspheres encapsulated with bfgf for therapeutic angiogenesis in a canine ischemic hind limb*. Journal of Biomaterials Science, 2011. **22**(4-6): p. 665-682.
97. Wolfe, A., B. O'Clair, V.E. Groppi, and D.P. McEwen, *Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds*. Journal of Biomolecular Screening, 2013. **18**(10): p. 1234-1245.
98. Kim, B.S., J.-Y. Park, H.-J. Kang, H.-J. Kim, and J. Lee, *Fucoidan/fgf-2 induces angiogenesis through jnk-and p38-mediated activation of akt/mmp-2 signalling*. Biochemical and Biophysical Research Communications, 2014. **450**(4): p. 1333-1338.
99. Butko, A., G. Bonat Celli, A. Paulson, and A. Ghanem, *Entrapment of basic fibroblast growth factor (bfgf) in a succinylated chitosan nanoparticle delivery system and release profile*. Journal of Biomaterials Science, 2016. **27**(10): p. 1045-1057.
100. Li, W., Y. Lan, R. Guo, Y. Zhang, W. Xue, and Y. Zhang, *In vitro and in vivo evaluation of a novel collagen/cellulose nanocrystals scaffold for achieving the sustained release of basic fibroblast growth factor*. Journal of Biomaterials Applications, 2015. **29**(6): p. 882-893.

101. Sato, N., J. Beitz, J. Kato, M. Yamamoto, J. Clark, P. Calabresi, A. Raymond, and A. Frackelton Jr, *Platelet-derived growth factor indirectly stimulates angiogenesis in vitro*. The American Journal of Pathology, 1993. **142**(4): p. 1119-1130.
102. Pepper, M.S., J.-D. Vassalli, L. Orci, and R. Montesano, *Biphasic effect of transforming growth factor- β 1 on in vitro angiogenesis*. Experimental Cell Research, 1993. **204**(2): p. 356-363.
103. Bauters, C., T. Asahara, L.P. Zheng, S. Takeshita, S. Bunting, N. Ferrara, J.F. Symes, and J.M. Isner, *Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor*. Journal of Vascular Surgery, 1995. **21**(2): p. 314-325.
104. Patil, S.D., F. Papadimitrakopoulos, and D.J. Burgess, *Concurrent delivery of dexamethasone and vegf for localized inflammation control and angiogenesis*. Journal of Controlled Release, 2007. **117**(1): p. 68-79.
105. Nagase, K., Y. Nagumo, M. Kim, H.J. Kim, H.W. Kyung, H.J. Chung, H. Sekine, T. Shimizu, H. Kanazawa, and T. Okano, *Local release of vegf using fiber mats enables effective transplantation of layered cardiomyocyte sheets*. Macromolecular Bioscience, 2017.
106. Silva, E. and D. Mooney, *Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis*. Journal of Thrombosis and Haemostasis, 2007. **5**(3): p. 590-598.
107. Sun, Q., R.R. Chen, Y. Shen, D.J. Mooney, S. Rajagopalan, and P.M. Grossman, *Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb*. Pharmaceutical Research, 2005. **22**(7): p. 1110-1116.
108. Golub, J.S., Y.-t. Kim, C.L. Duvall, R.V. Bellamkonda, D. Gupta, A.S. Lin, D. Weiss, W. Robert Taylor, and R.E. Guldberg, *Sustained vegf delivery via plga nanoparticles promotes vascular growth*. American Journal of Physiology, 2010. **298**(6): p. H1959-H1965.
109. Guo, X., C.G. Elliott, Z. Li, Y. Xu, D.W. Hamilton, and J. Guan, *Creating 3d angiogenic growth factor gradients in fibrous constructs to guide fast angiogenesis*. Biomacromolecules, 2012. **13**(10): p. 3262-3271.
110. Kim, M.S., S.-H. Bhang, H.S. Yang, N.G. Rim, I. Jun, S.I. Kim, B.-S. Kim, and H. Shin, *Development of functional fibrous matrices for the controlled release of basic fibroblast growth factor to improve therapeutic angiogenesis*. Tissue Engineering, 2010. **16**(10): p. 2999-3010.
111. Zhao, W., Q. Han, H. Lin, W. Sun, Y. Gao, Y. Zhao, B. Wang, X. Wang, B. Chen, and Z. Xiao, *Human basic fibroblast growth factor fused with kringle4 peptide binds to a fibrin scaffold and enhances angiogenesis*. Tissue Engineering, 2008. **15**(5): p. 991-998.
112. Tanihara, M., Y. Suzuki, E. Yamamoto, A. Noguchi, and Y. Mizushima, *Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate*. Journal of Biomedical Materials Research Part A, 2001. **56**(2): p. 216-221.
113. Chleboun, J., R. Martins, C. Mitchell, and T. Chirila, *Bfgf enhances the development of the collateral circulation after acute arterial occlusion*. Biochemical and Biophysical Research Communications, 1992. **185**(2): p. 510-516.
114. Garbern, J.C., E. Minami, P.S. Stayton, and C.E. Murry, *Delivery of basic fibroblast growth factor with a ph-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium*. Biomaterials, 2011. **32**(9): p. 2407-2416.
115. Bussolino, F., M. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, L. Naldini, G. Gaudino, L. Tamagnone, A. Coffer, and P. Comoglio, *Hepatocyte growth factor is a*

- potent angiogenic factor which stimulates endothelial cell motility and growth.* The Journal of Cell Biology, 1992. **119**(3): p. 629-641.
116. Morishita, R., S. Nakamura, S.-i. Hayashi, Y. Taniyama, A. Moriguchi, T. Nagano, M. Taiji, H. Noguchi, S. Takeshita, and K. Matsumoto, *Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy.* Hypertension, 1999. **33**(6): p. 1379-1384.
 117. Wickremasinghe, N.C., V.A. Kumar, S. Shi, and J.D. Hartgerink, *Controlled angiogenesis in peptide nanofiber composite hydrogels.* ACS Biomaterials Science & Engineering, 2015. **1**(9): p. 845-854.
 118. Kusumanto, Y., G. Hospers, N. Mulder, and R. Tio, *Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: A review.* International Journal of Cardiovascular Interventions, 2003. **5**(1): p. 27-34.
 119. Henry, T.D., B.H. Annex, G.R. McKendall, M.A. Azrin, J.J. Lopez, F.J. Giordano, P. Shah, J.T. Willerson, R.L. Benza, and D.S. Berman, *The viva trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis.* Circulation, 2003. **107**(10): p. 1359-1365.
 120. Aviles, R.J., B.H. Annex, and R.J. Lederman, *Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (fgf-2).* British Journal of Pharmacology, 2003. **140**(4): p. 637-646.
 121. Lazarous, D.F., E.F. Unger, S.E. Epstein, A. Stine, J.L. Arevalo, E.Y. Chew, and A.A. Quyyumi, *Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase i trial.* Journal of the American College of Cardiology, 2000. **36**(4): p. 1239-1244.
 122. Lederman, R.J., F.O. Mendelsohn, R.D. Anderson, J.F. Saucedo, A.N. Tenaglia, J.B. Hermiller, W.B. Hillegass, K. Rocha-Singh, T.E. Moon, and M. Whitehouse, *Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the traffic study): A randomised trial.* The Lancet, 2002. **359**(9323): p. 2053-2058.
 123. Simons, M., B.H. Annex, R.J. Laham, N. Kleiman, T. Henry, H. Dauerman, J.E. Udelson, E.V. Gervino, M. Pike, and M. Whitehouse, *Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial.* Circulation, 2002. **105**(7): p. 788-793.
 124. Unger, E.F., L. Goncalves, S.E. Epstein, E.Y. Chew, C.B. Trapnell, R.O. Cannon, A.A. Quyyumi, F. Loscalzo, and J.A. Stiber, *Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.* American Journal of Cardiology, 2000. **85**(12): p. 1414-1419.
 125. Laham, R.J., F.W. Sellke, E.R. Edelman, J.D. Pearlman, J.A. Ware, D.L. Brown, J.P. Gold, and M. Simons, *Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery.* Circulation, 1999. **100**(18): p. 1865-1871.
 126. Sellke, F.W., R.J. Laham, E.R. Edelman, J.D. Pearlman, and M. Simons, *Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results.* The Annals of Thoracic Surgery, 1998. **65**(6): p. 1540-1544.
 127. Ruel, M., R.J. Laham, J.A. Parker, M.J. Post, J.A. Ware, M. Simons, and F.W. Sellke, *Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein.* The Journal of Thoracic and Cardiovascular Surgery, 2002. **124**(1): p. 28-34.
 128. Schumacher, B., P. Pecher, B. Von Specht, and T. Stegmann, *Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease.* Circulation, 1998. **97**(7): p. 645-650.

129. Smiell, J.M., T.J. Wieman, D.L. Steed, B.H. Perry, A.R. Sampson, and B.H. Schwab, *Efficacy and safety of becaplermin (recombinant human platelet -derived growth factor -bb) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies*. *Wound Repair and Regeneration*, 1999. **7**(5): p. 335-346.
130. Ziyadeh, N., D. Fife, A.M. Walker, G.S. Wilkinson, and J.D. Seeger, *A matched cohort study of the risk of cancer in users of becaplermin*. *Advances in Skin & Wound Care*, 2011. **24**(1): p. 31-39.
131. Papanas, D. and E. Maltezos, *Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers*. *Drug Safety*, 2010. **33**(6): p. 455-461.
132. Wieman, T.J., J.M. Smiell, and Y. Su, *Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-bb (becaplermin) in patients with chronic neuropathic diabetic ulcers: A phase iii randomized placebo-controlled double-blind study*. *Diabetes Care*, 1998. **21**(5): p. 822-827.
133. Fang, R.C. and R.D. Galiano, *A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers*. *Biologics : Targets & Therapy*, 2008. **2**(1): p. 1-12.
134. Pepper, M.S., S.J. Mandriota, M. Jeltsch, V. Kumar, and K. Alitalo, *Vascular endothelial growth factor (vegf)-c synergizes with basic fibroblast growth factor and vegf in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity*. *Journal of Cellular Physiology*, 1998. **177**(3): p. 439-452.
135. Pepper, M., N. Ferrara, L. Orci, and R. Montesano, *Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro*. *Biochemical and Biophysical Research Communications*, 1992. **189**(2): p. 824-831.
136. Sun, X.-T., Y.-T. Ding, X.-G. Yan, L.-Y. Wu, Q. Li, N. Cheng, Y.-D. Qiu, and M.-Y. Zhang, *Angiogenic synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in an in vitro quantitative microcarrier-based three-dimensional fibrin angiogenesis system*. *World Journal of Gastroenterology*, 2004. **10**(17): p. 2524-2528.
137. Zieris, A., S. Prokoph, K.R. Levental, P.B. Welzel, M. Grimmer, U. Freudenberg, and C. Werner, *Fgf-2 and vegf functionalization of starpeg-heparin hydrogels to modulate biomolecular and physical cues of angiogenesis*. *Biomaterials*, 2010. **31**(31): p. 7985-7994.
138. Cao, Y., Z. Sun, L. Liao, Y. Meng, Q. Han, and R.C. Zhao, *Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo*. *Biochemical and Biophysical Research Communications*, 2005. **332**(2): p. 370-379.
139. Awada, H.K., N.R. Johnson, and Y. Wang, *Dual delivery of vascular endothelial growth factor and hepatocyte growth factor coacervate displays strong angiogenic effects*. *Macromolecular Bioscience*, 2014. **14**(5): p. 679-686.
140. Awada, H.K., N.R. Johnson, and Y. Wang, *Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction*. *Journal of Controlled Release*, 2015. **207**: p. 7-17.
141. Brudno, Y., A.B. Ennett-Shepard, R.R. Chen, M. Aizenberg, and D.J. Mooney, *Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors*. *Biomaterials*, 2013. **34**(36): p. 9201-9209.
142. Mammoto, T., A. Jiang, E. Jiang, and A. Mammoto, *Platelet rich plasma extract promotes angiogenesis through the angiotensin1-tie2 pathway*. *Microvascular Research*, 2013. **89**: p. 15-24.

143. Foster, T.E., B.L. Puskas, B.R. Mandelbaum, M.B. Gerhardt, and S.A. Rodeo, *Platelet-rich plasma: From basic science to clinical applications*. The American Journal of Sports Medicine, 2009. **37**(11): p. 2259-2272.
144. Kobayashi, M., T. Kawase, K. Okuda, L.F. Wolff, and H. Yoshie, *In vitro immunological and biological evaluations of the angiogenic potential of platelet-rich fibrin preparations: A standardized comparison with prp preparations*. International Journal of Implant Dentistry, 2015. **1**(1): p. 31-42.
145. Kaga, T., H. Kawano, M. Sakaguchi, T. Nakazawa, Y. Taniyama, and R. Morishita, *Hepatocyte growth factor stimulated angiogenesis without inflammation: Differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor*. Vascular Pharmacology, 2012. **57**(1): p. 3-9.
146. Hao, X., E.A. Silva, A. Månsson-Broberg, K.-H. Grinnemo, A.J. Siddiqui, G. Dellgren, E. Wårdell, L.Å. Brodin, D.J. Mooney, and C. Sylvén, *Angiogenic effects of sequential release of vegf-a165 and pdgf-bb with alginate hydrogels after myocardial infarction*. Cardiovascular Research, 2007. **75**(1): p. 178-185.
147. Tengood, J.E., R. Ridenour, R. Brodsky, A.J. Russell, and S.R. Little, *Sequential delivery of basic fibroblast growth factor and platelet-derived growth factor for angiogenesis*. Tissue Engineering, 2011. **17**(9-10): p. 1181-1189.
148. Freeman, I. and S. Cohen, *The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization*. Biomaterials, 2009. **30**(11): p. 2122-2131.
149. Whalen, G.F., Y. Shing, and J. Folkman, *The fate of intravenously administered bfgf and the effect of heparin*. Growth Factors, 1989. **1**(2): p. 157-64.
150. Eppler, S.M., D.L. Combs, T.D. Henry, J.J. Lopez, S.G. Ellis, J.H. Yi, B.H. Annex, E.R. McCluskey, and T.F. Zioncheck, *A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans*. Clin Pharmacol Ther, 2002. **72**(1): p. 20-32.
151. Kajio, T., K. Kawahara, and K. Kato, *Stabilization of basic fibroblast growth factor with dextran sulfate*. FEBS Letters, 1992. **306**(2-3): p. 243-246.
152. Chan, S.J., C. Love, M. Spector, S.M. Cool, V. Nurcombe, and E.H. Lo, *Endogenous regeneration: Engineering growth factors for stroke*. Neurochemistry International, 2017. **107**: p. 57-65.
153. Wijesinghe, S.J., L. Ling, S. Murali, Y.H. Qing, S.F. Hinkley, S.M. Carnachan, T.J. Bell, K. Swaminathan, J.H. Hui, A.J. van Wijnen, V. Nurcombe, and S.M. Cool, *Affinity selection of fgf2-binding heparan sulfates for ex vivo expansion of human mesenchymal stem cells*. J Cell Physiol, 2017. **232**(3): p. 566-575.
154. Chen, Y., M. Zhong, L. Liang, F. Gu, and H. Peng, *Interleukin-17 induces angiogenesis in human choroidal endothelial cells in vitro*. Investigative Ophthalmology & Visual Science, 2014. **55**(10): p. 6968-6975.
155. Amin, M.A., B.J. Rabquer, P.J. Mansfield, J.H. Ruth, H. Marotte, C.S. Haas, E.N. Reamer, and A.E. Koch, *Interleukin 18 induces angiogenesis in vitro and in vivo via src and jnk kinases*. Annals of the Rheumatic Diseases, 2010. **69**: p. 2204-2212.
156. Bae, J., D. Park, Y.-S. Lee, and D. Jeoung, *Interleukin-2 promotes angiogenesis by activation of akt and increase of ros*. Journal of Microbiology and Biotechnology, 2008. **18**(2): p. 377-382.
157. Saghiri, M.A., A. Asatourian, J. Orangi, C.M. Sorenson, and N. Sheibani, *Functional role of inorganic trace elements in angiogenesis - part i: N, fe, se, p, au, and ca*. Critical Reviews in Oncology / Hematology, 2015. **96**(1): p. 129-142.

158. Saghiri, M.A., A. Asatourian, J. Orangi, C.M. Sorenson, and N. Sheibani, *Functional role of inorganic trace elements in angiogenesis - part ii: Cr, si, zn, cu, and s*. Critical Reviews in Oncology / Hematology, 2015. **96**(1): p. 143-155.
159. Saghiri, M.A., J. Orangi, A. Asatourian, C.M. Sorenson, and N. Sheibani, *Functional role of inorganic trace elements in angiogenesis - part iii: Ti, li, ce, as, hg, va, nb and pb*. Critical Reviews in Oncology / Hematology, 2016. **98**: p. 290-301.
160. Nasulewicz, A., A. Mazur, and A. Opolski, *Role of copper in tumour angiogenesis-clinical implications*. Journal of Trace Elements in Medicine and Biology, 2004. **18**(1): p. 1-8.
161. Sen, C.K., S. Khanna, M. Venojarvi, P. Trikha, E.C. Ellison, T.K. Hunt, and S. Roy, *Copper-induced vascular endothelial growth factor expression and wound healing*. American Journal of Physiology, 2002. **282**(5): p. 1821-1827.
162. Li, Q.-f., X.-q. Ding, and Y.J. Kang, *Copper promotion of angiogenesis in isolated rat aortic ring: Role of vascular endothelial growth factor*. The Journal of Nutritional Biochemistry, 2014. **25**(1): p. 44-49.
163. Mroczek-Sosnowska, N., E. Sawosz, K.P. Vadalasetty, M. Łukasiewicz, J. Niemiec, M. Wierzbicki, M. Kutwin, S. Jaworski, and A. Chwalibog, *Nanoparticles of copper stimulate angiogenesis at systemic and molecular level*. International Journal of Molecular Sciences, 2015. **16**(3): p. 4838-4849.
164. Gérard, C., L.-J. Bordeleau, J. Barralet, and C.J. Doillon, *The stimulation of angiogenesis and collagen deposition by copper*. Biomaterials, 2010. **31**(5): p. 824-831.
165. Makris, E.A., D.J. Responde, N.K. Paschos, J.C. Hu, and K.A. Athanasiou, *Developing functional musculoskeletal tissues through hypoxia and lysyl oxidase-induced collagen cross-linking*. Proceedings of the National Academy of Sciences of the United States of America, 2014. **111**(45): p. E4832-E4841.
166. Eyre, D.R., M.A. Paz, and P.M. Gallop, *Cross-linking in collagen and elastin*. Annual Review of Biochemistry, 1984. **53**: p. 717-748.
167. Rucker, R.B. and J. Murray, *Cross-linking amino acids in collagen and elastin*. The American Journal of Clinical Nutrition, 1978. **31**(7): p. 1221-1236.
168. Bignon, M., C. Pichol-Thievend, J. Hardouin, M. Malbouyres, N. Brechot, L. Nasciutti, A. Barret, J. Teillon, E. Guillon, E. Etienne, M. Caron, R. Joubert-Caron, C. Monnot, F. Ruggiero, L. Muller, and S. Germain, *Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type iv collagen assembly in the endothelial basement membrane*. Blood, 2011. **118**(14): p. 3979-89.
169. Xie, H. and Y.J. Kang, *Role of copper in angiogenesis and its medicinal implications*. Current Medicinal Chemistry, 2009. **16**(10): p. 1304-1314.
170. Urso, E. and M. Maffia, *Behind the link between copper and angiogenesis: Established mechanisms and an overview on the role of vascular copper transport systems*. Journal of Vascular Research, 2015. **52**(3): p. 172-196.
171. Castaño, O., N.g. Sachot, E. Xuriguera, E. Engel, J.A. Planell, J.-H. Park, G.-Z. Jin, T.-H. Kim, J.-H. Kim, and H.-W. Kim, *Angiogenesis in bone regeneration: Tailored calcium release in hybrid fibrous scaffolds*. ACS Applied Materials & Interfaces, 2014. **6**(10): p. 7512-7522.
172. Zhai, W., H. Lu, L. Chen, X. Lin, Y. Huang, K. Dai, K. Naoki, G. Chen, and J. Chang, *Silicate bioceramics induce angiogenesis during bone regeneration*. Acta Biomaterialia, 2012. **8**(1): p. 341-349.
173. Yoshizawa, S., A. Brown, A. Barchowsky, and C. Sfeir, *Magnesium ion stimulation of bone marrow stromal cells enhances osteogenic activity, simulating the effect of magnesium alloy degradation*. Acta Biomaterialia, 2014. **10**(6): p. 2834-2842.

174. Villablanca, A.C., *Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro*. Journal of Applied Physiology, 1998. **84**(6): p. 2089-2098.
175. Heeschen, C., J.J. Jang, M. Weis, A. Pathak, S. Kaji, R.S. Hu, P.S. Tsao, F.L. Johnson, and J.P. Cooke, *Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis*. Nature Medicine, 2001. **7**(7): p. 833-839.
176. Carty, C.S., M. Huribal, B.U. Marsan, J.J. Ricotta, and M. Dryjski, *Nicotine and its metabolite cotinine are mitogenic for human vascular smooth muscle cells*. Journal of Vascular Surgery, 1997. **25**(4): p. 682-688.
177. Kao, Y.-H., C.-L. Yu, L.W. Chang, and H.-S. Yu, *Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro*. Chemical Research in Toxicology, 2003. **16**(4): p. 460-468.
178. Liem, P.H., N. Morimoto, R. Ito, K. Kawai, and S. Suzuki, *Treating a collagen scaffold with a low concentration of nicotine promoted angiogenesis and wound healing*. Journal of Surgical Research, 2013. **182**(2): p. 353-361.
179. Montesano, R. and L. Orci, *Tumor-promoting phorbol esters induce angiogenesis in vitro*. Cell, 1985. **42**(2): p. 469-477.
180. Cooke, J.P. and D.W. Losordo, *Nitric oxide and angiogenesis*. Circulation, 2002. **50**(1): p. 2133-2135.
181. Pipili-Synetos, E., E. Sakkoula, and M. Maragoudakis, *Nitric oxide is involved in the regulation of angiogenesis*. British Journal of Pharmacology, 1993. **108**(4): p. 855-857.
182. Wu, H.M., Q. Huang, Y. Yuan, and H.J. Granger, *Vegf induces no-dependent hyperpermeability in coronary venules*. American Journal of Physiology-Heart and Circulatory Physiology, 1996. **271**(6): p. H2735-H2739.
183. Morbidelli, L., C.-H. Chang, J.G. Douglas, H.J. Granger, F. Ledda, and M. Ziche, *Nitric oxide mediates mitogenic effect of vegf on coronary venular endothelium*. American Journal of Physiology-Heart and Circulatory Physiology, 1996. **270**(1): p. H411-H415.
184. Papapetropoulos, A., K.M. Desai, R.D. Rudic, B. Mayer, R. Zhang, M.P. Ruiz-Torres, G. García-Cardeña, J.A. Madri, and W.C. Sessa, *Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro*. The American Journal of Pathology, 1997. **150**(5): p. 1835-1844.
185. Lee, P.C., M.R. Kibbe, M.J. Schuchert, D.B. Stolz, S.C. Watkins, B.P. Griffith, T.R. Billiar, and L.L. Shears II, *Nitric oxide induces angiogenesis and upregulates $\alpha\beta 3$ integrin expression on endothelial cells*. Microvascular Research, 2000. **60**(3): p. 269-280.
186. Hood, J.D., C.J. Meininger, M. Ziche, and H.J. Granger, *Vegf upregulates ecnos message, protein, and no production in human endothelial cells*. American Journal of Physiology, 1998. **274**(3): p. H1054-H1058.
187. Mehta, V.B., Y. Zhou, A. Radulescu, and G.E. Besner, *Hb-egf stimulates enos expression and nitric oxide production and promotes enos dependent angiogenesis*. Growth Factors, 2008. **26**(6): p. 301-315.
188. Lu, A., L. Wang, and L. Qian, *The role of enos in the migration and proliferation of bone-marrow derived endothelial progenitor cells and in vitro angiogenesis*. Cell Biology International, 2015. **39**(4): p. 484-490.
189. Lau, Y.-T. and W.-C. Ma, *Nitric oxide inhibits migration of cultured endothelial cells*. Biochemical and Biophysical Research Communications, 1996. **221**(3): p. 670-674.
190. Pipili-Synetos, E., E. Sakkoula, G. Haralabopoulos, P. Andriopoulou, P. Peristeris, and M. Maragoudakis, *Evidence that nitric oxide is an endogenous antiangiogenic mediator*. British Journal of Pharmacology, 1994. **111**(3): p. 894-902.

191. Powell, J.A., S.N. Mohamed, J.S. Kerr, and S.A. Mousa, *Antiangiogenesis efficacy of nitric oxide donors*. Journal of Cellular Biochemistry, 2000. **80**(1): p. 104-14.
192. Wang, M.J., W.J. Cai, and Y.C. Zhu, *Mechanisms of angiogenesis: Role of hydrogen sulphide*. Clinical and Experimental Pharmacology & Physiology, 2010. **37**(7): p. 764-771.
193. Wang, M.J., W.J. Cai, N. Li, Y.J. Ding, Y. Chen, and Y.C. Zhu, *The hydrogen sulfide donor nabs promotes angiogenesis in a rat model of hind limb ischemia*. Antioxidants & Redox Signaling, 2010. **12**(9): p. 1065-77.
194. Cai, W.J., M.J. Wang, P.K. Moore, H.M. Jin, T. Yao, and Y.C. Zhu, *The novel proangiogenic effect of hydrogen sulfide is dependent on akt phosphorylation*. Cardiovascular Research, 2007. **76**(1): p. 29-40.
195. Tschank, G., M. Raghunath, V. Günzler, and H. Hanauske-Abel, *Pyridinedicarboxylates, the first mechanism-derived inhibitors for prolyl 4-hydroxylase, selectively suppress cellular hydroxyprolyl biosynthesis. Decrease in interstitial collagen and clq secretion in cell culture*. Biochemical Journal, 1987. **248**(3): p. 625-633.
196. Karvonen, K., L. Ala-Kokko, T. Pihlajaniemi, T. Helaakoski, S. Henke, V. Günzler, K. Kivirikko, and E. Savolainen, *Specific inactivation of prolyl 4-hydroxylase and inhibition of collagen synthesis by oxaproline-containing peptides in cultured human skin fibroblasts*. Journal of Biological Chemistry, 1990. **265**(15): p. 8415-8419.
197. Mole, D.R., I. Schlemminger, L.A. McNeill, K.S. Hewitson, C.W. Pugh, P.J. Ratcliffe, and C.J. Schofield, *2-oxoglutarate analogue inhibitors of hif prolyl hydroxylase*. Bioorganic & Medicinal Chemistry Letters, 2003. **13**(16): p. 2677-2680.
198. Switzer, B.R. and G.K. Summer, *Inhibition of collagen synthesis by α , α' -dipyridyl in human skin fibroblasts in culture*. In vitro, 1973. **9**(3): p. 160-166.
199. Knowles, H.J., Y.-M. Tian, D.R. Mole, and A.L. Harris, *Novel mechanism of action for hydralazine: Induction of hypoxia-inducible factor-1 α , vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases*. Circulation Research, 2004. **95**(2): p. 162-169.
200. Selvaraju, V., N.L. Parinandi, R.S. Adluri, J.W. Goldman, N. Hussain, J.A. Sanchez, and N. Maulik, *Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of hif-prolyl 4-hydroxylases for treatment of ischemic diseases*. Antioxidants & Redox Signaling, 2014. **20**(16): p. 2631-2665.
201. Shen, X., C. Wan, G. Ramaswamy, M. Mavalli, Y. Wang, C.L. Duvall, L.F. Deng, R.E. Guldberg, A. Eberhart, and T.L. Clemens, *Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice*. Journal of Orthopaedic Research, 2009. **27**(10): p. 1298-1305.
202. Sears, J.E., G. Hoppe, Q. Ebrahim, and B. Anand-Apte, *Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy*. Proceedings of the National Academy of Sciences, 2008. **105**(50): p. 19898-19903.
203. Nangaku, M., Y. Izuhara, S. Takizawa, T. Yamashita, Y. Fujii-Kuriyama, O. Ohneda, M. Yamamoto, C.v.Y. de Strihou, N. Hirayama, and T. Miyata, *A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia*. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007. **27**(12): p. 2548-2554.
204. Botusan, I.R., V.G. Sunkari, O. Savu, A.I. Catrina, J. Grünler, S. Lindberg, T. Pereira, S. Ylä-Herttua, L. Poellinger, and K. Brismar, *Stabilization of hif-1 α is critical to improve wound healing in diabetic mice*. Proceedings of the National Academy of Sciences, 2008. **105**(49): p. 19426-19431.
205. Holdstock, L., A.M. Meadowcroft, R. Maier, B.M. Johnson, D. Jones, A. Rastogi, S. Zeig, J.J. Lepore, and A.R. Cobitz, *Four-week studies of oral hypoxia-inducible*

- factor–prolyl hydroxylase inhibitor gsk1278863 for treatment of anemia*. Journal of the American Society of Nephrology, 2015: p. ASN. 2014111139.
206. Yeh, T.-L., T.M. Leissing, M.I. Abboud, C.C. Thinnes, O. Atasoylu, J.P. Holt-Martyn, D. Zhang, A. Tumber, K. Lippl, and C.T. Lohans, *Molecular and cellular mechanisms of hif prolyl hydroxylase inhibitors in clinical trials*. Chemical Science, 2017. **8**(11): p. 7651-7668.
 207. Berg, R.A. and D.J. Prockop, *The thermal transition of a non-hydroxylated form of collagen. Evidence for a role for hydroxyproline in stabilizing the triple-helix of collagen*. Biochemical and Biophysical Research Communications, 1973. **52**(1): p. 115-120.
 208. Hirsilä, M., P. Koivunen, V. Günzler, K.I. Kivirikko, and J. Myllyharju, *Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor*. Journal of Biological Chemistry, 2003. **278**(33): p. 30772-30780.
 209. Asikainen, T.M., A. Ahmad, B.K. Schneider, W.-B. Ho, M. Arend, M. Brenner, V. Günzler, and C.W. White, *Stimulation of hif-1 α , hif-2 α , and vegf by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells*. Free Radical Biology and Medicine, 2005. **38**(8): p. 1002-1013.
 210. Lim, S.H., C. Kim, A.R. Aref, R.D. Kamm, and M. Raghunath, *Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting*. Integrative Biology, 2013. **5**(12): p. 1474-84.
 211. Clement, P.M., H.M. Hanauske-Abel, E.C. Wolff, H.K. Kleinman, and M.H. Park, *The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro*. International Journal of Cancer, 2002. **100**(4): p. 491-8.
 212. Park, Y.K., T.-Y. Tu, S.H. Lim, I.J.M. Clement, S.Y. Yang, and R.D. Kamm, *In vitro microvessel growth and remodeling within a three-dimensional microfluidic environment*. Cellular and Molecular Bioengineering, 2014. **7**(1): p. 15-25.
 213. Ko, S.H., A. Nauta, S.D. Morrison, H. Zhou, A. Zimmermann, G.C. Gurtner, S. Ding, and M.T. Longaker, *Antimycotic ciclopirox olamine in the diabetic environment promotes angiogenesis and enhances wound healing*. PLoS One, 2011. **6**(11): p. e27844.
 214. Lim, N.S., A. Sham, S.M. Chee, C. Chan, and M. Raghunath, *Combination of ciclopirox olamine and sphingosine-1-phosphate as granulation enhancer in diabetic wounds*. Wound Repair and Regeneration, 2016. **24**(5): p. 795-809.
 215. McKay, M.J. and M.A. Gaballa, *Gene transfer therapy in vascular diseases*. Cardiovascular Therapeutics, 2001. **19**(3): p. 245-262.
 216. Storrie, H. and D.J. Mooney, *Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering*. Advanced Drug Delivery Reviews, 2006. **58**(4): p. 500-514.
 217. Iwaguro, H., J.-i. Yamaguchi, C. Kalka, S. Murasawa, H. Masuda, S.-i. Hayashi, M. Silver, T. Li, J.M. Isner, and T. Asahara, *Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration*. Circulation, 2002. **105**(6): p. 732-738.
 218. Babaei, S. and D.J. Stewart, *Overexpression of endothelial no synthase induces angiogenesis in a co-culture model*. Cardiovascular Research, 2002. **55**(1): p. 190-200.
 219. Bandara, N., S. Gurusinghe, H. Chen, S. Chen, L.-x. Wang, S.Y. Lim, and P. Strappe, *Minicircle DNA-mediated endothelial nitric oxide synthase gene transfer enhances angiogenic responses of bone marrow-derived mesenchymal stem cells*. Stem Cell Research & Therapy, 2016. **7**(48): p. 1-15.

220. Tzeng, E., Y.-M. Kim, B.R. Pitt, A. Lizonova, I. Kovesdi, and T.R. Billiar, *Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis*. *Surgery*, 1997. **122**(2): p. 255-263.
221. Cooney, R., S.O. Hynes, A.M. Duffy, F. Sharif, and T. O'Brien, *Adenoviral-mediated gene transfer of nitric oxide synthase isoforms and vascular cell proliferation*. *Journal of Vascular Research*, 2006. **43**(5): p. 462-472.
222. Kaur, S., T.S. Kumar, A. Uruno, A. Sugawara, K. Jayakumar, and C.C. Kartha, *Genetic engineering with endothelial nitric oxide synthase improves functional properties of endothelial progenitor cells from patients with coronary artery disease: An in vitro study*. *Basic Research in Cardiology*, 2009. **104**(6): p. 739-749.
223. Heikura, T., T. Nieminen, M.M. Roschier, H. Karvinen, M.U. Kaikkonen, A.J. Mähönen, H.P. Lesch, T.T. Rissanen, O.H. Laitinen, and K.J. Airene, *Baculovirus-mediated vascular endothelial growth factor- δ gene transfer induces angiogenesis in rabbit skeletal muscle*. *The Journal of Gene Medicine*, 2012. **14**(1): p. 35-43.
224. Kang, S.-W., H.-W. Lim, S.-W. Seo, O. Jeon, M. Lee, and B.-S. Kim, *Nanosphere-mediated delivery of vascular endothelial growth factor gene for therapeutic angiogenesis in mouse ischemic limbs*. *Biomaterials*, 2008. **29**(8): p. 1109-1117.
225. Mao, Z., H. Shi, R. Guo, L. Ma, C. Gao, C. Han, and J. Shen, *Enhanced angiogenesis of porous collagen scaffolds by incorporation of tmc/DNA complexes encoding vascular endothelial growth factor*. *Acta Biomaterialia*, 2009. **5**(8): p. 2983-2994.
226. Shepard, J.A., F.R. Virani, A.G. Goodman, T.D. Gossett, S. Shin, and L.D. Shea, *Hydrogel macroporosity and the prolongation of transgene expression and the enhancement of angiogenesis*. *Biomaterials*, 2012. **33**(30): p. 7412-7421.
227. Sacchi, V., R. Mittermayr, J. Hartinger, M.M. Martino, K.M. Lorentz, S. Wolbank, A. Hofmann, R.A. Largo, J.S. Marschall, and E. Groppa, *Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant vegf164*. *Proceedings of the National Academy of Sciences*, 2014. **111**(19): p. 6952-6957.
228. Carmeliet, P., *Vegf gene therapy: Stimulating angiogenesis or angioma-genesis?* *Nature Medicine*, 2000. **6**(10): p. 1102-1103.
229. Lee, R.J., M.L. Springer, W.E. Blanco-Bose, R. Shaw, P.C. Ursell, and H.M. Blau, *Vegf gene delivery to myocardium: Deleterious effects of unregulated expression*. *Circulation*, 2000. **102**(8): p. 898-901.
230. Melo, L.G., A.S. Pachori, D. Kong, M. Gneccchi, K. Wang, R.E. Pratt, and V.J. Dzau, *Gene and cell-based therapies for heart disease*. *The FASEB Journal*, 2004. **18**(6): p. 648-663.
231. Ash, J.D. and P.A. Overbeek, *Lens-specific vegf-a expression induces angioblast migration and proliferation and stimulates angiogenic remodeling*. *Developmental Biology*, 2000. **223**(2): p. 383-398.
232. Thurston, G., C. Suri, K. Smith, J. McClain, T. Sato, G. Yancopoulos, and D. McDonald, *Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1*. *Science*, 1999. **286**(5449): p. 2511-2514.
233. Drake, C.J. and C.D. Little, *Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization*. *Proceedings of the National Academy of Sciences*, 1995. **92**(17): p. 7657-7661.
234. Dor, Y., V. Djonov, R. Abramovitch, A. Itin, G.I. Fishman, P. Carmeliet, G. Goelman, and E. Keshet, *Conditional switching of vegf provides new insights into adult neovascularization and pro-angiogenic therapy*. *The EMBO Journal*, 2002. **21**(8): p. 1939-1947.

235. Mujagic, E., R. Gianni-Barrera, M. Trani, A. Patel, L. Gürke, M. Heberer, T. Wolff, and A. Banfi, *Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse vegf is species-dependent*. *Human Gene Therapy Methods*, 2013. **24**(1): p. 28-37.
236. Hiasa, K.-i., M. Ishibashi, K. Ohtani, S. Inoue, Q. Zhao, S. Kitamoto, M. Sata, T. Ichiki, A. Takeshita, and K. Egashira, *Gene transfer of stromal cell-derived factor-1 α enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: Next-generation chemokine therapy for therapeutic neovascularization*. *Circulation*, 2004. **109**(20): p. 2454-2461.
237. Schgoer, W., M. Theurl, J. Jeschke, A.G. Beer, K. Albrecht, R. Gander, S. Rong, D. Vasiljevic, M. Egger, and A.M. Wolf, *Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism*. *Circulation Research*, 2009. **105**(10): p. 994-1002.
238. Dobrucki, L.W., Y. Tsutsumi, L. Kalinowski, J. Dean, M. Gavin, S. Sen, M. Mendizabal, A.J. Sinusas, and R. Aikawa, *Analysis of angiogenesis induced by local igf-1 expression after myocardial infarction using microspect-ct imaging*. *Journal of Molecular and Cellular Cardiology*, 2010. **48**(6): p. 1071-1079.
239. Aoki, M., R. Morishita, Y. Taniyama, I. Kida, A. Moriguchi, K. Matsumoto, T. Nakamura, Y. Kaneda, J. Higaki, and T. Ogihara, *Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: Up-regulation of essential transcription factor for angiogenesis, ets*. *Gene Therapy*, 2000. **7**(5): p. 417-427.
240. Zhao, X.-Y., S.-J. Hu, J. Li, Y. Mou, C.-F. Chan, J. Jin, J. Sun, and Z.-H. Zhu, *Raav-mediated angiogenin gene transfer induces angiogenesis and modifies left ventricular remodeling in rats with myocardial infarction*. *Journal of Molecular Medicine*, 2006. **84**(12): p. 1033-1046.
241. Kondo, I., K. Ohmori, A. Oshita, H. Takeuchi, S. Fuke, K. Shinomiya, T. Noma, T. Namba, and M. Kohno, *Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: The first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction*. *Journal of the American College of Cardiology*, 2004. **44**(3): p. 644-653.
242. Deng, Q., B. Hu, S. Cao, H.-N. Song, J.-L. Chen, and Q. Zhou, *Improving the efficacy of therapeutic angiogenesis by utmd-mediated ang-1 gene delivery to the infarcted myocardium*. *International Journal of Molecular Medicine*, 2015. **36**(2): p. 335-344.
243. Korpany, G., S. Chen, R. Shohet, J.-h. Ding, B.-z. Yang, P. Frenkel, and P. Grayburn, *Targeting of vegf-mediated angiogenesis to rat myocardium using ultrasonic destruction of microbubbles*. *Gene Therapy*, 2005. **12**(17): p. 1305-1312.
244. Leong-Poi, H., M.A. Kuliszewski, M. Lekas, M. Sibbald, K. Teichert-Kuliszewska, A.L. Klibanov, D.J. Stewart, and J.R. Lindner, *Therapeutic arteriogenesis by ultrasound-mediated vegf165 plasmid gene delivery to chronically ischemic skeletal muscle*. *Circulation Research*, 2007. **101**(3): p. 295-303.
245. Sun, L., C.W. Huang, J. Wu, K.J. Chen, S.H. Li, R.D. Weisel, H. Rakowski, H.W. Sung, and R.K. Li, *The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium*. *Biomaterials*, 2013. **34**(8): p. 2107-2116.
246. Safi Jr, J., A.F. DiPaula Jr, T. Riccioni, J. Kajstura, G. Ambrosio, L.C. Becker, P. Anversa, and M.C. Capogrossi, *Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart*. *Microvascular Research*, 1999. **58**(3): p. 238-249.

247. He, S., T. Xia, H. Wang, L. Wei, X. Luo, and X. Li, *Multiple release of polyplexes of plasmids vegf and bfgf from electrospun fibrous scaffolds towards regeneration of mature blood vessels*. *Acta Biomaterialia*, 2012. **8**(7): p. 2659-2669.
248. Banfi, A., G. von Degenfeld, R. Gianni-Barrera, S. Reginato, M.J. Merchant, D.M. McDonald, and H.M. Blau, *Therapeutic angiogenesis due to balanced single-vector delivery of vegf and pdgf-bb*. *The FASEB Journal*, 2012. **26**(6): p. 2486-2497.
249. Kalka, C., H. Masuda, T. Takahashi, R. Gordon, O. Tepper, E. Gravereaux, A. Pieczek, H. Iwaguro, S.-I. Hayashi, and J.M. Isner, *Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects*. *Circulation Research*, 2000. **86**(12): p. 1198-1202.
250. Rosengart, T.K., L.Y. Lee, S.R. Patel, P.D. Kligfield, P.M. Okin, N.R. Hackett, O.W. Isom, and R.G. Crystal, *Six-month assessment of a phase i trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the vegf121 cDNA*. *Annals of Surgery*, 1999. **230**(4): p. 466.
251. Rosengart, T.K., L.Y. Lee, S.R. Patel, T.A. Sanborn, M. Parikh, G.W. Bergman, R. Hachamovitch, M. Szulc, P.D. Kligfield, and P.M. Okin, *Angiogenesis gene therapy: Phase i assessment of direct intramyocardial administration of an adenovirus vector expressing vegf121 cDNA to individuals with clinically significant severe coronary artery disease*. *Circulation*, 1999. **100**(5): p. 468-474.
252. Stewart, D.J., M.J. Kutryk, D. Fitchett, M. Freeman, N. Camack, Y. Su, A. Della Siega, L. Bilodeau, J.R. Burton, and G. Proulx, *Vegf gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: Results of the northern trial*. *Molecular Therapy*, 2009. **17**(6): p. 1109-1115.
253. Losordo, D.W., P.R. Vale, J.F. Symes, C.H. Dunnington, D.D. Esakof, M. Maysky, A.B. Ashare, K. Lathi, and J.M. Isner, *Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phvegf165 as sole therapy for myocardial ischemia*. *Circulation*, 1998. **98**(25): p. 2800-2804.
254. Symes, J.F., D.W. Losordo, P.R. Vale, K.G. Lathi, D.D. Esakof, M. Mayskiy, and J.M. Isner, *Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease*. *The Annals of Thoracic Surgery*, 1999. **68**(3): p. 830-836.
255. Losordo, D.W., P.R. Vale, R.C. Hendel, C.E. Milliken, F.D. Fortuin, N. Cummings, R.A. Schatz, T. Asahara, J.M. Isner, and R.E. Kuntz, *Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia*. *Circulation*, 2002. **105**(17): p. 2012-2018.
256. Kastrup, J., E. Jørgensen, A. Rück, K. Tägil, D. Glogar, W. Ruzyllo, H.E. Bøtker, D. Dudek, V. Drvota, and B. Hesse, *Direct intramyocardial plasmid vascular endothelial growth factor- α 165 gene therapy in patients with stable severe angina pectoris: A randomized double-blind placebo-controlled study: The euroinject one trial*. *Journal of the American College of Cardiology*, 2005. **45**(7): p. 982-988.
257. Rajagopalan, S., E.R. Mohler, R.J. Lederman, F.O. Mendelsohn, J.F. Saucedo, C.K. Goldman, J. Blebea, J. Macko, P.D. Kessler, and H.S. Rasmussen, *Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease*. *Circulation*, 2003. **108**(16): p. 1933-1938.
258. Shyu, K.-G., H. Chang, B.-W. Wang, and P. Kuan, *Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia*. *The American Journal of Medicine*, 2003. **114**(2): p. 85-92.
259. Mäkinen, K., H. Manninen, M. Hedman, P. Matsi, H. Mussalo, E. Alhava, and S. Ylä-Herttua, *Increased vascularity detected by digital subtraction angiography after*

- vegf gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase ii study.* *Molecular Therapy*, 2002. **6**(1): p. 127-133.
260. Kusumanto, Y., V. Van Weel, N. Mulder, A. Smit, J. Van Den Dungen, J. Hooymans, W. Sluiter, R. Tio, P. Quax, and R. Gans, *Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial.* *Human Gene Therapy*, 2006. **17**(6): p. 683-691.
261. Nikol, S., I. Baumgartner, E. Van Belle, C. Diehm, A. Visoná, M.C. Capogrossi, N. Ferreira-Maldent, A. Gallino, M.G. Wyatt, and L.D. Wijesinghe, *Therapeutic angiogenesis with intramuscular *nvIfgf* improves amputation-free survival in patients with critical limb ischemia.* *Molecular Therapy*, 2008. **16**(5): p. 972-978.
262. Belch, J., W.R. Hiatt, I. Baumgartner, I.V. Driver, S. Nikol, L. Norgren, and E. Van Belle, *Effect of fibroblast growth factor *nvIfgf* on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia.* *The Lancet*, 2011. **377**(9781): p. 1929-1937.
263. Morishita, R., H. Makino, M. Aoki, N. Hashiya, K. Yamasaki, J. Azuma, Y. Taniyama, Y. Sawa, Y. Kaneda, and T. Ogihara, *Phase i/iii clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia.* *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2011. **31**(3): p. 713-720.
264. Shigematsu, H., K. Yasuda, T. Iwai, T. Sasajima, S. Ishimaru, Y. Ohashi, T. Yamaguchi, T. Ogihara, and R. Morishita, *Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia.* *Gene Therapy*, 2010. **17**(9): p. 1152-1161.
265. Henry, T., A. Hirsch, J. Goldman, Y. Wang, D. Lips, W. McMillan, S. Duval, T. Biggs, and H. Keo, *Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: A phase i study.* *Gene Therapy*, 2011. **18**(8): p. 788-794.
266. Rajagopalan, S., J. Olin, S. Deitcher, A. Pieczek, J. Laird, P.M. Grossman, C.K. Goldman, K. McEllin, R. Kelly, and N. Chronos, *Use of a constitutively active hypoxia-inducible factor-1 α transgene as a therapeutic strategy in no-option critical limb ischemia patients: Phase i dose-escalation experience.* *Circulation*, 2007. **115**(10): p. 1234-1243.
267. Goldman, J., J.M. Rutkowski, J.D. Shields, M.C. Pasquier, Y. Cui, H.G. Schmökel, S. Willey, D.J. Hicklin, B. Pytowski, and M.A. Swartz, *Cooperative and redundant roles of *vegfr-2* and *vegfr-3* signaling in adult lymphangiogenesis.* *The FASEB Journal*, 2007. **21**(4): p. 1003-1012.
268. Hong, Y.K., N. Harvey, Y.H. Noh, V. Schacht, S. Hirakawa, M. Detmar, and G. Oliver, **Prox1* is a master control gene in the program specifying lymphatic endothelial cell fate.* *Developmental Dynamics*, 2002. **225**(3): p. 351-357.
269. Björndahl, M., R. Cao, L.J. Nissen, S. Clasper, L.A. Johnson, Y. Xue, Z. Zhou, D. Jackson, A.J. Hansen, and Y. Cao, *Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo.* *Proceedings of the National Academy of Sciences*, 2005. **102**(43): p. 15593-15598.
270. Szuba, A., M. Skobe, M.J. Karkkainen, W.S. Shin, D.P. Beynet, N.B. Rockson, N. Dakhil, S. Spilman, M.L. Goris, and H.W. Strauss, *Therapeutic lymphangiogenesis with human recombinant *vegf-c*.* *The FASEB Journal*, 2002. **16**(14): p. 1985-1987.
271. Güç, E., P.S. Briquez, D. Foretay, M.A. Fankhauser, J.A. Hubbell, W.W. Kilarski, and M.A. Swartz, *Local induction of lymphangiogenesis with engineered fibrin-binding*

- vegf-c promotes wound healing by increasing immune cell trafficking and matrix remodeling.* Biomaterials, 2017. **131**: p. 160-175.
272. Cao, R., M.A. Björndahl, M.I. Gallego, S. Chen, P. Religa, A.J. Hansen, and Y. Cao, *Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action.* Blood, 2006. **107**(9): p. 3531-3536.
273. Saaristo, A., T. Tammela, J. Timonen, S. Ylä-Herttuala, E. Tukiainen, S. Asko-Seljavaara, and K. Alitalo, *Vascular endothelial growth factor-c gene therapy restores lymphatic flow across incision wounds.* The FASEB Journal, 2004. **18**(14): p. 1707-1709.
274. Saaristo, A., T. Veikkola, T. Tammela, B. Enholm, M.J. Karkkainen, K. Pajusola, H. Bueler, S. Ylä-Herttuala, and K. Alitalo, *Lymphangiogenic gene therapy with minimal blood vascular side effects.* Journal of Experimental Medicine, 2002. **196**(6): p. 719-730.
275. Zhou, Q., R. Guo, R. Wood, B.F. Boyce, Q. Liang, Y.J. Wang, E.M. Schwarz, and L. Xing, *Vascular endothelial growth factor c attenuates joint damage in chronic inflammatory arthritis by accelerating local lymphatic drainage in mice.* Arthritis & Rheumatism, 2011. **63**(8): p. 2318-2328.
276. Yoon, Y.-s., T. Murayama, E. Gravereaux, T. Tkebuchava, M. Silver, C. Curry, A. Wecker, R. Kirchmair, C.S. Hu, and M. Kearney, *Vegf-c gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.* The Journal of Clinical Investigation, 2003. **111**(5): p. 717-725.
277. Saito, Y., H. Nakagami, R. Morishita, Y. Takami, Y. Kikuchi, H. Hayashi, T. Nishikawa, K. Tamai, N. Azuma, and T. Sasajima, *Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis.* Circulation, 2006. **114**(11): p. 1177-1184.
278. Goldman, J., T.X. Le, M. Skobe, and M.A. Swartz, *Overexpression of vegf-c causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin.* Circulation Research, 2005. **96**(11): p. 1193-1199.
279. Saaristo, A., T. Veikkola, B. Enholm, M. Hytonen, J. Arola, K. Pajusola, P. Turunen, M. Jeltsch, M.J. Karkkainen, and D. Kerjaschki, *Adenoviral vegf-c overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.* The FASEB Journal, 2002. **16**(9): p. 1041-1049.
280. Reher, P., N. Doan, B. Bradnock, S. Meghji, and M. Harris, *Effect of ultrasound on the production of il-8, basic fgf and vegf.* Cytokine, 1999. **11**(6): p. 416-423.
281. Barzelai, S., O. Sharabani-Yosef, R. Holbova, D. Castel, R. Walden, S. Engelberg, and M. Scheinowitz, *Low-intensity ultrasound induces angiogenesis in rat hind-limb ischemia.* Ultrasound Med Biol, 2006. **32**(1): p. 139-45.
282. Mizrahi, N., D. Seliktar, and E. Kimmel, *Ultrasound-induced angiogenic response in endothelial cells.* Ultrasound in Medicine & Biology, 2007. **33**(11): p. 1818-1829.
283. Hanawa, K., K. Ito, K. Aizawa, T. Shindo, K. Nishimiya, Y. Hasebe, R. Tuburaya, H. Hasegawa, S. Yasuda, H. Kanai, and H. Shimokawa, *Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia.* PLoS One, 2014. **9**(8): p. e104863.
284. Dungal, P., J. Hartinger, S. Chaudary, P. Slezak, A. Hofmann, T. Hausner, M. Strassl, E. Wintner, H. Redl, and R. Mittermayr, *Low level light therapy by led of different wavelength induces angiogenesis and improves ischemic wound healing.* Lasers Surg Med, 2014. **46**(10): p. 773-80.
285. Park, I.-S., P.-S. Chung, and J.C. Ahn, *Adipose-derived stromal cell cluster with light therapy enhance angiogenesis and skin wound healing in mice.* Biochemical and Biophysical Research Communications, 2015. **462**(3): p. 171-177.

286. Park, I.-S., P.-S. Chung, and J.C. Ahn, *Enhanced angiogenic effect of adipose-derived stromal cell spheroid with low-level light therapy in hind limb ischemia mice*. *Biomaterials*, 2014. **35**(34): p. 9280-9289.
287. Pan, Y., Y. Dong, W. Hou, Z. Ji, K. Zhi, Z. Yin, H. Wen, and Y. Chen, *Effects of pemf on microcirculation and angiogenesis in a model of acute hindlimb ischemia in diabetic rats*. *Bioelectromagnetics*, 2013. **34**(3): p. 180-8.
288. Li, R.-L., J.-J. Huang, Y.-Q. Shi, A. Hu, Z.-Y. Lu, L. Weng, S.-Q. Wang, Y.-P. Han, L. Zhang, C.-N. Hao, and J.-L. Duan, *Pulsed electromagnetic field improves postnatal neovascularization in response to hindlimb ischemia*. *American Journal of Translational Research*, 2015. **7**(3): p. 430-444.
289. Hao, C.-N., J.-J. Huang, Y.-Q. Shi, X.-W. Cheng, H.-Y. Li, L. Zhou, X.-G. Guo, R.-L. Li, W. Lu, Y.-Z. Zhu, and J.-L. Duan, *Pulsed electromagnetic field improves cardiac function in response to myocardial infarction*. *American Journal of Translational Research*, 2014. **6**(3): p. 281-290.
290. Scheel, C., E.N. Eaton, S.H. Li, C.L. Chaffer, F. Reinhardt, K.J. Kah, G. Bell, W. Guo, J. Rubin, A.L. Richardson, and R.A. Weinberg, *Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast*. *Cell*, 2011. **145**(6): p. 926-40.
291. Liang, X., Y. Ding, Y. Zhang, H.F. Tse, and Q. Lian, *Paracrine mechanisms of mesenchymal stem cell-based therapy: Current status and perspectives*. *Cell Transplant*, 2014. **23**(9): p. 1045-59.
292. Lu, H., K.R. Clauser, W.L. Tam, J. Fröse, X. Ye, E.N. Eaton, F. Reinhardt, V.S. Donnerberg, R. Bhargava, S.A. Carr, and R.A. Weinberg, *A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages*. *Nature Cell Biology*, 2014. **16**: p. 1105-1117.
293. Hetheridge, C., G. Mavria, and H. Mellor, *Uses of the in vitro endothelial-fibroblast organotypic co-culture assay in angiogenesis research*. *Biochemical Society Transactions*, 2011. **39**(6): p. 1597-1600.
294. Shen, C., P. Lie, T. Miao, M. Yu, Q. Lu, T. Feng, J. Li, T. Zu, X. Liu, and H. Li, *Conditioned medium from umbilical cord mesenchymal stem cells induces migration and angiogenesis*. *Mol Med Rep*, 2015. **12**(1): p. 20-30.
295. Todorova, D., S. Simoncini, R. Lacroix, F. Sabatier, and F. Dignat-George, *Extracellular vesicles in angiogenesis*. *Circulation Research*, 2017. **120**(10): p. 1658-1673.
296. Blocki, A., Y. Wang, M. Koch, P. Peh, S. Beyer, P. Law, J. Hui, and M. Raghunath, *Not all mscs can act as pericytes: Functional in vitro assays to distinguish pericytes from other mesenchymal stem cells in angiogenesis*. *Stem Cells and Development*, 2013. **22**(17): p. 2347-2355.
297. Blocki, A., Y. Wang, M. Koch, A. Goralczyk, S. Beyer, N. Agarwal, M. Lee, S. Moonshi, J.-Y. Dewavrin, and P. Peh, *Sourcing of an alternative pericyte-like cell type from peripheral blood in clinically relevant numbers for therapeutic angiogenic applications*. *Molecular Therapy*, 2015. **23**(3): p. 510-522.
298. Christman, K.L., A.J. Vardanian, Q. Fang, R.E. Sievers, H.H. Fok, and R.J. Lee, *Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium*. *Journal of the American College of Cardiology*, 2004. **44**(3): p. 654-660.
299. Kutschka, I., I.Y. Chen, T. Kofidis, T. Arai, G. von Degenfeld, A.Y. Sheikh, S.L. Hendry, J. Pearl, G. Hoyt, R. Sista, P.C. Yang, H.M. Blau, S.S. Gambhir, and R.C. Robbins, *Collagen matrices enhance survival of transplanted cardiomyoblasts and*

- contribute to functional improvement of ischemic rat hearts.* Circulation, 2006. **114**(1 Suppl): p. I167-I173.
300. Blocki, A., S. Beyer, J.-Y. Dewavrin, A. Goralczyk, Y. Wang, P. Peh, M. Ng, S.S. Moonshi, S. Vuddagiri, and M. Raghunath, *Microcapsules engineered to support mesenchymal stem cell (msc) survival and proliferation enable long-term retention of mscs in infarcted myocardium.* Biomaterials, 2015. **53**: p. 12-24.
 301. Compagna, R., B. Amato, S. Massa, M. Amato, R. Grande, L. Butrico, S. de Franciscis, and R. Serra, *Cell therapy in patients with critical limb ischemia.* Stem Cells International, 2015. **2015**: p. 931420.
 302. Murohara, T., H. Ikeda, J. Duan, S. Shintani, K.-i. Sasaki, H. Eguchi, I. Onitsuka, K. Matsui, and T. Imaizumi, *Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization.* Journal of Clinical Investigation, 2000. **105**(11): p. 1527-1536.
 303. Hristov, M., W. Erl, and P.C. Weber, *Endothelial progenitor cells: Isolation and characterization.* Trends in Cardiovascular Medicine, 2003. **13**(5): p. 201-206.
 304. Asahara, T., H. Masuda, T. Takahashi, C. Kalka, C. Pastore, M. Silver, M. Kearne, M. Magner, and J.M. Isner, *Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.* Circulation Research, 1999. **85**(3): p. 221-8.
 305. Shintani, S., T. Murohara, H. Ikeda, T. Ueno, K. Sasaki, J. Duan, and T. Imaizumi, *Augmentation of postnatal neovascularization with autologous bone marrow transplantation.* Circulation, 2001. **103**(6): p. 897-903.
 306. Gehling, U.M., S. Ergun, U. Schumacher, C. Wagener, K. Pantel, M. Otte, G. Schuch, P. Schafhausen, T. Mende, N. Kilic, K. Kluge, B. Schafer, D.K. Hossfeld, and W. Fiedler, *In vitro differentiation of endothelial cells from ac133-positive progenitor cells.* Blood, 2000. **95**(10): p. 3106-12.
 307. Peichev, M., A.J. Naiyer, D. Pereira, Z. Zhu, W.J. Lane, M. Williams, M.C. Oz, D.J. Hicklin, L. Witte, M.A. Moore, and S. Rafii, *Expression of vegfr-2 and ac133 by circulating human cd34(+) cells identifies a population of functional endothelial precursors.* Blood, 2000. **95**(3): p. 952-8.
 308. Asahara, T., T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B. Witzenbichler, G. Schatteman, and J.M. Isner, *Isolation of putative progenitor endothelial cells for angiogenesis.* Science, 1997. **275**(5302): p. 964-7.
 309. Kaushal, S., G.E. Amiel, K.J. Guleserian, O.M. Shapira, T. Perry, F.W. Sutherland, E. Rabkin, A.M. Moran, F.J. Schoen, A. Atala, S. Soker, J. Bischoff, and J.E. Mayer, Jr., *Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo.* Nat Med, 2001. **7**(9): p. 1035-40.
 310. Murohara, T., *Autologous adipose tissue as a new source of progenitor cells for therapeutic angiogenesis.* Journal of Cardiology, 2009. **53**(2): p. 155-163.
 311. Reyes, M., A. Dudek, B. Jahagirdar, L. Koodie, P.H. Marker, and C.M. Verfaillie, *Origin of endothelial progenitors in human postnatal bone marrow.* The Journal of Clinical Investigation, 2002. **109**(3): p. 337-46.
 312. Urbich, C., C. Heeschen, A. Aicher, E. Dernbach, A.M. Zeiher, and S. Dimmeler, *Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells.* Circulation, 2003. **108**(20): p. 2511-2516.
 313. Kalka, C., H. Masuda, T. Takahashi, W.M. Kalka-Moll, M. Silver, M. Kearney, T. Li, J.M. Isner, and T. Asahara, *Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization.* Proceedings of the National Academy of Sciences of the United States of America, 2000. **97**(7): p. 3422-7.

314. Kawamoto, A., H. Iwasaki, K. Kusano, T. Murayama, A. Oyamada, M. Silver, C. Hulbert, M. Gavin, A. Hanley, H. Ma, M. Kearney, V. Zak, T. Asahara, and D.W. Losordo, *Cd34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells*. *Circulation*, 2006. **114**(20): p. 2163-9.
315. Wang, C., Q. Wang, W. Gao, Z. Zhang, Y. Lou, H. Jin, X. Chen, B. Lei, H. Xu, and C. Mao, *Highly efficient local delivery of endothelial progenitor cells significantly potentiates angiogenesis and full-thickness wound healing*. *Acta Biomaterialia*, 2018. **69**: p. 156-169.
316. Kawamoto, A., M. Katayama, N. Handa, M. Kinoshita, H. Takano, M. Horii, K. Sadamoto, A. Yokoyama, T. Yamanaka, R. Onodera, A. Kuroda, R. Baba, Y. Kaneko, T. Tsukie, Y. Kurimoto, Y. Okada, Y. Kihara, S. Morioka, M. Fukushima, and T. Asahara, *Intramuscular transplantation of g-csf-mobilized cd34(+) cells in patients with critical limb ischemia: A phase i/ii, multicenter, single-blinded, dose-escalation clinical trial*. *Stem Cells*, 2009. **27**(11): p. 2857-64.
317. Losordo, D.W., M.R. Kibbe, F. Mendelsohn, W. Marston, V.R. Driver, M. Sharafuddin, V. Teodorescu, B.N. Wiechmann, C. Thompson, L. Kraiss, T. Carman, S. Dohad, P. Huang, C.E. Junge, K. Story, T. Weistroffer, T.M. Thorne, M. Millay, J.P. Runyon, and R. Schainfeld, *A randomized, controlled pilot study of autologous cd34+ cell therapy for critical limb ischemia*. *Circulation: Cardiovascular Interventions*, 2012. **5**(6): p. 821-830.
318. Burt, R.K., A. Testori, Y. Oyama, H.E. Rodriguez, K. Yaung, M. Villa, J.M. Bucha, F. Milanetti, J. Sheehan, N. Rajamannan, and W.H. Pearce, *Autologous peripheral blood cd133+ cell implantation for limb salvage in patients with critical limb ischemia*. *Bone Marrow Transplantation*, 2010. **45**(1): p. 111-116.
319. Giraldi-Guimaraes, A., H.T. de Freitas, P. Coelho Bde, H. Macedo-Ramos, R. Mendez-Otero, L.A. Cavalcante, and W. Baetas-da-Cruz, *Bone marrow mononuclear cells and mannose receptor expression in focal cortical ischemia*. *Brain Research*, 2012. **1452**: p. 173-84.
320. Tateishi-Yuyama, E., H. Matsubara, T. Murohara, U. Ikeda, S. Shintani, H. Masaki, K. Amano, Y. Kishimoto, K. Yoshimoto, and H. Akashi, *Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial*. *The Lancet*, 2002. **360**(9331): p. 427-435.
321. Kamihata, H., H. Matsubara, T. Nishiue, S. Fujiyama, Y. Tsutsumi, R. Ozono, H. Masaki, Y. Mori, O. Iba, E. Tateishi, A. Kosaki, S. Shintani, T. Murohara, T. Imaizumi, and T. Iwasaka, *Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines*. *Circulation*, 2001. **104**(9): p. 1046-52.
322. Fujita, Y., M. Ihara, T. Ushiki, H. Hirai, S. Kizaka-Kondoh, M. Hiraoka, H. Ito, and R. Takahashi, *Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow*. *Stroke*, 2010. **41**(12): p. 2938-43.
323. Hamano, K., M. Nishida, K. Hirata, A. Mikamo, T.-S. Li, M. Harada, T. Miura, M. Matsuzaki, and K. Esato, *Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease*. *Japanese Circulation Journal*, 2001. **65**(9): p. 845-847.

324. Chang, M.-Y., T.-T. Huang, C.-H. Chen, B. Cheng, S.-M. Hwang, and P.C.H. Hsieh, *Injection of human cord blood cells with hyaluronan improves postinfarction cardiac repair in pigs*. *Stem Cells Translational Medicine*, 2016. **5**(1): p. 56-66.
325. Huang, P.P., X.F. Yang, S.Z. Li, J.C. Wen, Y. Zhang, and Z.C. Han, *Randomised comparison of g-csf-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans*. *Thrombosis and Haemostasis*, 2007. **98**(6): p. 1335-1342.
326. Dash, N.R., S.N. Dash, P. Routray, S. Mohapatra, and P.C. Mohapatra, *Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells*. *Rejuvenation Research*, 2009. **12**(5): p. 359-366.
327. Zhu, Y., Y. Hojo, U. Ikeda, and K. Shimada, *Production of hepatocyte growth factor during acute myocardial infarction*. *Heart*, 2000. **83**(4): p. 450-5.
328. Hojo, Y., U. Ikeda, Y. Zhu, M. Okada, S. Ueno, H. Arakawa, H. Fujikawa, T.-a. Katsuki, and K. Shimada, *Expression of vascular endothelial growth factor in patients with acute myocardial infarction*. *Journal of the American College of Cardiology*, 2000. **35**(4): p. 968-973.
329. Walter, D.H., H. Krankenberg, J.O. Balzer, C. Kalka, I. Baumgartner, M. Schluter, T. Tonn, F. Seeger, S. Dimmeler, E. Lindhoff-Last, and A.M. Zeiher, *Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: A randomized-start, placebo-controlled pilot trial (provasa)*. *Circulation: Cardiovascular Interventions*, 2011. **4**(1): p. 26-37.
330. Madaric, J., A. Klepanec, M. Valachovicova, M. Mistrik, M. Bucova, I. Olejarova, R. Necpal, T. Madaricova, L. Paulis, and I. Vulev, *Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia*. *Stem Cell Research & Therapy*, 2016. **7**(1): p. 1-8.
331. Huang, P., S. Li, M. Han, Z. Xiao, R. Yang, and Z.C. Han, *Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes*. *Diabetes Care*, 2005. **28**(9): p. 2155-2160.
332. Poncelet, A.J., A.L. Hiel, J. Vercruyse, D. Hermans, F. Zech, and P. Gianello, *Intracardiac allogeneic mesenchymal stem cell transplantation elicits neo-angiogenesis in a fully immunocompetent ischaemic swine model*. *European Journal of Cardio-thoracic Surgery*, 2010. **38**(6): p. 781-7.
333. Fujita, Y. and A. Kawamoto, *Stem cell-based peripheral vascular regeneration*. *Advanced Drug Delivery Reviews*, 2017. **120**: p. 25-40.
334. Miao, C., M. Lei, W. Hu, S. Han, and Q. Wang, *A brief review: The therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction*. *Stem Cell Research & Therapy*, 2017. **8**(1): p. 242.
335. Kobayashi, T., K. Hamano, T.-S. Li, T. Katoh, S. Kobayashi, M. Matsuzaki, and K. Esato, *Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model*. *Journal of Surgical Research*, 2000. **89**(2): p. 189-195.
336. Iwase, T., N. Nagaya, T. Fujii, T. Itoh, S. Murakami, T. Matsumoto, K. Kangawa, and S. Kitamura, *Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia*. *Cardiovasc Research* 2005. **66**(3): p. 543-551.
337. Wu, Y., L. Chen, P.G. Scott, and E.E. Tredget, *Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis*. *Stem Cells*, 2007. **25**(10): p. 2648-2659.
338. Kim, C.H., J.H. Lee, J.H. Won, and M.K. Cho, *Mesenchymal stem cells improve wound healing in vivo via early activation of matrix metalloproteinase-9 and vascular*

- endothelial growth factor*. Journal of Korean Medical Science, 2011. **26**(6): p. 726-733.
339. Chen, S., J. Shi, M. Zhang, Y. Chen, X. Wang, L. Zhang, Z. Tian, Y. Yan, Q. Li, and W. Zhong, *Mesenchymal stem cell-laden anti-inflammatory hydrogel enhances diabetic wound healing*. Scientific Reports, 2015. **5**: p. 18104.
340. Gupta, P.K., M. Krishna, A. Chullikana, S. Desai, R. Murugesan, S. Dutta, U. Sarkar, R. Raju, A. Dhar, R. Parakh, L. Jeyaseelan, P. Viswanathan, P.K. Vellotare, R.N. Seetharam, C. Thej, M. Rengasamy, S. Balasubramanian, and A.S. Majumdar, *Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to buerger's disease: Phase ii study report suggests clinical efficacy*. Stem Cells Translational Medicine, 2017. **6**(3): p. 689-699.
341. Chen, S.-l., W.-w. Fang, F. Ye, Y.-H. Liu, J. Qian, S.-j. Shan, J.-j. Zhang, R.Z. Chunhua, L.-m. Liao, S. Lin, and J.-p. Sun, *Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction*. The American Journal of Cardiology, 2004. **94**(1): p. 92-95.
342. Wollert, K.C., G.P. Meyer, J. Lotz, S. Ringes Lichtenberg, P. Lippolt, C. Breidenbach, S. Fichtner, T. Korte, B. Hornig, D. Messinger, L. Arseniev, B. Hertenstein, A. Ganser, and H. Drexler, *Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The boost randomised controlled clinical trial*. The Lancet, 2004. **364**(9429): p. 141-148.
343. Jeevanantham, V., M. Butler, A. Saad, A. Abdel-Latif, E.K. Zuba-Surma, and B. Dawn, *Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: A systematic review and meta-analysis*. Circulation, 2012. **126**(5): p. 551-68.
344. Gyongyosi, M., I. Lang, M. Dettke, G. Beran, S. Graf, H. Sochor, N. Nyolczas, S. Charwat, R. Hemetsberger, G. Christ, I. Edes, L. Balogh, K.T. Krause, K. Jaquet, K.H. Kuck, I. Benedek, T. Hintea, R. Kiss, I. Preda, V. Kotevski, H. Pejkov, S. Zamini, A. Khorsand, G. Sodeck, A. Kaider, G. Maurer, and D. Glogar, *Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: The mystar prospective, randomized study*. Nature Clinical Practice. Cardiovascular Medicine, 2009. **6**(1): p. 70-81.
345. Patila, T., M. Lehtinen, A. Vento, J. Schildt, J. Sinisalo, M. Laine, P. Hammainen, A. Nihtinen, R. Alitalo, P. Nikkinen, A. Ahonen, M. Holmstrom, K. Lauerma, R. Poyhia, M. Kupari, E. Kankuri, and A. Harjula, *Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: A prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass*. The Journal of the Heart and Lung Transplantation, 2014. **33**(6): p. 567-74.
346. Hare, J.M., J.E. Fishman, G. Gerstenblith, D.L. DiFede Velazquez, J.P. Zambrano, V.Y. Suncion, M. Tracy, E. Ghersin, P.V. Johnston, J.A. Brinker, E. Breton, J. Davis-Sproul, I.H. Schulman, J. Byrnes, A.M. Mendizabal, M.H. Lowery, D. Rouy, P. Altman, C. Wong Po Foo, P. Ruiz, A. Amador, J. Da Silva, I.K. McNiece, A.W. Heldman, R. George, and A. Lardo, *Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial*. Jama, 2012. **308**(22): p. 2369-79.
347. Bang, O.Y., J.S. Lee, P.H. Lee, and G. Lee, *Autologous mesenchymal stem cell transplantation in stroke patients*. Annals of Neurology, 2005. **57**(6): p. 874-882.

348. Bhasin, A., M.P. Srivastava, S.S. Kumaran, S. Mohanty, R. Bhatia, S. Bose, S. Gaikwad, A. Garg, and B. Airan, *Autologous mesenchymal stem cells in chronic stroke*. *Cerebrovascular Diseases Extra*, 2011. **1**(1): p. 93-104.
349. Hess, D.C., C.A. Sila, A.J. Furlan, L.R. Wechsler, J.A. Switzer, and R.W. Mays, *A double-blind placebo-controlled clinical evaluation of multistem for the treatment of ischemic stroke*. *International Journal of Stroke*, 2014. **9**(3): p. 381-386.
350. Keimpema, E., M. Fokkens, Z. Nagy, V. Agoston, P. Luiten, C. Nyakas, H. Boddeke, and J. Copray, *Early transient presence of implanted bone marrow stem cells reduces lesion size after cerebral ischaemia in adult rats*. *Neuropathology and Applied Neurobiology*, 2009. **35**(1): p. 89-102.
351. Komatsu, K., O. Honmou, J. Suzuki, K. Houkin, H. Hamada, and J.D. Kocsis, *Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia*. *Brain Research*, 2010. **1334**: p. 84-92.
352. Ishizaka, S., N. Horie, K. Satoh, Y. Fukuda, N. Nishida, and I. Nagata, *Intra-arterial cell transplantation provides timing-dependent cell distribution and functional recovery after stroke*. *Stroke*, 2013. **44**(3): p. 720-726.
353. Kawabori, M., S. Kuroda, M. Ito, H. Shichinohe, K. Houkin, Y. Kuge, and N. Tamaki, *Timing and cell dose determine therapeutic effects of bone marrow stromal cell transplantation in rat model of cerebral infarct*. *Neuropathology*, 2013. **33**(2): p. 140-148.
354. Rehman, J., D. Traktuev, J. Li, S. Merfeld-Clauss, C.J. Temm-Grove, J.E. Bovenkerk, C.L. Pell, B.H. Johnstone, R.V. Considine, and K.L. March, *Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells*. *Circulation*, 2004. **109**(10): p. 1292-1298.
355. Nakagami, H., K. Maeda, R. Morishita, S. Iguchi, T. Nishikawa, Y. Takami, Y. Kikuchi, Y. Saito, K. Tamai, T. Ogihara, and Y. Kaneda, *Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells*. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2005. **25**(12): p. 2542-7.
356. Rubina, K., N. Kalinina, A. Efimenko, T. Lopatina, V. Melikhova, Z. Tsokolaeva, V. Sysoeva, V. Tkachuk, and Y. Parfyonova, *Adipose stromal cells stimulate angiogenesis via promoting progenitor cell differentiation, secretion of angiogenic factors, and enhancing vessel maturation*. *Tissue Engineering Part A*, 2009. **15**(8): p. 2039-2050.
357. Cai, L., B.H. Johnstone, T.G. Cook, J. Tan, M.C. Fishbein, P.-S. Chen, and K.L. March, *Human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function*. *Stem Cells* 2009. **27**(1): p. 230-237.
358. Zheng, Y., J. Qin, X. Wang, Z. Peng, P. Hou, and X. Lu, *Dynamic imaging of allogeneic adipose-derived regenerative cells transplanted in ischemic hind limb of apolipoprotein e mouse model*. *International Journal of Nanomedicine*, 2017. **12**: p. 61-71.
359. Kondo, K., S. Shintani, R. Shibata, H. Murakami, R. Murakami, M. Imaizumi, Y. Kitagawa, and T. Murohara, *Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis*. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2009. **29**(1): p. 61-6.
360. Zhang, X., H. Wang, X. Ma, A. Adila, B. Wang, F. Liu, B. Chen, C. Wang, and Y. Ma, *Preservation of the cardiac function in infarcted rat hearts by the transplantation of adipose-derived stem cells with injectable fibrin scaffolds*. *Experimental Biology and Medicine*, 2010. **235**(12): p. 1505-1515.

361. Houtgraaf, J.H., W.K. den Dekker, B.M. van Dalen, T. Springeling, R. de Jong, R.J. van Geuns, M.L. Geleijnse, F. Fernandez-Aviles, F. Zijlsta, P.W. Serruys, and H.J. Duckers, *First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with st-segment elevation myocardial infarction*. Journal of the American College of Cardiology, 2012. **59**(5): p. 539-540.
362. Perin, E.C., R. Sanz-Ruiz, P.L. Sanchez, J. Lasso, R. Perez-Cano, J.C. Alonso-Farto, E. Perez-David, M.E. Fernandez-Santos, P.W. Serruys, H.J. Duckers, J. Kastrup, S. Chamuleau, Y. Zheng, G.V. Silva, J.T. Willerson, and F. Fernandez-Aviles, *Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The precise trial*. American Heart Journal, 2014. **168**(1): p. 88-95.e2.
363. Bura, A., V. Planat-Benard, P. Bourin, J.-S. Silvestre, F. Gross, J.-L. Grolleau, B. Saint-Lebese, J.-A. Peyrafitte, S. Fleury, M. Gadelorge, M. Taurand, S. Dupuis-Coronas, B. Leobon, and L. Casteilla, *Phase i trial: The use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia*. Cytotherapy, 2014. **16**(2): p. 245-257.
364. Gaengel, K., G. Genove, A. Armulik, and C. Betsholtz, *Endothelial-mural cell signaling in vascular development and angiogenesis*. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009. **29**(5): p. 630-8.
365. Nehls, V., K. Denzer, and D. Drenckhahn, *Pericyte involvement in capillary sprouting during angiogenesis in situ*. Cell and Tissue Research, 1992. **270**(3): p. 469-474.
366. Blocki, A., S. Beyer, F. Jung, and M. Raghunath, *The controversial origin of pericytes during angiogenesis - implications for cell-based therapeutic angiogenesis and cell-based therapies*. Clinical Hemorheology and Microcirculation, 2018. **69**(1-2): p. 215-232.
367. Gerhardt, H. and C. Betsholtz, *Endothelial-pericyte interactions in angiogenesis*. Cell and Tissue Research, 2003. **314**(1): p. 15-23.
368. Caplan, A.I., *All mscs are pericytes?* Cell Stem Cell, 2008. **3**(3): p. 229-230.
369. Armulik, A., G. Genové, and C. Betsholtz, *Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises*. Developmental Cell, 2011. **21**(2): p. 193-215.
370. Chen, C.W., M. Okada, J.D. Proto, X. Gao, N. Sekiya, S.A. Beckman, M. Corselli, M. Crisan, A. Saparov, K. Tobita, B. Peault, and J. Huard, *Human pericytes for ischemic heart repair*. Stem Cells, 2013. **31**(2): p. 305-16.
371. Katare, R., F. Riu, K. Mitchell, M. Gubernator, P. Campagnolo, Y. Cui, O. Fortunato, E. Avolio, D. Cesselli, A.P. Beltrami, G. Angelini, C. Emanuelli, and P. Madeddu, *Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-rna-132*. Circulation Research, 2011. **109**(8): p. 894-906.
372. Quinn, C. and A.W. Flake, *In vivo differentiation potential of mesenchymal stem cells: Prenatal and postnatal model systems*. Transfusion Medicine and Hemotherapy, 2008. **35**(3): p. 239-247.
373. Zhang, J., X. Huang, H. Wang, X. Liu, T. Zhang, Y. Wang, and D. Hu, *The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy*. Stem Cell Research & Therapy, 2015. **6**: p. 234.
374. Brahimi-Horn, M.C. and J. Pouyssegur, *Oxygen, a source of life and stress*. FEBS Letters, 2007. **581**(19): p. 3582-3591.
375. Rosova, I., M. Dao, B. Capoccia, D. Link, and J.A. Nolte, *Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells*. Stem Cells, 2008. **26**(8): p. 2173-82.

376. Shweiki, D., A. Itin, D. Soffer, and E. Keshet, *Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis*. *Nature*, 1992. **359**(6398): p. 843-845.
377. Kudo, T., T. Hosoyama, M. Samura, S. Katsura, A. Nishimoto, N. Kugimiya, Y. Fujii, T.-S. Li, and K. Hamano, *Hypoxic preconditioning reinforces cellular functions of autologous peripheral blood-derived cells in rabbit hindlimb ischemia model*. *Biochemical and Biophysical Research Communications*, 2014. **444**(3): p. 370-375.
378. Han, K.-H., A.-K. Kim, M.-H. Kim, D.-H. Kim, H.-N. Go, and D.-I. Kim, *Enhancement of angiogenic effects by hypoxia-preconditioned human umbilical cord-derived mesenchymal stem cells in a mouse model of hindlimb ischemia*. *Cell Biology International*, 2016. **40**(1): p. 27-35.
379. Wei, L., J.L. Fraser, Z.Y. Lu, X. Hu, and S.P. Yu, *Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats*. *Neurobiology of Disease*, 2012. **46**(3): p. 635-645.
380. Fan, L., C. Zhang, Z. Yu, Z. Shi, X. Dang, and K. Wang, *Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and osteogenesis in rabbit femoral head osteonecrosis*. *Bone*, 2015. **81**: p. 544-553.
381. Bader, A.M., K. Klose, K. Bieback, D. Korinth, M. Schneider, M. Seifert, Y.H. Choi, A. Kurtz, V. Falk, and C. Stamm, *Hypoxic preconditioning increases survival and pro-angiogenic capacity of human cord blood mesenchymal stromal cells in vitro*. *PLoS ONE*, 2015. **10**(9): p. e0138477.
382. Hu, X., S.P. Yu, J.L. Fraser, Z. Lu, M.E. Ogle, J.-A. Wang, and L. Wei, *Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis*. *The Journal of Thoracic and Cardiovascular Surgery*, 2008. **135**(4): p. 799-808.
383. Hamano, K., T.-S. Li, T. Kobayashi, S. Kobayashi, M. Matsuzaki, and K. Esato, *Angiogenesis induced by the implantation of self-bone marrow cells: A new material for therapeutic angiogenesis*. *Cell Transplantation*, 2000. **9**(3): p. 439-443.
384. Perez-Amodio, S., W.M. Tra, H.A. Rakhurst, S.E. Hovius, and J.W. van Neck, *Hypoxia preconditioning of tissue-engineered mucosa enhances its angiogenic capacity in vitro*. *Tissue Engineering*, 2011. **17**(11-12): p. 1583-93.
385. Von Offenbergsweeney, N., P.M. Cummins, E.J. Cotter, P.A. Fitzpatrick, Y.A. Birney, E.M. Redmond, and P.A. Cahill, *Cyclic strain-mediated regulation of vascular endothelial cell migration and tube formation*. *Biochemical and Biophysical Research Communications*, 2005. **329**(2): p. 573-582.
386. Morrow, D., J.P. Cullen, P.A. Cahill, and E.M. Redmond, *Cyclic strain regulates the notch/cbf-1 signaling pathway in endothelial cells: Role in angiogenic activity*. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2007. **27**(6): p. 1289-96.
387. Ingber, D.E., *Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology*. *Circulation research*, 2002. **91**(10): p. 877-887.
388. Matsumoto, T., Y.C. Yung, C. Fischbach, H.J. Kong, R. Nakaoka, and D.J. Mooney, *Mechanical strain regulates endothelial cell patterning in vitro*. *Tissue Engineering*, 2007. **13**(1): p. 207-17.
389. Glaeser, J.D., S. Geissler, A. Ode, C.J. Schipp, G. Matziolis, W.R. Taylor, P. Knaus, C. Perka, G.N. Duda, and G. Kasper, *Modulation of matrix metalloprotease-2 levels by mechanical loading of three-dimensional mesenchymal stem cell constructs: Impact on in vitro tube formation*. *Tissue Engineering*, 2010. **16**(10): p. 3139-3148.

390. Cassino, T.R., L. Drowley, M. Okada, S.A. Beckman, B. Keller, K. Tobita, P.R. LeDuc, and J. Huard, *Mechanical loading of stem cells for improvement of transplantation outcome in a model of acute myocardial infarction: The role of loading history*. Tissue Engineering, 2012. **18**(11-12): p. 1101-1108.
391. Lee, E., D.Y. Kim, E. Chung, E.A. Lee, K.S. Park, and Y. Son, *Transplantation of cyclic stretched fibroblasts accelerates the wound-healing process in streptozotocin-induced diabetic mice*. Cell Transplantation, 2014. **23**(3): p. 285-301.
392. Yen - Patton, G.A., W.F. Patton, D.M. Beer, and B.S. Jacobson, *Endothelial cell response to pulsed electromagnetic fields: Stimulation of growth rate and angiogenesis in vitro*. Journal of Cellular Physiology, 1988. **134**(1): p. 37-46.
393. Tepper, O.M., M.J. Callaghan, E.I. Chang, R.D. Galiano, K.A. Bhatt, S. Baharestani, J. Gan, B. Simon, R.A. Hopper, J.P. Levine, and G.C. Gurtner, *Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of fgf-2*. The FASEB Journal, 2004. **18**(11): p. 1231-3.
394. Delle Monache, S., R. Alessandro, R. Iorio, G. Gualtieri, and R. Colonna, *Extremely low frequency electromagnetic fields (elf-emfs) induce in vitro angiogenesis process in human endothelial cells*. Bioelectromagnetics, 2008. **29**(8): p. 640-648.
395. Hao, C.N., J.J. Huang, Y.Q. Shi, X.W. Cheng, H.Y. Li, L. Zhou, X.G. Guo, R.L. Li, W. Lu, Y.Z. Zhu, and J.L. Duan, *Pulsed electromagnetic field improves cardiac function in response to myocardial infarction*. American Journal of Translational Research, 2014. **6**(3): p. 281-290.
396. Callaghan, M.J., E.I. Chang, N. Seiser, S. Aarabi, S. Ghali, E.R. Kinnucan, B.J. Simon, and G.C. Gurtner, *Pulsed electromagnetic fields accelerate normal and diabetic wound healing by increasing endogenous fgf-2 release*. Plastic and Reconstructive Surgery, 2008. **121**(1): p. 130-141.
397. Lu, Z.-Y., H.-S. Zhou, Z.-X. Su, J. Qi, J. Zhang, G.-H. Xue, Y. Li, C.-N. Hao, Y.-Q. Shi, and J.-L. Duan, *Therapeutic ultrasound plus pulsed electromagnetic field improves recovery from peripheral arterial disease in hypertension*. American Journal of Translational Research, 2017. **9**(9): p. 4184.
398. Funk, R.H., *Coupling of pulsed electromagnetic fields (pemf) therapy to molecular grounds of the cell*. American Journal of Translational Research, 2018. **10**(5): p. 1260-1272.
399. Pall, M.L., *Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects*. Journal of Cellular and Molecular Medicine, 2013. **17**(8): p. 958-965.
400. Efimenko, A., N. Dzhoyashvili, N. Kalinina, T. Kochegura, R. Akchurin, V. Tkachuk, and Y. Parfyonova, *Adipose-derived mesenchymal stromal cells from aged patients with coronary artery disease keep mesenchymal stromal cell properties but exhibit characteristics of aging and have impaired angiogenic potential*. Stem Cells Translational Medicine, 2014. **3**(1): p. 32-41.
401. Haider, H.K., L. Ye, S. Jiang, R. Ge, P.K. Law, T. Chua, P. Wong, and E.K. Sim, *Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor*. Journal of Molecular Medicine, 2004. **82**(8): p. 539-549.
402. Lu, Y., J. Shansky, M. Del Totto, P. Ferland, X. Wang, and H. Vandenberg, *Recombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis*. Circulation, 2001. **104**(5): p. 594-599.

403. Supp, D.M., A.P. Supp, S.T. Boyce, and S.M. Bell, *Enhanced vascularization of cultured skin substitutes genetically modified to overexpress vascular endothelial growth factor*. *Journal of Investigative Dermatology*, 2000. **114**(1): p. 5-13.
404. Nishiyama, K., K. Takaji, K. Kataoka, Y. Kurihara, M. Yoshimura, A. Kato, H. Ogawa, and H. Kurihara, *Id1 gene transfer confers angiogenic property on fully differentiated endothelial cells and contributes to therapeutic angiogenesis*. *Circulation*, 2005. **112**(18): p. 2840-2850.
405. Yang, F., S.-W. Cho, S.M. Son, S.R. Bogatyrev, D. Singh, J.J. Green, Y. Mei, S. Park, S.H. Bhang, and B.-S. Kim, *Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles*. *Proceedings of the National Academy of Sciences*, 2010. **107**(8): p. 3317-3322.
406. Gao, F., T. He, H. Wang, S. Yu, D. Yi, W. Liu, and Z. Cai, *A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats*. *Canadian Journal of Cardiology*, 2007. **23**(11): p. 891-898.
407. Matsumoto, R., T. Omura, M. Yoshiyama, T. Hayashi, S. Inamoto, K.-R. Koh, K. Ohta, Y. Izumi, Y. Nakamura, and K. Akioka, *Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction*. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2005. **25**(6): p. 1168-1173.
408. Deuse, T., C. Peter, P.W. Fedak, T. Doyle, H. Reichenspurner, W.H. Zimmermann, T. Eschenhagen, W. Stein, J.C. Wu, and R.C. Robbins, *Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction*. *Circulation*, 2009. **120**: p. S247-S254.
409. Mangi, A.A., N. Noiseux, D. Kong, H. He, M. Rezvani, J.S. Ingwall, and V.J. Dzau, *Mesenchymal stem cells modified with akt prevent remodeling and restore performance of infarcted hearts*. *Nature Medicine*, 2003. **9**(9): p. 1195-1201.
410. Ahmed, R.P., K.H. Haider, J. Shujia, M.R. Afzal, and M. Ashraf, *Sonic hedgehog gene delivery to the rodent heart promotes angiogenesis via inos/netrin-1/pkc pathway*. *PloS ONE*, 2010. **5**(1): p. e8576.
411. Xiang, Q., Y. Liao, H. Chao, W. Huang, J. Liu, H. Chen, D. Hong, Z. Zou, A.P. Xiang, and W. Li, *Isl1 overexpression enhances the survival of transplanted human mesenchymal stem cells in a murine myocardial infarction model*. *Stem Cell Research & Therapy*, 2018. **9**: p. 51.
412. Shevchenko, E.K., P.I. Makarevich, Z.I. Tsokolaeva, M.A. Boldyreva, V.Y. Sysoeva, V.A. Tkachuk, and Y.V. Parfyonova, *Transplantation of modified human adipose derived stromal cells expressing vegf165 results in more efficient angiogenic response in ischemic skeletal muscle*. *Journal of Translational Medicine*, 2013. **11**(1): p. 138.
413. Paul, A., M. Nayan, A.A. Khan, D. Shum-Tim, and S. Prakash, *Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: Investigation in rat heart with acute infarction*. *International Journal of Nanomedicine*, 2012. **7**: p. 663-682.
414. Sen, S., J. Merchan, J. Dean, M. Li, M. Gavin, M. Silver, T. Tkebuchava, Y.S. Yoon, J.E. Rasko, and R. Aikawa, *Autologous transplantation of endothelial progenitor cells genetically modified by adeno-associated viral vector delivering insulin-like growth factor-1 gene after myocardial infarction*. *Human Gene Therapy*, 2010. **21**(10): p. 1327-1334.
415. Fu, S.S., F.J. Li, Y.Y. Wang, A.B. You, Y.L. Qie, X. Meng, J.R. Li, B.C. Li, Y. Zhang, and Q. Da Li, *Kallikrein gene-modified epcs induce angiogenesis in rats with*

- ischemic hindlimb and correlate with integrin $\alpha\beta 3$ expression*. PloS ONE, 2013. **8**(9): p. e73035.
416. Emanuelli, C., A. Zacheo, A. Minasi, J. Chao, L. Chao, M.B. Salis, T. Stacca, S. Straino, M.C. Capogrossi, and P. Madeddu, *Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle*. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000. **20**(11): p. 2379-2385.
417. Thomas, C.E., A. Ehrhardt, and M.A. Kay, *Progress and problems with the use of viral vectors for gene therapy*. Nature Reviews Genetics, 2003. **4**(5): p. 346-58.
418. Al-Dosari, M.S. and X. Gao, *Nonviral gene delivery: Principle, limitations, and recent progress*. The AAPS Journal, 2009. **11**(4): p. 671-681.
419. Kuchroo, P., V. Dave, A. Vijayan, C. Viswanathan, and D. Ghosh, *Paracrine factors secreted by umbilical cord-derived mesenchymal stem cells induce angiogenesis in vitro by a vegf-independent pathway*. Stem Cells and Development, 2014. **24**(4): p. 437-450.
420. Doorn, J., J. van de Peppel, J.P. van Leeuwen, N. Groen, C.A. van Blitterswijk, and J. de Boer, *Pro-osteogenic trophic effects by pka activation in human mesenchymal stromal cells*. Biomaterials, 2011. **32**(26): p. 6089-6098.
421. Khan, M., F. Ali, S. Mohsin, S. Akhtar, A. Mehmood, M.S. Choudhery, S.N. Khan, and S. Riazuddin, *Preconditioning diabetic mesenchymal stem cells with myogenic medium increases their ability to repair diabetic heart*. Stem Cell Research & Therapy, 2013. **4**(3): p. 58-58.
422. Waters, R., P. Alam, S. Pacelli, A.R. Chakravarti, R.P.H. Ahmed, and A. Paul, *Stem cell-inspired secretome-rich injectable hydrogel to repair injured cardiac tissue*. Acta Biomaterialia, 2018. **69**: p. 95-106.
423. Burlacu, A., G. Grigorescu, A.-M. Rosca, M.B. Preda, and M. Simionescu, *Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro*. Stem Cells and Development, 2012. **22**(4): p. 643-653.
424. Kasper, G., N. Dankert, J. Tuischer, M. Hoeft, T. Gaber, J.D. Glaeser, D. Zander, M. Tschirschmann, M. Thompson, G. Matziolis, and G.N. Duda, *Mesenchymal stem cells regulate angiogenesis according to their mechanical environment*. Stem Cells, 2007. **25**(4): p. 903-910.
425. Takahashi, A., R. Okada, K. Nagao, Y. Kawamata, A. Hanyu, S. Yoshimoto, M. Takasugi, S. Watanabe, M.T. Kanemaki, C. Obuse, and E. Hara, *Exosomes maintain cellular homeostasis by excreting harmful DNA from cells*. Nature Communications, 2017. **8**: p. 15287.
426. Théry, C., L. Zitvogel, and S. Amigorena, *Exosomes: Composition, biogenesis and function*. Nature Reviews Immunology, 2002. **2**: p. 569.
427. Tkach, M. and C. Thery, *Communication by extracellular vesicles: Where we are and where we need to go*. Cell, 2016. **164**(6): p. 1226-1232.
428. Conlan, R.S., S. Pisano, M.I. Oliveira, M. Ferrari, and I. Mendes Pinto, *Exosomes as reconfigurable therapeutic systems*. Trends in Molecular Medicine, 2017. **23**(7): p. 636-650.
429. Zhang, J., C. Chen, B. Hu, X. Niu, X. Liu, G. Zhang, C. Zhang, Q. Li, and Y. Wang, *Exosomes derived from human endothelial progenitor cells accelerate cutaneous wound healing by promoting angiogenesis through erk1/2 signaling*. International Journal of Biological Sciences, 2016. **12**(12): p. 1472-1487.
430. Li, X., C. Jiang, and J. Zhao, *Human endothelial progenitor cells-derived exosomes accelerate cutaneous wound healing in diabetic rats by promoting endothelial function*. Journal of Diabetes and its Complications, 2016. **30**(6): p. 986-992.

431. Liang, X., L. Zhang, S. Wang, Q. Han, and R.C. Zhao, *Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring mir-125a*. *Journal of Cell Science*, 2016. **129**(11): p. 2182-2189.
432. Shabbir, A., A. Cox, L. Rodriguez-Menocal, M. Salgado, and E.V. Badiavas, *Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro*. *Stem Cells and Development*, 2015. **24**(14): p. 1635-1647.
433. Zhang, H.-C., X.-B. Liu, S. Huang, X.-Y. Bi, H.-X. Wang, L.-X. Xie, Y.-Q. Wang, X.-F. Cao, J. Lv, and F.-J. Xiao, *Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo*. *Stem Cells and Development*, 2012. **21**(18): p. 3289-3297.
434. Hu, G.W., Q. Li, X. Niu, B. Hu, J. Liu, S.M. Zhou, S.C. Guo, H.L. Lang, C.Q. Zhang, Y. Wang, and Z.F. Deng, *Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice*. *Stem Cell Research & Therapy*, 2015. **6**: p. 10.
435. Zhang, B., X. Wu, X. Zhang, Y. Sun, Y. Yan, H. Shi, Y. Zhu, L. Wu, Z. Pan, W. Zhu, H. Qian, and W. Xu, *Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the wnt4/beta-catenin pathway*. *Stem Cells Transl Med*, 2015. **4**(5): p. 513-22.
436. Arslan, F., R.C. Lai, M.B. Smeets, L. Akeroyd, A. Choo, E.N. Agur, L. Timmers, H.V. van Rijen, P.A. Doevendans, G. Pasterkamp, S.K. Lim, and D.P. de Kleijn, *Mesenchymal stem cell-derived exosomes increase atp levels, decrease oxidative stress and activate pi3k/akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury*. *Stem Cell Research*, 2013. **10**(3): p. 301-312.
437. Mathiyalagan, P., Y. Liang, D. Kim, S. Misener, T. Thorne, C.E. Kamide, E. Klyachko, D.W. Losordo, R.J. Hajjar, and S. Sahoo, *Angiogenic mechanisms of human cd34(+) stem cell exosomes in the repair of ischemic hindlimb*. *Circulation Research*, 2017. **120**(9): p. 1466-1476.
438. Reiner, A.T., K.W. Witwer, B.W. Van Balkom, J. De Beer, C. Brodie, R.L. Corteling, S. Gabriellsson, M. Gimona, A.G. Ibrahim, and D. De Kleijn, *Developing best-practice models for the therapeutic use of extracellular vesicles*. *Stem Cells Translational Medicine*, 2017. **6**(8): p. 1730-1739.
439. Bennuru, S. and T.B. Nutman, *Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: Implications for pathogenesis*. *PLoS Pathogens*, 2009. **5**(12): p. e1000688.
440. Qi, S. and J. Pan, *Cell-based therapy for therapeutic lymphangiogenesis*. *Stem Cells and Development*, 2014. **24**(3): p. 271-283.
441. Kawai, Y., H. Shiomi, H. Abe, S. Naka, Y. Kurumi, and T. Tani, *Cell transplantation therapy for a rat model of secondary lymphedema*. *Journal of Surgical Research*, 2014. **189**(1): p. 184-191.
442. Shimizu, Y., R. Shibata, S. Shintani, M. Ishii, and T. Murohara, *Therapeutic lymphangiogenesis with implantation of adipose-derived regenerative cells*. *Journal of the American Heart Association*, 2012. **1**(4): p. 1-15.
443. Yoshida, S., R. Hamuy, Y. Hamada, H. Yoshimoto, A. Hirano, and S. Akita, *Adipose-derived stem cell transplantation for therapeutic lymphangiogenesis in a mouse secondary lymphedema model*. *Regenerative Medicine*, 2015. **10**(5): p. 549-562.
444. Yan, A., T. Avraham, J.C. Zampell, Y.S. Haviv, E. Weitman, and B.J. Mehrara, *Adipose-derived stem cells promote lymphangiogenesis in response to vegf-c stimulation or tgf- β 1 inhibition*. *Future Oncology*, 2011. **7**(12): p. 1457-1473.

445. Conrad, C., H. Niess, R. Huss, S. Huber, I. von Luetlichau, P.J. Nelson, H.C. Ott, K.-W. Jauch, and C.J. Bruns, *Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo*. *Circulation*, 2009. **119**(2): p. 281-289.
446. Hwang, J.H., I.G. Kim, J.Y. Lee, S. Piao, D.S. Lee, T.S. Lee, J.C. Ra, and J.Y. Lee, *Therapeutic lymphangiogenesis using stem cell and vegf-c hydrogel*. *Biomaterials*, 2011. **32**(19): p. 4415-4423.
447. Maldonado, G.E.M., C.A.A. Pérez, E.E.A. Covarrubias, S.A.M. Cabriales, L.A. Leyva, J.C.J. Pérez, and D.G. Almaguer, *Autologous stem cells for the treatment of post-mastectomy lymphedema: A pilot study*. *Cytotherapy*, 2011. **13**(10): p. 1249-1255.
448. Hou, C., X. Wu, and X. Jin, *Autologous bone marrow stromal cells transplantation for the treatment of secondary arm lymphedema: A prospective controlled study in patients with breast cancer related lymphedema*. *Japanese Journal of Clinical Oncology*, 2008. **38**(10): p. 670-674.
449. Freyman, T., G. Polin, H. Osman, J. Crary, M. Lu, L. Cheng, M. Palasis, and R.L. Wilensky, *A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction*. *European Heart Journal*, 2006. **27**(9): p. 1114-1122.
450. Sekine, H., T. Shimizu, I. Dobashi, K. Matsuura, N. Hagiwara, M. Takahashi, E. Kobayashi, M. Yamato, and T. Okano, *Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection*. *Tissue Engineering*, 2011. **17**(23-24): p. 2973-2980.
451. Kim, D.W., I. Jun, T.-J. Lee, J. hye Lee, Y.J. Lee, H.-K. Jang, S. Kang, K.D. Park, S.-W. Cho, and B.-S. Kim, *Therapeutic angiogenesis by a myoblast layer harvested by tissue transfer printing from cell-adhesive, thermosensitive hydrogels*. *Biomaterials*, 2013. **34**(33): p. 8258-8268.
452. Ishii, M., R. Shibata, Y. Numaguchi, T. Kito, H. Suzuki, K. Shimizu, A. Ito, H. Honda, and T. Murohara, *Enhanced angiogenesis by transplantation of mesenchymal stem cell sheet created by a novel magnetic tissue engineering method*. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2011. **31**(10): p. 2210-2215.
453. Bhang, S.H., S. Lee, T.-J. Lee, W.-G. La, H.-S. Yang, S.-W. Cho, and B.-S. Kim, *Three-dimensional cell grafting enhances the angiogenic efficacy of human umbilical vein endothelial cells*. *Tissue Engineering*, 2011. **18**(3): p. 310-319.
454. Bhang, S.H., S. Lee, J.-Y. Shin, T.-J. Lee, and B.-S. Kim, *Transplantation of cord blood mesenchymal stem cells as spheroids enhances vascularization*. *Tissue Engineering*, 2012. **18**(19-20): p. 2138-2147.
455. Chen, D.-Y., H.-J. Wei, K.-J. Lin, C.-C. Huang, C.-C. Wang, C.-T. Wu, K.-T. Chao, K.-J. Chen, Y. Chang, and H.-W. Sung, *Three-dimensional cell aggregates composed of huvecs and cbmscs for therapeutic neovascularization in a mouse model of hindlimb ischemia*. *Biomaterials*, 2013. **34**(8): p. 1995-2004.
456. Udelson, J.E., V. Dilsizian, R.J. Laham, N. Chronos, J. Vansant, M. Blais, J.R. Galt, M. Pike, C. Yoshizawa, and M. Simons, *Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease*. *Circulation*, 2000. **102**(14): p. 1605-1610.
457. Hendel, R.C., T.D. Henry, K. Rocha-Singh, J.M. Isner, D.J. Kereiakes, F.J. Giordano, M. Simons, and R.O. Bonow, *Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect*. *Circulation*, 2000. **101**(2): p. 118-121.

458. Olson, E., L. Demopoulos, T.F. Haws, E. Hu, Z. Fang, K.M. Mahar, P. Qin, J. Lepore, T.A. Bauer, and W.R. Hiatt, *Short-term treatment with a novel hif-prolyl hydroxylase inhibitor (gsk1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease*. *Vascular Medicine*, 2014. **19**(6): p. 473-482.
459. Akizawa, T., Y. Tsubakihara, M. Nangaku, Y. Endo, H. Nakajima, T. Kohno, Y. Imai, N. Kawase, K. Hara, J. Lepore, and A. Cobitz, *Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in japanese hemodialysis subjects*. *Am J Nephrol*, 2017. **45**(2): p. 127-135.
460. Holdstock, L., A.M. Meadowcroft, R. Maier, B.M. Johnson, D. Jones, A. Rastogi, S. Zeig, J.J. Lepore, and A.R. Cobitz, *Four-week studies of oral hypoxia-inducible factor–prolyl hydroxylase inhibitor gsk1278863 for treatment of anemia*. *Journal of the American Society of Nephrology : JASN*, 2016. **27**(4): p. 1234-1244.
461. Provenzano, R., A. Besarab, C.H. Sun, S.A. Diamond, J.H. Durham, J.L. Cangiano, J.R. Aiello, J.E. Novak, T. Lee, R. Leong, B.K. Roberts, K.G. Saikali, S. Hemmerich, L.A. Szczech, K.-H.P. Yu, and T.B. Neff, *Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (fg-4592) for the treatment of anemia in patients with ckd*. *Clinical Journal of the American Society of Nephrology* 2016. **11**(6): p. 982-991.
462. Besarab, A., E. Chernyavskaya, I. Motylev, E. Shutov, L.M. Kumbar, K. Gurevich, D.T.M. Chan, R. Leong, L. Poole, M. Zhong, K.G. Saikali, M. Franco, S. Hemmerich, K.-H.P. Yu, and T.B. Neff, *Roxadustat (fg-4592): Correction of anemia in incident dialysis patients*. *Journal of the American Society of Nephrology : JASN*, 2016. **27**(4): p. 1225-1233.
463. Pergola, P.E., B.S. Spinowitz, C.S. Hartman, B.J. Maroni, and V.H. Haase, *Vadadustat, a novel oral hif stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease*. *Kidney International*, 2016. **90**(5): p. 1115-1122.
464. Stewart, D., J. Hilton, J. Arnold, J. Gregoire, A. Rivard, S. Archer, F. Charbonneau, E. Cohen, M. Curtis, and C. Buller, *Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of advegf 121 versus maximum medical treatment*. *Gene Therapy*, 2006. **13**(21): p. 1503-1511.
465. Vale, P.R., D.W. Losordo, C.E. Milliken, M.C. McDonald, L.M. Gravelin, C.M. Curry, D.D. Esakof, M. Maysky, J.F. Symes, and J.M. Isner, *Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia*. *Circulation*, 2001. **103**(17): p. 2138-2143.
466. Grines, C.L., M.W. Watkins, G. Helmer, W. Penny, J. Brinker, J.D. Marmur, A. West, J.J. Rade, P. Marrott, and H.K. Hammond, *Angiogenic gene therapy (agent) trial in patients with stable angina pectoris*. *Circulation*, 2002. **105**(11): p. 1291-1297.
467. Comerota, A.J., R.C. Throm, K.A. Miller, T. Henry, N. Chronos, J. Laird, R. Sequeira, C.K. Kent, M. Bacchetta, and C. Goldman, *Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase i trial*. *Journal of Vascular Surgery*, 2002. **35**(5): p. 930-936.
468. Morishita, R., M. Aoki, N. Hashiya, H. Makino, K. Yamasaki, J. Azuma, Y. Sawa, H. Matsuda, Y. Kaneda, and T. Ogihara, *Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease*. *Hypertension*, 2004. **44**(2): p. 203-209.

469. Powell, R.J., P. Goodney, F.O. Mendelsohn, E.K. Moen, and B.H. Annex, *Safety and efficacy of patient specific intramuscular injection of hgf plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: Results of the hgf-0205 trial*. Journal of Vascular Surgery, 2010. **52**(6): p. 1525-1530.
470. Gu, Y., J. Zhang, L. Guo, S. Cui, X. Li, D. Ding, J.M. Kim, S.H. Ho, W. Hahn, and S. Kim, *A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia*. The Journal of Gene Medicine, 2011. **13**(11): p. 602-610.
471. Kim, H.-J., S.Y. Jang, J.-I. Park, J. Byun, D.-I. Kim, Y.-S. Do, J.-M. Kim, S. Kim, B.-M. Kim, and W.-B. Kim, *Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease*. Experimental & Molecular Medicine, 2004. **36**(4): p. 336-344.
472. Baumgartner, I., A. Pieczek, O. Manor, R. Blair, M. Kearney, K. Walsh, and J.M. Isner, *Constitutive expression of phvegf165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia*. Circulation, 1998. **97**(12): p. 1114-1123.
473. Creager, M.A., J.W. Olin, J.J.F. Belch, G.L. Moneta, T.D. Henry, S. Rajagopalan, B.H. Annex, and W.R. Hiatt, *Effect of hypoxia-inducible factor-1 α gene therapy on walking performance in patients with intermittent claudication*. Circulation, 2011. **124**(16): p. 1765.
474. Tateishi-Yuyama, E., H. Matsubara, T. Murohara, U. Ikeda, S. Shintani, H. Masaki, K. Amano, Y. Kishimoto, K. Yoshimoto, H. Akashi, K. Shimada, T. Iwasaka, and T. Imaizumi, *Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial*. Lancet, 2002. **360**(9331): p. 427-435.
475. Lu, D., B. Chen, Z. Liang, W. Deng, Y. Jiang, S. Li, J. Xu, Q. Wu, Z. Zhang, B. Xie, and S. Chen, *Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial*. Diabetes Research and Clinical Practice, 2011. **92**(1): p. 26-36.
476. Matoba, S., T. Tatsumi, T. Murohara, T. Imaizumi, Y. Katsuda, M. Ito, Y. Saito, S. Uemura, H. Suzuki, and S. Fukumoto, *Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (therapeutic angiogenesis by cell transplantation [tact] trial) in patients with chronic limb ischemia*. American Heart Journal, 2008. **156**(5): p. 1010-1018.
477. Prochazka, V., J. Gumulec, F. Jaluvka, D. Salounova, T. Jonszta, D. Czerny, J. Krajca, R. Urbanec, P. Klement, J. Martinek, and G.L. Klement, *Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer*. Cell Transplantation, 2010. **19**(11): p. 1413-1424.
478. Benoit, E., T.F. O'Donnell, Jr., M.D. Iafrazi, E. Asher, D.F. Bandyk, J.W. Hallett, A.B. Lumsden, G.J. Pearl, S.P. Roddy, K. Vijayaraghavan, and A.N. Patel, *The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: Implications for clinical trial design*. Journal of Translational Medicine, 2011. **9**: p. 165.
479. Li, M., H. Zhou, X. Jin, M. Wang, S. Zhang, and L. Xu, *Autologous bone marrow mononuclear cells transplant in patients with critical leg ischemia: Preliminary clinical results*. Experimental and Clinical Transplantation, 2013. **11**(5): p. 435-439.
480. Gupta, P.K., A. Chullikana, R. Parakh, S. Desai, A. Das, S. Gottipamula, S. Krishnamurthy, N. Anthony, A. Pherwani, and A.S. Majumdar, *A double blind*

- randomized placebo controlled phase i/ii study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia.* Journal of Translational Medicine, 2013. **11**: p. 143.
481. Van Tongeren, R.B., J.F. Hamming, W.E. Fibbe, V. Van Weel, S.J. Frerichs, A.M. Stiggelbout, J.H. Van Bockel, and J.H. Lindeman, *Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: A clinical trial in patients with advanced limb ischemia.* The Journal of Cardiovascular Surgery, 2008. **49**(1): p. 51-58.
482. Pignon, B., M.A. Sevestre, L. Kanagaratnam, G. Pernod, D. Stephan, J. Emmerich, C. Clement, G. Sarlon, C. Boulon, C. Tournois, and P. Nguyen, *Autologous bone marrow mononuclear cell implantation and its impact on the outcome of patients with critical limb ischemia - results of a randomized, double-blind, placebo-controlled trial.* Circulation Journal, 2017. **81**(11): p. 1713-1720.
483. Janssens, S., C. Dubois, J. Bogaert, K. Theunissen, C. Deroose, W. Desmet, M. Kalantzi, L. Herbots, P. Sinnaeve, J. Dens, J. Maertens, F. Rademakers, S. Dymarkowski, O. Gheysens, J. Van Cleemput, G. Bormans, J. Nuyts, A. Belmans, L. Mortelmans, M. Boogaerts, and F. Van de Werf, *Autologous bone marrow-derived stem-cell transfer in patients with st-segment elevation myocardial infarction: Double-blind, randomised controlled trial.* Lancet, 2006. **367**(9505): p. 113-21.
484. Skóra, J., A. Pupka, D. Janczak, P. Barć, T. Dawiskiba, K. Korta, D. Baczyńska, A. Mastalerz-Migas, and J. Garcarek, *Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia.* Archives of Medical Science : AMS, 2015. **11**(2): p. 325-331.
485. Ozturk, A., Y. Kucukardali, F. Tangi, A. Erikci, G. Uzun, C. Bashekim, H. Sen, H. Terekeci, Y. Narin, M. Ozyurt, S. Ozkan, O. Sayan, O. Rodop, S. Nalbant, O. Sildiroglu, F.F. Yalniz, I.V. Senkal, H. Sabuncu, and C. Oktenli, *Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia.* Journal of Diabetes and its Complications, 2012. **26**(1): p. 29-33.
486. Sung, P.H., F.Y. Lee, M.S. Tong, J.Y. Chiang, S.N. Pei, M.C. Ma, Y.C. Li, Y.L. Chen, C.J. Wu, J.J. Sheu, M.S. Lee, and H.K. Yip, *The five-year clinical and angiographic follow-up outcomes of intracoronary transfusion of circulation-derived cd34+ cells for patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention - phase i clinical trial.* Critical Care Medicine, 2018. **46**(5): p. 411-418.
487. Lenk, K., V. Adams, P. Lurz, S. Erbs, A. Linke, S. Gielen, A. Schmidt, D. Scheinert, G. Biamino, F. Emmrich, G. Schuler, and R. Hambrecht, *Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia.* European Heart Journal, 2005. **26**(18): p. 1903-1909.
488. Menasche, P., O. Alfieri, S. Janssens, W. McKenna, H. Reichenspurner, L. Trinquart, J.T. Vilquin, J.P. Marolleau, B. Seymour, J. Larghero, S. Lake, G. Chatellier, S. Solomon, M. Desnos, and A.A. Hagege, *The myoblast autologous grafting in ischemic cardiomyopathy (magic) trial: First randomized placebo-controlled study of myoblast transplantation.* Circulation, 2008. **117**(9): p. 1189-200.
489. Bartunek, J., A. Behfar, D. Dolatabadi, M. Vanderheyden, M. Ostojic, J. Dens, B. El Nakadi, M. Banovic, B. Beleslin, M. Vrolix, V. Legrand, C. Vrints, J.L. Vanoverschelde, R. Crespo-Diaz, C. Homsy, M. Tendera, S. Waldman, W. Wijns, and A. Terzic, *Cardiopoietic stem cell therapy in heart failure: The c-cure (cardiopoietic stem cell therapy in heart failure) multicenter randomized trial with lineage-specified biologics.* Journal of the American College of Cardiology, 2013. **61**(23): p. 2329-38.

Table 1: Clinical studies describing growth factor delivery

Phase	Growth factor	Delivery method	Condition	Outcome	Reference
Phase 1	bFGF	Intra-arterial injection	Atherosclerotic peripheral arterial disease	Improved blood flow in ischemic leg	[121]
Phase 1	bFGF	Intracoronary injection	Angina pectoris	No symptomatic improvements	[124]
Phase 2	bFGF	Intra-arterial injection	Myocardial and limb ischemia	Improved walking time	[122]
Phase 1	bFGF	Epicardial implantation of heparin / alginate capsules	Coronary artery disease	Reduced angina, improved blood perfusion.	[127]
Phase 1	bFGF	Intracoronary injection	Coronary heart disease	No significant long term symptomatic improvements.	[123]
Phase 1	bFGF	Intracoronary or intravenous injection	Coronary heart disease	Improved resting perfusion.	[456]
Phase 1 / 2	VEGF	Intracoronary and intravenous injections	Exertional angina	Reduced angina with high dose VEGF at 120 days post-treatment.	[119]
Phase 1	VEGF	Intracoronary injection	Coronary artery disease	Trend for improved blood perfusion a high dose VEGF	[457]
Phase 1	FGF-1	Intracoronary injection	Chronic myocardial ischemia	Improved vascularisation	[128]
Phase 1	GSK1278863	Oral	Peripheral artery disease	No symptomatic or performance benefit ensued	[458]
Phase 2	GSK1278863	Oral	Chronic kidney disease	GSK1278863 produced dose-dependent effects on haemoglobin; no differences in VEGF levels	[459, 460]

Phase 2	FG-4592	Oral	Chronic kidney disease	Increased haemoglobin levels	[461, 462]
Phase 2	AKB-6548	Oral	Chronic kidney disease	Increase haemoglobin levels and enhanced iron mobilization	[463]

Table 2: Clinical studies describing gene delivery.

Phase	Gene	Delivery method	Condition	Outcome	Reference
Phase 1	VEGF ₁₂₁	Adenovirus, intramyocardial	Coronary artery disease	Improvement in angina and treadmill exercise time	[250, 251]
Phase 2	VEGF ₁₂₁	Adenovirus, intramyocardial	Chronic myocardial ischemia	Improved angina and exercise time. No significant difference in perfusion	[464]
Phase 1	VEGF ₁₆₅	Plasmid, intramyocardial	Chronic myocardial ischemia	Improvement in angina and myocardial perfusion	[253]
Phase 1	VEGF ₁₆₅	Plasmid, intramyocardial	Coronary artery disease	No difference in perfusion though ischemic area reduced significantly in all groups	[252]
Phase 1	VEGF ₁₆₅	Plasmid, intramyocardial	Angina pectoris	Improved angina, reduce nitroglycerin intake, improved ischemia, improved collateral perfusion	[254]
Phase 2	VEGF ₁₆₅	Plasmid, percutaneous and intramyocardial	Angina pectoris	Angina improved without significance , no differences in perfusion	[256]
Phase 1 / 2	VEGF2	Naked plasmid, percutaneous	Chronic myocardial ischemia	Angina improved significantly	[255]
Phase 0 / 1	VEGF2	Plasmid, percutaneous and intramyocardial	Chronic myocardial ischemia	Decrease episodes of angina, reduced ischemic area, improved perfusion	[465]
Phase 1	FGF-4	Adenoviral, intracoronary	Angina pectoris	Exercise time and angina increased but not significantly	[466]
Phase 3	FGF-1	Plasmid, intramuscular	Critical limb ischemia	No significant difference in limb survival	[262]
Phase 1	FGF-1	Plasmid, intramyocardial	Critical limb ischemia	Decreased pain, improved ulcer healing, increased transcutaneous oxygen pressure and ankle-brachial index	[467]
Phase 1	FGF-1	Plasmid, intramuscular	Critical limb ischemia	Improved ulcer healing and limb survival	[261]
Phase 1 / 2	HGF	Plasmid, intramuscular	Peripheral artery disease	Reduced ulcer size, increase ankle-brachial index, improved rest pain and walking time. No dose-dependent	[263, 468]

				effect observed.	
Phase 1	HGF	Plasmid, intramuscular	Critical limb ischemia	Improvement of rest pain and ulcer size	[264]
Phase 1	HGF	Plasmid, intramuscular	Critical limb ischemia	Improved ankle-brachial index and ulcer healing, decreased pain	[265]
Phase 1	HGF	Plasmid, intramuscular	Critical limb ischemia	Decreased pain	[469]
Phase 1	HGF	Naked DNA, intramuscular	Critical limb ischemia	Improved ulcer healing and pain, increased oxygenation of limb	[470]
Phase 2	VEGF ₁₂₁	Adenoviral, intramuscular	Peripheral artery disease	No significant improvements	[257]
Phase 1	VEGF ₁₆₅	Plasmid, intramuscular	Critical limb ischemia	Higher doses led to improved healing of ulcers and less rest pain	[258]
Phase 2	VEGF	Plasmid and liposome, percutaneous	Critical limb ischemia	Significant improved vascularity in VEGF-treated groups. No significant difference in ulcers, amputations or pain.	[259]
Phase 1	VEGF ₁₆₅	Naked plasmid, intramuscular	Peripheral artery disease	Inconclusive regarding dosage. Improved ulcer healing, pain and collateral neo-vessels	[471]
Phase 1	VEGF ₁₆₅	Plasmid, intramuscular	Critical limb ischemia	Improved skin ulcers and haemodynamic improvement. Limb survival and pain did not change significantly	[260]
Phase 1	VEGF ₁₆₅	Naked plasmid, intramuscular	Critical limb ischemia	Increase walking time	[472]
Phase 1	HIF-1 α	Adenoviral, intramuscular	Critical limb ischemia	High amputation rate but high adverse effects on placebo too, vision disorders, though improved ulcer healing is described	[266]
Phase 2	HIF-1 α	Adenoviral, intramuscular	Peripheral arterial disease	No significant differences in claudication, ankle-brachial index or quality of life measurements	[473]

Table 3: Clinical studies describing cell delivery.

Phase	Cells	Delivery method	Disease	Outcome	Reference
Pilot	Autologous bone marrow (BM) cells	Local implantation into the ungraftable area	Severe ischemic heart disease	Improved coronary perfusion	[323]
Pilot, Phase 1	BM-MNCs vs Peripheral blood-MNCs (PB-MNCs)	Intramuscular injection	Unilateral ischaemia of the leg	Improved ABI, TcPO ₂ , rest pain, pain-free walking with BM MNC vs. PB MNCs	[474]
Pilot	BM-MSCs vs BM-MNCs	Intramuscular injection	Diabetic critical limb ischaemia	Improved ulcer healing, ABI and TcO ₂ in BM MSC	[475]
Phase 2	BM-MNCs	Intramuscular injection	Chronic limb ischaemia	Improved rest pain and ulcer healing	[476]
Phase 1/2	BM-MNCs	Intramuscular injection	Critical limb ischaemia	Reduced amputation rate	[477]
Pilot	BM-MNCs	Intramuscular injection	Critical limb ischaemia	Non-significant trend for reduced amputation rate vs. placebo	[478]
Pilot, Phase 1, Phase 1/2	BM-MNCs	Intramuscular/intra-arterial injection	Critical limb ischaemia	Improved rest pain, ulcer healing, ABI with BM MNC	[329, 479-481]
Phase 1	BM-MNCs	Intramuscular injection	Critical limb ischemia	Comparable improvements in rest pain and in TcO ₂ with cell therapy and control groups	[482]
Phase 2	BM-MSCs	Intramuscular injection	Critical limb ischaemia	Reduced rest pain and improved ulcer healing with high dose BM-MSCs	[340]
Phase 1/2	BM-MSCs	Intracoronary injection	Acute myocardial infarction	Improved left ventricular ejection fraction (LVEF), infarct size and remodelling with BM-SCs transplantation compared to standard therapy	[341-343]

Phase 1/2	BM-SCs	Intramyocardial vs intracoronary injection	Acute myocardial infarction	Changes in the LVEF were significantly higher than at baseline in both groups, but not significantly difference between groups	[344]
Phase 2	BM-SCs	Intracoronary injection	Myocardial infarction	BM-SCs did not augment recovery of global LV function, but could favourably affect infarct remodelling.	[483]
Phase 2	BM-MNCs	Intramyocardial injection	Ischemic heart failure	Cell therapy failed to improve LVEF, but reduced myocardial scar size	[345]
Phase 1	BM-MNCs + VEGF	Intramuscular injection	Critical limb ischaemia	Cell therapy group exhibited increased ABI and ulcer healing	[484]
Phase 1/2	MSCs	Trans-endocardial injection	Ischemic cardiomyopathy	MSCs reduced infarct size but did not increase LVEF	[346]
Phase 1	ADSCs	Trans-endocardial injections	Ischemic cardiomyopathy	No significant changes	[362]
Pilot, Phase 1	Granulocyte colony-stimulating factor (G-CSF)-mobilized PB-MNCs vs placebo	Subcutaneous injections	Critical limb ischaemia of diabetic patients	Improved rest pain, ulcer healing, blood perfusion	[331, 485]
Phase 1/2	G-CSF-mobilized PB-MNCs vs BM-MNCs	Intramuscular injection	Lower limb arteriosclerosis obliterans	Improved rest pain and ABI with G-CSF-mobilized PB-MNCs vs. BM	[325]
Pilot	Peripheral blood CD34 ⁺ cells	Intracoronary transfusion	End-stage diffuse coronary artery disease	Significantly and progressively increased neovascularization	[486]
Pilot	CD34 ⁺	Intramuscular injection	Critical limb ischaemia	Decreased amputation rate	[317]
Phase 1	Circulating blood PCs	Intra-arterial injection	Critical peripheral arterial occlusive disease	A significant increase in the ABI, TcO ² was seen in the CPCs group	[487]
Phase 1	Autologous skeletal myoblasts	Intramyocardial injection	Left ventricular dysfunction or myocardial infarction	Myoblast transfer did not improve regional or global LV function beyond that seen in control group	[488]

Phase 2/3	Cardiopoietic stem cells	Endomyocardial injections	Chronic heart failure	LVEF was improved by cell therapy vs standard care alone	[489]
-----------	--------------------------	---------------------------	-----------------------	--	-------